sartorius group 2014 annual report order intake sale revenue underlying ebitda1 million million 6811 7495 8668 9123 8196 9292 1102 1366 1611 1726 1623 1868 950 6593 7331 8457 8873 7916 8912 200 financial schedule 850 175 annual shareholder meeting goettingen germany april 9 2015 750 150 1 payment dividend april 10 2015 publication firstquarter figure 2015 april 20 2015 650 125 publication firsthalf figure 2015 july 22 2015 550 100 publication ninemonth figure 2015 october 20 2015 2010 2011 2012 2013 2013 2014 2010 2011 2012 2013 2013 2014 continuing continuing german equity forum frankfurt main germany november 23 2015 operation operation order intake publication preliminary figure fiscal 2015 january 2016 sale revenue annual press conference goettingen germany march 2016 key figure annual shareholder meeting goettingen germany april 7 2016 figure given million according 2014 2013 2013 2012 2011 2010 publication firstquarter figure 2016 april 2016 ifrs unless otherwise specified restated order intake sale revenue earnings 1 subject approval annual shareholder meeting order intake 9292 8196 9123 8668 7495 6811 sale revenue 8912 7916 8873 8457 7331 6593 underlying ebitda 1 1868 1623 1726 1611 1366 1102 underlying ebitda1 sale revenue 210 205 195 190 186 167 relevant net profit continuing operations2 661 592 contact relevant net profit2 737 648 648 630 528 390 research development cost 504 477 538 490 443 426 petra kirchhoff andreas theisen financial data per share vice president director earnings per share continuing operations2 corporate communication ir investor relation per ordinary share 387 346 7 phone 495513081686 phone 495513081668 per preference share 389 348 7 petrakirchhoffsartoriuscom andreastheisensartoriuscom earnings per share2 per ordinary share 431 379 379 369 3097 228 per preference share 433 381 381 371 3117 230 dividend per ordinary share 1063 100 100 094 0807 060 publication 3 per preference share 108 102 102 096 0827 062 balance sheet published financial reporting system firesys balance sheet total 12724 11813 11766 10709 9602 7 8077 sartorius ag michael konrad gmbh equity 4971 4503 4503 4044 36617 3272 corporate communication frankfurt main germany equity ratio 391 381 383 378 3817 405 37070 goettingen germany photography financials editorial deadline peter ginter capital expenditure excluding financial asset goodwill 809 606 629 742 5187 244 february 24 2015 lohmar germany capital expenditure sale 91 77 71 88 717 37 amortization depreciation 527 458 477 406 3287 319 published net cash flow operating activity 12574 9704 1033 532 7907 960 february 27 2015 net debt 33565 34515 3451 3038 26487 1969 5 5 ratio net debt underlying ebitda 17 20 20 19 197 18 total number employee december 31 5611 51586 58636 5491 48877 4515 1 underlying adjusted extraordinary item 2 noncontrolling interest adjusted extraordinary item well noncash amortization based normalized financial result translation original 3 amount suggested supervisory board executive board sartorius ag 4 continuing operation germanlanguage annual report 5 including discontinued operation 6 excluding tap biosystems 7 excluding biohit mission sartorius leading international pharmaceutical laboratory equipment supplier wide array product help customer biopharmaceu tical industry manufacture innovative medication safely economically laboratory research quality assurance name sartorius synony mous premium lab instrument consumables service make sophisticated task easier efficient partner understand customer requirement last detail already working solution meet need today tomorrow seek systematically expand position applicationoriented technology group future well based clearcut strategy continue sustainably create value custo mers shareholder alike translate growth high profitability division glance sartorius globally operating company 5500 employee worldwide subsidiary based 30 country business subdivided two division bioprocess solution offer integrated solution biopharmaceutical manufacture lab product service provides instrument consumables service laboratory report business development two division starting page 42 provide insight strategy page 24 25 bioprocess solution page 42 key figure bioprocess solution fo cuses bioprocess business million 2014 2013 1δ pharmaceutical customer extensive product portfolio division help customer manufacture order intake 6527 5497 183 2 medication vaccine safely efﬁciently major sale revenue 6156 5178 185 2 goal optimize pharmaceutical production process primarily increasing deployment singleuse underlying ebitda 1456 1189 225 product solution division global leader ﬁltration fermentation cell cultivation membrane sale 237 230 chromatography ﬂuid management employees3 3527 3115 132 lab product service page 46 key figure premium laboratory instrument consumables million 2014 2013 1δ excellent service lab product service division positioned broadbased laboratory supplier order intake 2765 2700 32 2 concentrate laboratory research sale revenue 2755 2738 14 2 quality assurance unit pharmaceutical biopharma ceutical company academic research institute underlying ebitda 412 434 51 division serf customer chemical food industry sartoriusbrand laboratory product sale 150 159 enable reliable efﬁcient analysis lab helping employees3 2084 2043 20 drive accelerate scientiﬁc progress division among market leader laboratory balance pipette lab consumables 1 restated 2 constant currency 3 dec 31 01 shareholder 8 report executive board 10 sartorius group executive committee 12 report supervisory board 15 sartorius share annual report contains statement concerning sartorius group future performance statement based assumption estimate although convinced forwardlooking statement realistic cannot guarantee actually apply assumption harbor risk uncertainty could lead actual result diverging substantially expected one planned update forwardlooking statement translation original germanlanguage annual report sartorius shall assume liability correctness translation original german annual report legally binding version furthermore sartorius reserve right responsible topicality correctness completeness quality information provided liability claim regarding damage caused use informa tion provided including kind information incomplete incorrect therefore rejected throughout annual report difference may apparent result rounding addition content 02 combined group 04 consolidated financial management report statement note 22 structure management group 100 statement proﬁt loss comprehensive income 24 strategy goal 102 statement financial position 27 macroeconomic environment condition sector 103 statement cash flow 30 assessment economic position 104 statement change equity 31 group business development 105 note financial statement 39 net worth financial position 122 note statement proﬁt loss 42 business development bioprocess solution 125 note statement financial position 46 business development lab product service 149 disclosure 51 discontinued operation 152 declaration executive board 52 annual financial statement sartorius ag 153 independent auditor report 56 opportunity risk report 154 executive board supervisory board 63 forecast report 67 report material event 68 description key feature internal control risk management system 05 supplementary information 71 explanatory report executive board 160 glossary 72 corporate governance report 162 index 75 remuneration report 164 local presence worldwide 166 address 03 sustainability report 86 sustainability sartorius 87 sustainable corporate management 91 ecological sustainability 95 contributing society 97 gri g4 index leerseite dummy shareholder report executive board dear shareholder business partner fiscal 2014 yet another successful year expected phaseout nonstrategic sartorius met extent even exceeded product line still continued noticeable im sale earnings target addition imple pact business lab product service mented important element longterm strategy supply premium laboratory instrument lab con sartorius 2020 growth initiative two core sumables especially first three quarter division made strong headway long momentum picking yearend division grew planned sale smallest group division industrial 14 achieving underlying ebitda margin 150 technology completed effect year end business found strong new 2014 consolidated order intake whole owner japanese minebea group offer jumped 134 sale revenue climbed 126 good potential synergy promising growth plan 891 million euro achieved increase looking beyond also well track underlying ebitda margin 210 205 multiyear infrastructure project previous year system production capacity based positive development supervisory let u briefly review key business figure board executive board submit proposal 2014 context refer continuing annual shareholder meeting april 9 2015 operation word sartorius group raise dividend 108 per preference share two division bioprocess solution lab 106 per ordinary share connection product service also pleased report share price increased double digit based performance growth engine driving overall dynamic per past fiscal year formance largest division bioprocess solution focus singleuse product 2015 beyond continue execute manufacture biopharmaceuticals gain sartorius 2020 agenda provides roadmap 185 sale revenue underlying ebitda creating profitable growth strategic core margin 237 division expanded product business important element generate segment region two acquisition substantial organic sale growth plan achieve tap biosystems cell culture medium business gaining market share north america also showed exceptionally positive development also expanding overproportionally asia acquiring majority stake u startup allpure moreover potential division technology additionally extended portfolio acquire suitable company add complemen another innovative group singleuse product tary product product range make u even attractive customer regarding dear shareholder customer business partner profitability striving continue successful would like express appreciation performance past year increase trust often extending back many year underlying ebitda margin step step open dialogue time cordially invite continue u road success line strong business prospect innovative highly profitable technology set ambitious target 2015 well specifically group plan increase sale revenue constant currency around 4 7 underlying ebitda margin sincerely 215 division region expected contribute development general economic condition trend bio process solution division highly stable scarcely dependent business cycle degree uncertainty currently surround projection lab division however due economic imponder ables key market especially european dr joachim kreuzburg union china russia ceo executive board chairman besides focusing strategic operational tar get described implement multi year investment project therefore expect investment ratio slightly longterm average coming year current year thus plan invest sum equal approximately 10 sale primarily expand production capacity various site combine two largest plant headquarters goettingen germany point would like sincerely thank staff made possible u achieve strong result fiscal 2014 based expertise motivation dedication sartorius group executive committee group executive committee gec consists member executive board sartorius ag member executive committee subgroup sartorius stedim biotech additional top manager appointed executive board necessary gec key management committee sartorius group serf coordinate control global business activity function gecs activity supplement executive board sartorius ag board director sartorius stedim biotech sa lay groundwork board legally binding decisionmaking joachim kreuzburg chairman corporate strategy legal compliance communication ceo sartorius ag chairman board director ceo sartorius stedim biotech sa sartorius 16 year oscarwerner reif research development member board director sartorius stedim biotech sa sartorius 20 year jörg pﬁrrmann finance human resource information technology member executive board sartorius ag sartorius 16 year volker niebel procurement production supply chain management business process management member board director sartorius stedim biotech sa sartorius 13 year reinhard vogt marketing sale service business development bioprocess solution division member executive board sartorius ag member board director sartorius stedim biotech sa sartorius 31 year michael melingo marketing sale service business development lab product service division sartorius since april 1 2014 report supervisory board dear shareholder summarize opinion supervisory board latter board matter regular conference look back upon 2014 another successful fiscal primarily revolved around development sale year sartorius company succeeded yet revenue earnings employment group growing region expanding earn financial situation company affiliate ings despite facing challenging market situation strategic project area besides reaching financial target sartorius also made strategic headway growth meeting february 25 2014 supervisory initiative designed strengthen core business board fully discussed annual consolidated consistently pursued shortly year end financial statement fiscal 2013 endorsed company implemented important component based report given audit commit longterm strategic approach signing agreement tee independent auditor present sell industrial weighing technology division item agenda moreover con ferred upon approved agenda along fiscal 2014 supervisory board intensively dealt proposed resolution 2014 annual sharehold situation prospect company er meeting proposal appropriation advised executive board performed task annual profit addition resolved adjust execu assigned german corporate law company tive board remuneration 2014 prior decision article association executive board kept u intensively reviewed whether compensation informed providing regular prompt detailed line usual market condition report written verbal relevant level paid peer company place corporate planning strategic development issue within area company based ex progress business division situation ecutive task committee prior report prepared fur group including risk situation risk manage thermore executive board informed u ment internal control system compli status negotiation contemplated acquisition ance company significant transaction startup company allpure well discussed depth executive task com result employee survey conducted mittee audit committee respectively responsible end 2013 well full supervisory board basis report provided executive board various strategic project focus following thorough review executive board meeting april 10 2014 receiving thorough report proposed resolution voted information executive board approved extent vote required acquisition allpure addition executive board provided overview operational cooperation supervisory board measure designed support strong growth executive board always characterized openness bioprocess solution division fluid management constructive dialogue trust area reported status investment project progress focus supervisory board conference meeting september 2 2014 obtained information project strategy various sale initi reporting year supervisory board convened atives lab product service division four ordinary meeting executive board executive board additionally gave detailed status also attended provided meeting concern report sartorius 2020 strategy based report ascertained group track next supervisory board meeting february 24 2015 especially view organic growth target item agenda dealt earnings development moreover compliance system company risk management system current place sartorius presented discussed risk situation determined discernible risk could jeopardize future exist meeting december 16 2014 supervisory ence group furthermore examined board thoroughly dealt planned sale result efficiency review work industrial technology division minebea group consented transaction decided extend dr joachim kreuzburgs appointment activity report committee chairman ceo executive board ahead time another five year november 10 2020 four committee support work supervisory supervisory board pleased gained board prepare topic dealt dr kreuzburg term thanks full supervisory board individual case executive task committee successful negotia take decision lieu full board far tions held meeting well supervisory permitted committee chairman reported regularly board agreed commission law office hengeler supervisory board detail mueller whose partner prof gerd krieger member committee work supervisory board draft resolution voted next annual shareholder executive task committee met meeting authorization use company average rate nine time reporting year share finance acquisition remunera conferred intensively various strategic measure tion component executive board member company among sale industrial recommendation audit committee also technology division addition committee dealt agreed conclude new longterm syndicated loan matter involving executive board pre agreement based upon sartorius replaced pared decision latter remuneration consolidated two existing loan ahead schedule well extension contract addition also approved budget submitted current executive board chairman ceo com executive board 2015 mittee also received information progress project rollout groupwide erp system topic corporate governance item thoroughly discussed succession planning top agenda discussed detail manager consultation decided upon wording declaration compliance accordance year review audit committee held german corporate governance code declaration five meeting committee prepared full confirms sartorius complies recommen supervisory board conference endorsement dations current code full extent approval consolidated annual financial state additionally dealt process retendering ments fiscal 2013 discussed quarterly external auditor review financial statement firsthalf financial report 2014 focus company initiated audit com monitoring effectiveness group mittee due new eu audit reform regulation wide risk management internal control system decision auditor recommend annual well well inhouse auditing compliance shareholder meeting scheduled made committee also conferred subject 14 shareholder report supervisory board group financing particularly consolidation two meeting february 24 2015 endorsed finan separate loan agreement term new cial statement sartorius ag group rec syndicated loan contract signed december ommendation audit committee annual 2014 beyond item committee reviewed financial statement thus approved supervisory internal audit department report indi board executive board submit proposal cate material discrepancy business transac annual shareholder meeting april 9 2015 tions also considered department plan shareholder paid dividend 108 per pref upcoming month respect audit erence share 106 per ordinary share annual financial statement fiscal 2014 com retained profit mittee confirmed independence auditor conferred detail selection auditor recommend annual shareholder meeting composition supervisory board appointment commissioning appointed auditor executive board perform audit review well defining monitoring audit procedure focal point fiscal 2014 personnel change audit focus reporting year supervisory board february 28 2014 mr gerd tender offer audit fiscal 2015 uwe boguslawski employee representative vice audit committee monitored supervisory board chairman supervisory board left board fulfillment obligation following thorough reaching retirement age behalf entire consultation result tender offer board would like thank mr boguslawski committee recommended suggest supervisory many year valuable service upon recommendation board meeting february 24 2015 german metalworker union ig metall kpmg ag auditing company proposed appoint local court appointed mr manfred zaffke succeed ment annual shareholder meeting member supervisory board effective march 1 2014 mr zaffke elected super nomination committee meet past visory board vice chairman member year conciliation committee pursuant sec various committee change tion 27 subsection 3 german codetermination membership executive board reporting law mitbestg likewise convened year position held dr joachim kreuzburg executive board chairman ceo extended ahead time term five year audit annual consolidated november 10 2020 financial statement supervisory board would like thank execu annual consolidated financial statement tive board employee across globe prepared executive board fiscal 2014 great commitment successful hard work management report sartorius ag fiscal year ended addition supervisory reviewed independent auditing company board express appreciation shareholder deloitte touche gmbh wirtschaftsprüfungsgesell confidence shown yet schaft based hanover germany company company commissioned audit committee supervisory board pursuant resolution passed munich february 2015 annual shareholder meeting april 10 2014 independent auditor issued unqualified audit supervisory board certificate attended audit committee meet ing february 23 2015 supervisory meeting february 24 2015 reported essential result audit sufficient time allotted discussion issue auditor written formation audit report sent super visory board member time discussed detail meeting mentioned basis prof dr dres hc arnold picot examination annual sartorius ag consolidated financial statement sartorius ag chairman management report group management port supervisory board concurred result audit conducted deloitte touche shareholder sartorius share 15 sartorius share share market state high volatility doubledigit increase sartorius share price reporting year german dax share index reporting year sartorius share performed showed volatile performance whole well yet sartorius ordinary share thus rose index supported primarily expansionist ecb 153 closing 9800 yearend 2014 com policy first half year geopolitical panys preference share gained 170 reporting tension worsening economic prospect fueled year closing 10125 uncertainty consequence leading german stock index fell annual low 8571 point sartorius ordinary share hit low 8600 october 15 driven liquidity dax reached beginning reporting period january 2 2014 alltime high 10084 point december 4 year company preference share reached low end index 9806 point represented 7683 october 16 2014 ordinary overall gain 27 compared year earlier preference share peaked december 22 2014 german technology index tecdax 10355 ord 10445 prf respectively sartorius also belongs rose period 175 much dynamically dax closing criterion admission tecdax freefloat 1371 point december 31 2014 market capitalization turnover last twelve month frankfurt stock exchange yearend sartorius preference share ranked 14th based criterion market capitalization 28th stockexchange turnover criterion 16 shareholder sartorius share fact share isin de0007165607 ordinary share de0007165631 preference share designated sponsor oddo seydler bank ag hsbc trinkaus burkhardt ag market segment prime standard index tecdax cdax prime share index technology share index nisax20 stock exchange xetra frankfurt hanover duesseldorf munich berlin hamburg bremen stuttgart number share 18720000 nopar individual share certificate calculated par value 1 per share 9360000 ordinary share 9360000 preference share share outstanding 8528056 ordinary share 8519017 preference share trading volume share price development change 2014 2013 preference share xetra yearend closing price 10125 8652 170 ordinary share xetra yearend closing price 9800 8498 153 market capitalization million 1 1698 14618 162 average daily trading volume preference share 8324 14243 416 average daily trading volume ordinary share 592 929 363 trading volume preference share million 1924 2873 330 trading volume ordinary share million 107 195 452 total trading volume million 2031 3068 338 tecdax 1371 1167 175 dax 9806 9552 27 1 without treasury share source bloomberg deutsche börse ag shareholder sartorius share 17 sartorius share january 4 2010 december 31 2014 120 100 80 60 40 20 0 preference ordinary share share 2010 2011 2012 2013 2014 ordinary share preference share sartorius share comparison dax tecdax nasdaq biotechnology index january 4 2010 december 31 2014 700 600 500 400 300 200 100 0 preference ordinary dax nasdaqshare tecdax biotechnology index share 2010 2011 2012 2013 2014 tecdax preference share ordinary share dax nasdaq biotechnology index 18 shareholder sartorius share market capitalization trading volume research coverage institute date recommended market capitalization sartorius ordinary deutsche bank january 28 2015 hold preference share 17 billion december 31 dz bank january 28 2015 buy 2014 compared prioryear figure 15 billion equates increase 162 nord lb january 28 2015 hold oddo seydler january 28 2015 buy average number preference share traded daily berenberg january 27 2015 buy frankfurt stock exchange xetra trading commerzbank january 23 2015 buy floor decreased reporting year 14243 hsbc trinkaus burckhardt october 21 2014 buy 8324 share among reason decline cheuvreux july 22 2014 hold increase trading alternative security plat form corresponding trading volume sartorius dividend preference share 1924 million sartorius group applies dividend policy intended average number ordinary share traded daily ensure shareholder adequately rewarded 592 relative 929 previous year due company success line policy endeavor low free float principle distribute 25 30 underlying net profit see page 34 definition investor relation activity supervisory board executive board submit proposal annual shareholder meeting sartorius investor relation activity focus main april 9 2015 paying dividend 108 previous taining ongoing open dialogue shareholder year 102 per preference share 106 previous potential investor financial analyst year 100 per ordinary share fiscal 2014 besides providing quarterly firsthalf annual dividend report well holding quarterly telephone confer ences also regularly published press release pre senting significant company business development 062 062 082 082 096 096 102 102 108 108 060 060 080 080 094 094 100 100 106 106 material event reporting year 2014 moreover management team available 120 capital market participant site goettingen germany aubagne france conference 090 roadshows conducted financial market cen ters london paris frankfurt main new york 060 hold oneonone meeting first capital market day hosted september goettingen also 030 provided indepth view group strategy busi ness model positioning division well 000 future business potential 2010 2011 2012 2013 20141 information publication company preference share ordinary share share provided website wwwsartoriuscom 1 amount suggested supervisory board executive board sartorius ag analyst would increase total profit distributed assessment recommendation financial 59 172 million 182 million total analyst serve important foundation profit distributed based relevant net result decision private institutional investor would 247 compared 266 year earlier acquiring share reporting year maintained based 2014 yearend share price ongoing dialogue eight institution total sartorius preference ordinary share would give dividend yield 11 share class pre vious year 11 treasury share held company entitled dividend payment shareholder sartorius share 19 shareholder structure recent information available u company biorad laboratory inc hold around 33 sartorius ag issued capital comprises 936 million company ordinary share according current ordinary share number preference information remaining portion comprising around share calculated par value 1 per 3 ordinary share free float share good 50 ordinary share held sartorius family management around 91 company preference share executor approximately 5 owned directly free float roughly 9 held treasury share member family approximately 9 held corporation treasury share corporation according shareholder structure ordinary share shareholder structure preference share administered executor 50 treasury share 9 biorad laboratory inc 33 free float 91 treasury share 9 member family 5 free float 3 key figure sartorius share 2014 2013 2012 2011 2010 1 ordinary share reporting date 9800 8498 6530 3083 2821 high 10355 9048 7400 3900 2920 low 8600 6525 3095 2650 1540 preference share 1 reporting date 10125 8652 6725 3550 2745 high 10445 9015 7205 3900 2787 low 7638 6870 3400 2600 1584 market capitalization2 million 16983 14618 11298 5653 4744 dividend per ordinary share3 106 100 094 080 060 dividend per preference share3 108 102 096 082 062 total dividend 3 4 million 182 172 162 138 104 payout ratio3 5 247 266 257 262 267 dividend yield per ordinary share6 11 11 14 26 21 dividend yield per preference share6 11 11 14 23 23 1 xetra daily closing price 2 without treasury share 3 2014 amount suggested supervisory board executive board sartorius ag 4 calculated basis number share entitled dividend 5 based relevant net profit net profit adjusted extraordinary item noncash amortization based normalized financial result including corresponding tax effect 6 relation closing price year concerned 20 shareholder sartorius share combined group management report 22 group management report structure management group structure management group group legal structure change group portfolio sartorius globally operating company subsidiary consolidated financial statement include 30 country parent company parent company sartorius ag major affiliate sartorius group sartorius ag holding sartorius ag controlling interest pur company control group direct indirect suant ifrs 10 affiliate sartorius ag headquartered goettingen germany listed franfurt stock exchange april 2014 sartorius stedim biotech acquired majority stake allpure technology llc startup sartorius stedim biotech run legally independ company headquartered new oxford pennsylvania ent subgroup focus especially biopro usa specializes singleuse product aspetic cess business december 31 2014 sartorius ag sampling biopharmaceutical application com held approximately 74 share around plements product portfolio bioprocess solu 85 voting right parent company sarto tions division allpure initially consolidated rius stedim biotech sa listed paris reporting date transaction april 28 2014 bourse sartorius stedim biotech sa headquartered aubagne southern france december 19 2014 sartorius concluded contract japanese minebea group partner sale manufacturing company development bank japan sell industrial laboratory business operated legally owned technology division additional information given rule 100 sartorius ag crossdivisional report material event page 67 controlling administrative function finance human resource combined service company group management report structure management group 23 organization management group financial controlling key performance indicator sartorius group consistently organized func tion worldwide accordingly controlled sartorius group managed using number key core operating function performance indicator also decisive determination variable remuneration compo sale industrial weighing operation nent executive board manager previously mentioned sartorius operating business conducted two division bioprocess solu key management parameter sartorius us tions lab product service division measure development volume currency combine respective business cu adjusted growth order intake sale revenue tomer group field application share certain infrastructure central service based key profitability measure ebitda adjusted organization described sartorius suitable extraordinary item ie underlying ebitda structure place meet prerequisite corresponding margin beyond indicator ebit flexible successful development relevant net profit year net profit earn group ings per share reported group central management entity sartorius important indicator ratio net debt group executive committee gec currently underlying ebitda membership six member executive board sartorius ag executive member addition following financial nonfinancial board director sartorius stedim biotech sa indicator reported regular basis one senior manager crossdivisional responsibility capex ratio equity ratio functional responsibility also assigned global net working capital level across site region senior man net cash flow operating activity agement tier immediately beneath gec imple number employee menting group various strategy project local level responsibility national rule annual financial forecast pub affiliate management body local compa lished management beginning fiscal year ny manage organization accordance group division refers develop applicable statutory provision article associa ment sale revenue underlying ebitda tion rule procedure keeping expected capex ratio well directional forecast principle corporate governance apply ratio net debt underlying ebitda addi throughout sartorius group worldwide tionally indicated group sale revenue order intake mostly similar level sartorius due structure generally show considerable timing difference subject similar growth assumption reason order intake usually budgeted separately component financial forecast 24 group management report strategy goal strategy goal sartorius group business organized according two business sartorius focus particular division bioprocess solution lab product singleuse product represent around three service division setup strategy follows quarter division sale revenue cu tomers singleuse product innovative alter native conventional reusable stainless steel system bioprocess solution provide considerable cost time saving reduce risk contamination sartorius bioprocess solution division sartorius extensive portfolio singleuse technology leading international supplier product industry technology manufacture medication vaccine biological basis socalled biopharma product division address attractive ceuticals market aboveaverage growth potential sale distribution activity carried globally part strategy total solution provider field force customer manufacturing offer biopharmaceutical industry product process validated respective authority portfolio cover nearly step production product quality assurance supply essential process encompass cell culture medium seed fermentation cultivation various bioreactor size see leading market position division cell propagation well range technology process filtration fluid management fermentation equipment filter aseptic bag membrane chromatography good stepping cell harvesting purification concentration stone sustained dynamic profitable growth way final filling future besides realizing organic growth poten tial division also plan continue expanding complementary acquisition alliance upstream bioprocessing downstream bioprocessing medium seed production cell removal capture polishing viral formulation preparation fermentation fermentation clariﬁcation clearance final fill service evaluation optimization engineering design implementation technical service group management report strategy goal 25 lab product service assurance research laboratory reason nonstrategic product line phased lab product service division focus past two year research quality assurance laboratory pharma ceutical biopharmaceutical company lab product service sell product academic research institute division additionally three distribution channel specialized dealer serf customer chemical food beverage distributor direct sale ebusiness industry product portfolio cover instrument distributor channel long wellestablished consumables laboratory require instance direct sale ebusiness channel sample preparation use standard applica expanded strengthen division market position tions laboratory instrument lab balance pipette laboratory water system contribute doubledigit share market sartorius around 60 division sale revenue wellknown laboratory brand premium seg consumables product microbiological ment based company history market posi test pipette tip service account 40 tions differ quite considerably depending total sale region product group however back ground see significant potential lab prod beginning 2012 three formerly separate ucts service division grow organically due activity comprised laboratory weighing busi economy scale growth projected ness laboratory consumables unit liquid accompanied increase margin beyond handling entity combined one business target division aim expand offering subsequently division product portfolio complementary laboratory product streamlined focus application quality alliance acquisition lab instrument lab consumables service portfolio product 60 40 revenue revenue distribution channel lab distributor direct sale ebusiness segment customer clinical diagnostics pharma biotech academia chemical food beverage 26 group management report strategy goal strategic planning sartorius 2020 sartorius aim grow sustainably profitably future well group thus plan generate sale revenue around 2 billion 2020 approxi mately twothirds growth achieved organically around one third acquisition moreover sartorius plan increase underlying ebitda margin around 23 sartorius executed 2020 strategic plan developed 2011 im plementing number initiative related regional growth product portfolio infrastructure view organic growth continued im provement profitability track achieve goal however sale revenue contributed acquisition substantially depends availability appropriate takeover target regionally north america focus sartorius growth strategy manufacture biopharmaceuti cals laboratory product north america world largest market sartorius still belowaverage market share region also usa home market vast majority competitor gain market share strengthened capa city primarily sale distribution service enhanced sale process second regional focus asia especially china india market tremendous po tential growing higherthanaverage rate participate momentum best possible way sartorius considerably invested sale infra structure region well addition acquisition primarily focused comple mentary technology product contribute future growth past year success fully expanded wide array product service several small mediumsized acquisition make business process efficient sartorius globally introducing new erp system already use group headquarters goettingen germany moreover continuously expanding capacity manufacturing site goettingen combining plant site still located separate area one location part multiyear project time extending local produc tion capacity group management report macroeconomic environment condition sector 27 macroeconomic environment condition sector two division sartorius group operate reporting year pace expansion germany sector different economic sensitivity bio france slowed relative first half attaining 14 process solution division active environment 04 respectively italian economy largely unaffected economic fluctuation continued shrink 02 lab product service division contrast conduct business activity also sector fueled strong private consumption rising dependent economic development vestment uk economy grew 32 political crisis ukraine associated sanction led macroeconomic environment stagnation russian economy 2014 global economy expanded rate economic growth asia 65 nearly prior previous year 33 according international year level momentum chinese economy slowed monetary fund imf view overall weak start slightly reporting period gain 74 year pace expansion slightly less recorded following growth 77 previous year 36 rate originally forecasted contrast momentum indian economy im proved due rising export investment econo gained 56 compared 2013 japan economic global development gdp 2010 2014 performance rose reporting year 09 51 51 38 38 32 32 33 33 33 33 gross domestic product region 60 33 33 0808 22 22 09 09 65 65 45 33 33 04 04 22 22 15 15 66 66 9 30 6 15 3 00 2010 2011 2012 2013 2014 0 source international monetary fund 3 global euro area u japan asia1 following sluggish start 2014 mainly weather induced u economy performed robustly 2014 2013 latter course year balance growth u 22 2014 thus 1 asia china india asean5 indonesia malaysia previous year level driven primarily rising gov philippine thailand vietnam ernment spending besides strong private consumption source international monetary fund national economy europe showed quite uneven development reporting year euro zone continued affected consequence financial crisis overall high sovereign debt member nation comparably high unem ployment rate negative impact yet contracting several year eurozone economy however record slight increase 08 28 group management report macroeconomic environment condition sector exchange rate trend pharmerging market continued expand dynamically whole reporting period growth important currency sartorius group besides market driven expansion state euro include especially u dollar well healthcare higher private spending currency like chinese yuan indian rupee growth regional pharma market exchange rate euro u dollar impacted reporting year continuing weak 33 33 117 117 33 33 9090 economy europe robust economic devel 30 30 4040 35 35 100 100 opment usa result european single 12 currency sharply depreciated course year hitting annual low 121 u dollar 9 december 31 6 interest rate trend 3 year review average interest rate 0 dropped new historic low european central europe united state japan pharmerging bank cut base rate two step reporting year markets1 025 record low 005 3month euribor rate rate interest fixedterm deposit 2014 2013 denominated euro interbank business still low level 008 december 31 2014 1 china brazil russia india algeria argentina columbia egypt relative 029 previous year indonesia mexico nigeria pakistan poland romania saudi arabia south africa thailand turkey ukraine venezuela vietnam source international monetary fund world economic outlook october 2014 bloomberg ecb deeuriborrateseu source ims health sector condition continued aboveaverage growth biotechnology market key customer sartorius group serf biopharmaceutical pharmaceutical global market pharmaceutical manufactured dustries public research institute chem using biotech method grew overproportionately ical food sector accordingly trend reporting year around 9 outperforming specific sector considerably influence business global pharmaceutical market attributable development sartorius group mainly launch many new biopharmaceuticals past year expanded indication existing medicine proportion sale revenue strong growth pharmaceutical market accounted biologically produced medication risen continuously past year 2014 international market research institute ims health stood around 22 23 currently therapeutic estimate global pharmaceutical market protein play important role treat grown around 7 2014 compared gain ment condition including diabetes chronic 4 5 20131 anemia still make largest category active pharmaceutical ingredient manufactured using bio significant acceleration growth primarily tech method monoclonal antibody also con attributed comparably low number patent tinuing gain importance used expiration developed market many new instance treatment cancer hiv auto medical drug approved addition introduction immune disease multiple sclerosis rheu government health insurance usa matism according study conducted boston positive impact consulting group 330 monoclonal antibody undergoing clinical development phase iiii 2013 significantly 2012 1 prioryear figure adjusted discount rebate considered group management report macroeconomic environment condition sector 29 strong trend towards singleuse system competitive position biopharmaceutical production competitive environment varies two compared classic procedure biotechnological core division production process vastly complex costintensive reason manufacturer bioprocess solution division operates total supplier intensively working develop solution provider covering core process step efficient production technology singleuse product biopharmaceutical manufacture hold leading playing crucial role effort require global position key technological field offering significantly less capital expenditure moreover extensive portfolio singleuse technology reduce cost cleaning validation minimize sector division main competitor include downtime beyond advantage singleuse product emd millipore pall general electric thermo fisher provide considerable flexibility help accelerate time market thanks particular cost efficiency lab product service division positioned singleuse product already well established premium provider product along excellent many process step service serf research quality assur ance laboratory across many industry product range cover laboratory balance pipette well continued soft demand wide array consumables name exam public research sector ples segment division rank among leading provider worldwide main competitor proportion demand laboratory prod include mettler toledo thermo fisher emd millipore ucts come public research sector many pall eppendorf country research budget declining result excessive public debt according frost source boston consulting group medizinische biotechnologie sullivan demand public research sector deutschland 2014 medical biotechnology germany 2014 reporting year slightly prioryear level ims global outlook medicine 2018 evaluate pharma world preview 2018 june 2013 frost sullivan 2014 midyear report forecast analysis global market laboratory chemical sector moderate growth product vci quartalsbericht q3 2014 cefic chemical industry benefit general economic recovery june 2014 industry expert estimate chemical industry europe made moderate progress 2014 increas ing production 20 according european chemical industry council cefic attribut ed particular rise demand auto motive industry addition stabilization building sector positive effect north america asia also saw increasing demand chemical product 30 group management report assessment economic position assessment economic position sartorius fiscal 2014 industrial technology division discontinued operation sartorius enjoyed another year strong progress fiscal 2014 achieving case exceeding december 2014 contract sale financial target set management begin dustrial technology division concluded ning year moreover sartorius focused minebea group partner development bank portfolio envisaged sartorius 2020 strategic japan accordance ifrs 5 division plan sale industrial technology consequently reported consolidated financial smallest group division two remaining statement group management report dis division bioprocess solution lab product continued operation mean order intake service sharpened strategic focus sale revenue earnings asset liability including core customer biopharmaceutical industry borrowing cash flow industrial technolo laboratory respectively bioprocess solution gy division shown separately financial product range gained another innovative strand reporting original statement profit loss 2014 acquisition majority stake 2013 accordingly restated line ifrs 5 allpure technology contrast statement financial position restated given industrial technology division included group guidance 2014 published section discontinued operation page 51 beginning year accordingly also retained provides information business development following comparison financial target industrial technology fiscal 2014 actual performance subsequent part group management report however report continu ing operation accordance presentation consolidated financial statement note sartorius grew considerably yet 2014 sale revenue rose 113 constant currency thus slightly exceeding forecast range 8 10 announced beginning year profit margin based underlying ebitda rose 202 slightly forecast approximately 20 facilitate future growth sartorius expanded capaci tie several production facility invested system reporting year capex ratio rela tive sale revenue amounted 86 well line 8 10 range forecasted beginning year group financial position remained broadly un changed stable equity ratio 391 381 2013 thus remained comfortable level ratio net debt underlying ebitda last twelve month 17 following 20 2013 thus developed slightly better fore casted start year application irfs 5 minor effect particular division result comparison respective forecast provided chapter division group management report group business development 31 group business development sartorius group business development presented regarding division performance bioprocess solu continuing operation ie division tions division major growth driver bioprocess solution product service reporting year achieving doubledigit gain division order intake climbed 183 6527 million sale revenue surged 185 6156 million order intake sale revenue division organic growth around 10 mean acquisition excluded rate business performance sartorius group change constant currency positive whole year review significant doubledigit gain reported order intake sale revenue growth sale revenue order intake rose 134 million unless otherwise specified 9292 million period group sale revenue increased 126 8912 million rate change 8912 8912 6156 6156 2755 2755 constant currency 7916 7916 5178 5178 2738 2738 1000 order intake sale revenue 750 million 8196 8196 9292 9292 500 7916 7916 8912 8912 950 250 850 0 group bioprocess lab product 750 solution service 2014 650 20131 1 restated 550 20131 2014 order intake sale revenue growth growth1 sale revenue million 1 restated group 8912 126 126 bioprocess solution 6156 189 185 lab product service 2755 06 14 1 constant currency sale revenue division bioprocess solution 691 reporting year lab product service division received order amounting 2765 million relative 2700 million year ago equal lab product service 309 increase 32 division sale revenue rose 14 2755 million 2738 million 2013 rate change constant currency information business development group division given page 42 et seq bioprocess solution division page 46 et seq lab product service division 32 group management report group business development sale revenue region1 group sale revenue region1 million unless otherwise specified europe 472 4211 4211 2416 2416 2010 2010 275 275 3935 3935 1824 1824 1838 1838 319 319 north america 271 480 360 240 asia pacific 226 120 market 31 0 europe north asia 1 acc customer location america pacific market 2014 20132 europe region account around 47 1 acc customer location sartorius group business thus highest 2 restated sale share sale revenue 66 high base previous year bioprocess solu tions division reported doubledigit sale gain sale revenue growth growth2 113 sale revenue lab product service million division slightly prioryear level group 8912 126 126 12 primarily due phaseout non europe 4211 70 66 strategic product rate change constant north america 2416 325 320 currency asia pacific 2010 93 109 market 275 139 139 north america represented approximately 27 group revenue reporting year grew 1 acc customer location dynamically recording gain 320 fueled 2 constant currency division bioprocess solution division reported surge sale 371 partly induced acquisition addition business ex panded also organically significant pace driven strong demand product segment sale revenue lab product service likewise increased sharply 133 rate change constant currency asia pacific region account around 23 consolidated sale saw doubledigit gain 109 year review key growth driver bioprocess solution division boosted sale revenue 174 performance driven large equipment order strong demand singleuse product given weak market environment especially beginning year lab product service division reported sale growth 14 rate change constant currency group management report group business development 33 development cost earnings already mentioned industrial technology division reported discontinued operation net reporting year cost sale profit tax activity 45 million 4616 million rise 134 primarily due previous year level increase production volume complete consolidation medium business higher reporting year net profit attributable share depreciation related expansion production holder sartorius ag 485 million relative capacity cost sale ratio 518 relative 524 million year earlier noncontrolling interest 514 year ago stood 199 million 2013 182 million essen tially reflected share sartorius stedim biotech sa functional cost sartorius group developed held sartorius group fiscal 2014 follows selling distribution cost rose underproportionately 102 relative sale revenue 2002 million ratio selling statement profit loss distribution cost sale revenue 225 com million 2014 20131 pared 229 previous year sale revenue 8912 7916 126 cost sale 4616 4070 134 expense research development rose reporting year group division whole gross profit sale 4296 3846 117 rd cost increased 57 504 million selling distribution cost 2002 1816 102 equates 57 sale revenue compared 60 research development cost 504 477 57 prior year general administrative expense 583 497 173 operating income expense 55 44 247 concerning general administrative expense earnings interest ported 173 increase 583 million tax ebit 1262 1100 147 primarily attributed recent acquisition relation financial income 34 20 677 sale revenue general administrative expense financial expense 333 166 1005 65 relative 63 previous year financial result 299 146 1050 profit tax 963 954 09 fiscal 2014 balance operating income income tax 324 293 105 expense 55 million relative 44 million profit tax year earlier continuing operation 639 661 33 profit tax overall group operating expense rose 122 year discontinued operation 45 45 02 year accordingly ebit increased overproportion net profit period 684 706 31 ately respect sale revenue 147 attributable 1262 million group ebit margin 142 equity holder sartorius ag 485 524 74 2013 139 noncontrolling interest 199 182 94 significant change financial result 1 restated according ifrs 5 299 million 2014 relative 146 million 2013 especially reflects valuation effect hedging instrument connection refinancing syndicated loan effect amounted approximately 8 million reporting year income tax totaled 324 million 2013 293 million company tax rate 336 307 year 34 group management report group business development underlying ebitda relevant net profit sartorius group us underlying ebitda earnings relevant net profit attributable shareholder interest tax depreciation amortization sartorius ag 737 million 648 million adjusted extraordinary item key prof year ago figure calculated adjusting itability indicator information extraordinary extraordinary item eliminating noncash amortization item provided page 115 fair value adjustment hedging instrument based normalized financial result well reconciliation ebit underlying ebitda corresponding tax effect item million 2014 20131 respective underlying earnings per ordinary share amounted 431 379 year earlier ebit 1262 1100 per preference share 433 euro 381 extraordinary item 83 65 euro year ago amortization depreciation 523 458 underlying ebitda 1868 1623 million 2014 20131 1 restated ebit 1262 1100 extraordinary item 83 65 amortization 140 125 fiscal 2014 sartorius group increased earn normalized financial result2 202 152 ings overproportionately yet underlying ebitda normalized income tax 2014 thus rose 151 1868 million group respec 30 2013 303 385 341 tive underlying ebitda margin improved 205 underlying earnings 898 796 210 noncontrolling interest 237 205 underlying earnings tax underlying underlying noncontrolling interest 661 592 ebitda ebitda margin underlying earnings per share million per ordinary share 387 346 group 1868 210 per preference share 389 348 bioprocess solution 1456 237 relevant net profit non lab product service 412 150 controlling interest4 737 648 underlying earnings per share per ordinary share 431 379 bioprocess solution division increased per preference share 433 381 lying ebitda 225 1189 million 1 1456 million overproportionate increase relative restated 2 financial result excluding fair value adjustment hedging sale revenue driven economy scale instrument nonperiodic expense income division margin rose 230 237 lab 3 underlying income tax based underlying profit product service division reported underlying tax noncash amortization 4 ebitda 412 million v 434 million year ago including discontinued operation 150 division margin remained pre vious year level 159 mainly induced sale information earnings development extraordinary item group division given consolidated ebit including extraordinary item page 42 et seq 46 et seq 83 million 2013 65 million mainly related integration tap biosystems severance payment various crossdivisional project depreciation amortization reached 1262 million 2013 1100 million group respective ebit margin 142 previous year 139 group management report group business development 35 underlying earnings per share12 research development 230 230 311 311 371 371 381 381 433 433 spending research development rd across 228 228 309 309 369 369 379 379 431 431 sartorius group amounted reporting year 500 504 million represents yearonyear increase 57 2013 477 million ratio rd cost 375 sale revenue stood 57 2013 60 250 development investment significanty increased reporting period driven successful completion several larger project amounted 125 137 million compared 86 million 2013 equates share 214 2013 152 000 group total rd expense depreciation related 2010 2011 2012 2013 2014 capitalized development cost amounted preference share 85 million reporting year 2013 68 million ordinary share 1 adjusted extraordinary item noncash amortization based research development activity aim normalized financial result including corresponding providing innovative product solution tax effect help customer run production lab oper 2 including discontinued operation ations efficiently term time cost endeavor expand range product continuously via research development appropriation profit integrating technology alliance supervisory board executive board sartorius operates strategic property right policy submit proposal annual shareholder meeting across division protect expertise en april 9 2015 raise dividend fiscal 2014 tail systematic program detect infringement according proposal dividend set right plus review based cost benefit crease 102 year ago 108 per preference approach determine specific individual right share 100 year earlier 106 per ordi need maintained nary share total amount disbursed proposal would thus rise 59 172 million filed total 167 application property right 182 million 2014 2013 182 issued 228 patent trademark also result past application previ ous year 172 balance sheet date total 2987 patent trademark portfolio 2013 2721 information provided section covering individual division beginning page 42 et seq 46 et seq 36 group management report group business development capital expenditure employee increased capital expenditure considerably following number employee include staff reporting year planned 809 million 2013 member apart vocational trainee intern em 606 million ployees extended leaf absence par ticipating early retirement plan number fiscal 2014 substantial part capital ex recorded head count meaning employ penditures related investment expansion ee counted regardless whether work full production capacity particular filter part time manufacture goettingen site december 31 2014 sartorius group em completed preparation international ployed 5611 people continuing business seg rollout new erp system reporting year ments 453 previous year 173 began implementation site usa employee british company tap biosystems sartorius acquired end 2013 31 moreover sartorius started multiyear project staff member sartorius recent acquisition 2014 consolidate expand headquarters allpure technology included first time goettingen fiscal 2014 reporting employee 2014 201312 growth bioprocess solution 3527 3115 132 lab product service 2084 2043 20 continuing operation 5611 5158 88 discontinued operation 707 705 03 total group 6318 5863 78 1 restated 2 excluding tap biosystems 2014 yearend majority total group workforce 629 employed bioprocess solution division 371 worked lab product service division division reported gain respective workforce headcount increase 132 20 respectively employee central administrative function reported according continuing division performed task group management report group business development 37 employee region1 number employee function show production unit accounted largest share 569 3724 3724 748 748 953 953 186 186 group total workforce head count increased 3397 3397 656 656 907 907 198 198 94 primarily resulted sartorius ex 4000 panded personnel capacity french puerto rican manufacturing site response sustained 3000 strong demand singleuse product addition majority staff tap biosystems 2000 acquired previous year work production good quarter total group workforce em ployed marketing sale function part 1000 sale initiative sartorius strengthened sale team region led increase head count 0 78 compared prior year 128 europe north asia percentage gain number employee america pacific market highest research development unit 2014 area bioprocess solution division hired 20132 new staff end reporting year 90 1 continuing operation workforce employed administrative unit 2 restated include finance human resource among unit functional area recorded lowest rate increase gain 50 head count increased three core region reporting year 2014 yearend around twothirds employee age total workforce employed europe 2014 20131 head count grew 96 gain 29 ger number number man group site employ 401 total 16 20 year 24 04 21 04 staff north america recorded highest staff 21 30 year 1184 211 1145 222 crease 140 number people employed 31 40 year 1666 297 1516 294 asia pacific region end fiscal year 41 50 year 1472 262 1367 265 rose 51 representing 170 total group 51 60 year 1092 195 962 186 workforce yearend 61 year 173 31 147 29 1 employee function1 restated 3192 3192 1501 1501 414 414 505 505 sartorius group employed 3549 men 2062 2918 2918 1392 1392 367 367 481 481 woman december 31 2014 meaning men 3600 make 632 total workforce 2013 627 woman 368 2013 373 half 2700 employee age 31 50 aver age employee age across entire workforce 1800 reporting period virtually unchanged 408 year 2013 404 year 900 0 production marketing research administration sale development 2014 20132 1 continuing operation 2 restated 38 group management report group business development new hire attrition rate average seniority absenteeism 2014 20131 new hire 731 844 departures2 75 66 attrition rate 3 86 93 average seniority year 98 98 absence rate 36 39 1 restated 2 departure companydriven dismissal layoff recorded first time 2013 group whole 3 number people leaving company percentage average head count 2014 5571 including expired fixed term contract contract terminated either employee employer retirement reason employee leaving company attrition rate express number people leaving company percentage average head count fell 86 group reporting year previous year 93 attrition rate generally varies region region also true sartorius german site rate typically low 2014 stood 44 39 previous year country high average attrition rate china india sartorius suc cessfully lowered rate various employee retention motivation activity result attrition rate asia dropped considerably 119 84 fiscal year review absence rate proportion planned work ing time worked due general absence decreased reporting year across group even average time missed per employee due illness dropped 71 day 2013 66 fiscal 2014 detailed information sartorius employer human resource strategy people development please see chapter sustainable corporate management starting page 87 group management report net worth financial position 39 net worth financial position cash flow consolidated statement financial position reporting year net cash flow operating accordance ifrs 5 prioryear statement activity sartorius group rose financial position required adjusted con 1033 million 1297 million especially due cerning disclosure asset liability dis positive development earnings cash continued operation material impact inflow discontinued operation accounted discontinuation described following 40 million 2014 63 million 2013 balance sheet total sartorius group rose planned investment 2014 higher 911 million 12724 million reporting previous year net cash outflow investing date december 31 2014 figure includes asset activity increased 820 million 562 million liability 759 million 306 million 2013 investment activity focused spectively discontinued industrial technology expansion production capacity various site division amount disclosed current rollout new system measure related item combination two separate plant one group headquarters goettingen germany noncurrent asset slightly rose 233 million discontinued operation accounted investment 8364 million increase mainly attributed 36 million following 22 million year expansion production capacity group discontinued operation asset originally ported noncurrent item 201 million cash outflow related acquisition amounted year ended december 31 2014 disclosed cur 43 million takeover majority stake rent asset allpure technology figure significantly amount 451 million prior year current asset increased 3683 million sartorius acquired lonza cell culture 4361 million inter alia due change medium business tap biosystems disclosure mentioned thus sartorius group financed investment acquisition entirely operating cash flow key figure working capital previous year day 2014 201313 rate turnover inventory cash flow statement inventory x 360 59 57 summary sale revenue million 2014 2013 rate turnover receivables net cash flow operating activity 1297 1033 trade receivables x 360 57 52 discontinued operation 40 63 sale revenue net cash flow investing activity acquisition 863 1013 rate turnover net working capital discontinued operation 36 22 net working capital2 x 360 79 76 net cash flow financing activity 419 103 sale revenue discontinued operation 00 00 1 cash cash equivalent 406 519 restated 2 sum inventory trade receivables less trade gross debt 3921 3970 payable net debt 3356 3451 3 including pro forma sale revenue tap biosystems 40 group management report net worth financial position key balance sheet figure gross debt comprised liability bank 2014 2013 including note loan schuldscheindarlehen finance lease stood 3921 million slightly equity ratio prioryear figure 3970 million net equity balance sheet total 391 381 debt defined gross debt less cash cash equiva lent slightly decreased 3451 million 3356 million longtermcapitalto fixedassets ratio longterm capital ratio longterm capital fixed asset margin fixed asset 1260 1221 ally increased 1260 reporting date relative 1221 december 31 2013 equity increased driven earnings 4503 million 4971 million equity ratio sartorius group rose 381 2013 391 2014 noncurrent liability year year 5092 million 5265 million group dis continued operation liability originally reported noncurrent item 96 million year ended december 31 2014 disclosed current liability current liability rose 2219 million 2013 2489 million reporting year figure includes liability totaling 306 million discontinued operation sartorius group balance sheet structure asset equity liability 381 381 391 391 688 688 657 657 431 431 413 413 312 312 343 343 188 188 196 196 100 50 0 2013 2014 2013 2014 noncurrent equity asset noncurrent current liability asset current liability group management report net worth financial position 41 financing treasury ratio net debt underlying ebitda12 financing sartorius group consists various 18 18 19 19 19 19 20 20 17 17 element largely renewed reporting 40 year benefit attractive market environ ment increase flexibility 30 major pillar financing syndicated credit 20 line 400 million concluded december 2014 maturity term five year new financing arrangement sartorius replaced two syndicated 10 credit line ahead schedule consolidated financing within group 00 2010 2011 2012 2013 2014 additional component company financing 1 underlying note loan schuldscheindarlehen placed 2 including discontinued operation 2012 volume 100 million maturity five ten year consequence global business activity addition several longterm loan totaling around sartorius group exposed fluctuation foreign 100 million available expand production exchange rate main foreign currency include capacity among project u dollar japanese yen british pound using global manufacturing network production beyond component diverse working facility north america uk china india capital guaranteed credit line totaling approxi among place sartorius compensate mately 60 million factoring program majority currency fluctuation natural hedging volume 500 million generally hedge approximately twothirds sartorius group financed longterm well remaining net currency exposure period diversified basis financing component comprise 15 year suitable currency transaction instrument fixed variable interest rate variable interestrate bank loan hedged increase general interest rate level ratio net debt underlying ebitda decreased december 31 2014 17 year earlier ratio 20 ratio include discontin ued operation sartorius group business development bioprocess solution signiﬁcant growth across product range region performance slightly stronger expected organic growth acquisitionled sale increase earnings margin due economy scale key figure sale revenue region according customer location europe 446 million 2014 2013 1δ order intake 6527 5497 183 2 north america 320 sale revenue 6156 5178 185 2 6156 mn underlying ebitda 1456 1189 225 sale 237 230 asia paciﬁc 208 employees3 3527 3115 132 market 26 product biopharmaceutical manufacture singleuse bag fermentation storage scaleup level filter sterilization biopharmaceutical medium culture medium buffer cell cultivation membrane chromatography singleuse bioreactor system safe efﬁcient cell cultivation process puriﬁcation bioprocesses 2000 l 1 restated 2 constant currency 3 dec 31 group management report business development bioprocess solution 43 order intake sale revenue bioprocess solution sale revenue region1 million unless otherwise specified bioprocess solution division increased order 2749 2749 1971 1971 1277 1277 160 160 intake reporting year 183 6527 million 2450 2450 1431 1431 1100 1100 198 198 constant currency compared high prior 300 year base 225 bioprocess solution order intake sale revenue million 150 6527 6527 6156 6156 5497 5497 5178 5178 75 700 0 europe north asia 600 america pacific market 500 2014 2013 400 1 acc customer location 300 order intake sale revenue sale revenue1 growth growth2 2014 million 2013 bioprocess solution 6156 189 185 europe 2749 122 113 sale revenue rose period 185 north america 1971 377 371 constant currency 6156 million thus surpassing asia pacific 1277 161 174 12 15 range predicted beginning market 160 193 193 year organic growth around 10 exceeded expectation driven product line also 1 acc customer location 2 recent acquisition cell culture medium busi constant currency ness tap biosystems developed dynamically reporting period performed better anticipated beginning year 2014 main region reported doubledigit gain sale revenue especially europe north america acquisition mentioned contributed signifi cantly growth europe region generating highest sale accounting around 45 division revenue reported increase sale revenue 113 2749 million north america represented 32 division sale revenue registered highest growth dynamic report ing period sale region significantly increased 371 1971 million asia pacific accounted around 21 total sale 2014 recording gain 174 1277 million rate change constant currency 44 group management report business development bioprocess solution earnings acquisition strengthen product range earnings bioprocess solution division advanced acquisition british company tap biosystems significantly reporting period based strong end 2013 added two smallvolume singleuse growth sale revenue due economy scale un bioreactor system process development applica derlying ebitda increased overproportionally 225 tions product range innovative system 1456 million division respective margin rose enable customer perform large number 230 237 thus slightly exceeding guidance cell culture experiment simultaneously providing around 235 communicated outset year quick costeffective way determine optimal development condition cell culture al bioprocess solution underlying ebitda low u begin working customer ebitda margin early stage process development 2014 20131 underlying ebitda 1456 1189 product range gained new sampling system underlying ebitda margin 237 230 acquisition majority stake u startup allpure technology allpure system 1 restated based singleuse technology allows sample taken bioreactor sterile closed environ ment technology replaces traditional reusable division recorded extraordinary item sampling system pose greater risk con 59 million reporting year relative tamination 39 million year ago extensive range service product sale sophisticated manufacturing process employed bioprocess solution division provides product customer subject strict regulation cover virtually step biopharmaceutical production quality control quality assurance compliance process medium cell cultivation bioreactors regulation subject regular check various size cell propagation filter purifying relevant authority offer extensive range cell material system storage transport service encompassing validation consulting activ intermediate finished product offering com ities well equipment installation maintenance plemented range service including consulting repair help customer comply applicable validation applicationspecific package regulatory requirement division launched new generation existing product line reporting year added several sale distribution activity expanded completely new product notably area fluid management fermentation bioprocess solution division market product portfolio exclusively direct channel maintains team field sale representative new generation singleuse bag also global key account management team coordinate support sale distribution activ together cooperation partner developed ities key account reporting year sartorius new polyethylene film based launched began introduce new global crm system pro new singleuse bag fermentation application vide support sale distribution activi reporting year one main benefit tie also stepped sale distribution activity new film interact cell asia reporting year connection terial stable cell growth ensured new implementation 2020 strategy film combine robustness flexibility new application center opened shanghai exam time meaning also used large ple allows presentation key product volume cultivation fermentation storage process plus demonstration variety different applica e wide range application another ad tions customer vantage customer single film material validated pave way significant reduction validation time cost group management report business development bioprocess solution 45 research development production supply chain management research development activity encompass bioprocess solution division operates well inhouse development area core developed global production network plant technology well integration product europe north america asia largest produc alliance partner university tion site located germany france puerto industry rico sartorius also manufacturing operation switzerland uk tunisia india inhouse research development sartorius focus particular following technology area production site generally serf membrane core component center competence particular technology type filter product several base technology group largest plant goettingen example con broad spectrum application bioprocesses like centrates chiefly production membrane singleuse container sensor well control filter aubagne mohamdia site primarily technology eg fermentation moreover manufacture singleuse bag plant yauco sup extensive expertise bioprocess application ply membrane filter singleuse bag principally development u market guxhagen site specializes bioreactors system bioprocess applica regional perspective largest rd site tions collaborates closely bangalore site located goettingen additional key rd mainly manufacture stainless steel unit activity aubagne guxhagen bangalore royston system overall research development activity becoming increasingly international production capacity expanded one rd priority reporting year develop additional application new polyeth sartorius expanded production capacity various ylene film thus continued effort bring site reporting year response dynamic new film market area storage freeze growth bioprocess business thus new bag thaw application production system commissioned yauco aubagne mohamdia plant sartorius installed connection acquisition allpure technol new casting machine production filter ogies began work reporting year develop membrane goettingen site reporting new standardized product taking sample year scheduled commissioned 2015 bioreactors production capacity also expanded bangalore plant fermentation also collaborating industrial university partner development new control technol ogies manufacturing process active medical central distribution center ingredient socalled process analytical tool sartorius joint venture partner built new spending research development biopro highly automated logistics center goettingen cess solution division amounted 365 million site reporting year facility handle product reporting year corresponding ratio rd shipping well supplying production unit cost sale revenue 59 compared 66 goettingen plant sartorius intends implement prior year central distribution center asian market future based suzhou site china business development lab product service development sale revenue earnings impacted portfolio cleaning new product featuring userfriendliness data management focus direct sale key account ebusiness key figure sale revenue region according customer location europe 531 million 2014 2013 1δ north america 161 order intake 2765 2700 32 2 sale revenue 2755 2738 14 2 2755 mn underlying ebitda 412 434 51 asia paciﬁc 266 sale 150 159 employees3 2084 2043 20 market 42 product laboratory quality assurance research laboratory balance lab water system reliable convenient singleuse bag system weighing process storage puriﬁed water lightest smallest innovative membrane electronic pipette transfer agar system market microbiological testing mass comparators climate module automatically measure environmental parameter 1 restated 2 constant currency 3 dec 31 group management report business development lab product service 47 order intake sale revenue lab product service sale revenue region1 million unless otherwise specified reporting year order intake lab product 1463 1463 445 445 733 733 115 115 service division rose 32 constant currency 1485 1485 393 393 738 738 122 122 2700 million 2765 million phaseout 160 nonstrategic product merchandise article laboratory balance lowend basic 120 segment marginal impact order intake 80 lab product service order intake sale revenue million 40 2765 2765 2755 2755 2700 2700 2738 2738 0 300 europe north asia america pacific market 250 2014 20132 200 1 acc customer location 2 restated 150 100 sale revenue1 growth growth2 million order intake sale revenue lab product service 2755 06 14 2014 20131 europe 1463 15 12 north america 445 132 133 1 restated asia pacific 733 08 14 market 115 52 52 contrast portfolio adjustment mentioned 1 acc customer location continued deferred impact sale 2 constant currency 2 percentage point expected accordingly sale revenue reporting period rose 14 constant currency 2738 million 2755 million thus lower end growth forecast 1 4 europe region contributing highest share sale revenue 50 sale revenue quite reach high prioryear level 12 discontinuation nonstrategic product still noticeable impact sale year review asia pacific account around 27 business lab product service division sale revenue grew 14 figure affected weak market environment beginning year particularly china north america generated approximately 16 division revenue sale revenue climbed significantly 133 strong demand laboratory instrument well consumable product service contributed growth rate change constant currency 48 group management report business development lab product service earnings product sale reporting period lab product service lab product service division extensive range division achieved underlying ebitda 412 million premium laboratory instrument consumables relative 434 million year ago development service make attractive partner research essentially due moderate expansion sale quality assurance laboratory industrial revenue result portfolio cleaning accordingly academic sector division consolidated division underlying ebitda margin 150 range past two year phasing compared 159 year earlier thus reached nonstrategic product line portfolio guidance adjusted toward middle year also streamlined brand strategy based actual sale progress margin origi nally projected reach approximately 165 division sell product three channel sale distribution specialized lab product service underlying ebitda laboratory dealer already well established ebitda margin direct sale ebusiness activity 2014 20131 expanded underlying ebitda 412 434 underlying ebitda margin 150 159 userfriendly operating concept 1 restated sartorius develops refines product helping laboratory work efficiently comply reporting year extraordinary item amounted official regulatory requirement automated data 24 million 2013 26 million management play essential role context new generation electronic pipette example consequently record measurement result mainte nance history entry similar data la boratories regulatory sector submit regular verification pipette integrated common laboratory information system measurement result automatically availa ble centrally new device moreover eliminate certain manual hence errorprone step alto gether new device typically equipped intui tive user guidance assistance system make operation easier efficient even less suscep tible error service competitive edge sartorius offer wide range service covering entire life cycle product device installa tion commissioning verification calibration regular maintenance repair service limited sartorius instrument include device manufacturer well extensive range interest many customer looking mini mize number service provider use duce complexity cost impetus growth service business come sector like pharmaceutical industry quality standard high regulatory requirement increasing group management report business development lab product service 49 sartorius opened two additional calibration lab research development pipette laboratory balance india singapore reporting year well commissioned new lab division core area technical expertise application laboratory shanghai customer include weighing technology mechatronics soft test product take training course ware development laboratory instrument manufac turing well membrane technology injection molding process consumables additional com expanding direct sale ebusiness plementary expertise technology liquid handling come aboard result acquisition sartorius enjoys strong presence lab equip division rd team centrally located ment market overall doubledigit market share goettingen site rd activity company instance historical reason share acquired kept original site still vary considerably product group approach brings sartorius benefit collaboration region situation present significant potential across technology site growth existing portfolio division accordingly launched series multiyear product development priority sartorius initiative addressing different area fiscal year ended included standardized intuitive user interface laboratory equipment associated past two year sartorius integrated new concept already implemented bal sale service team formerly separate busi ances moisture analyzer laboratory water purifi ness activity trained sale staff promoting cation system design work entire product range company also began instrument progress field particular rolling new crm system covering region interest include data management process auto division 2014 provide access uniform data mation example activity area include base sale team ongoing development qapps special program customerspecific guide lab staff lab division effort build direct sale key weighing process send correspond account benefiting substantially pharma ing data laboratory management system ceutical biotech sector close customer relationship established contact developed sartorius collaborates closely industrial bioprocess solution division major research insti academic technology partner addition pursuing tutions also served directly field sale staff mem rd fraunhofer application center bers relieved number administrative plasma photonics joined extensive research duty enabling focus closely contact network germany reporting year sartorius customer also involved member smartlab working group design laboratory future sartorius building ebusiness activity presented lab technology trade fair labvolu enhancing quantity quality product tion 2015 sartorius stepping collaboration information provides electronic channel international partner notably universi well boosting electronic sale expansion tie china ebusiness intended primarily simplify order ing process lab distributor help u reach cu sartorius invested 139 million rd lab tomers directly served sale operation product service division reporting year 2013 135 million rd ratio increased 51 49 year ago 50 group management report business development lab product service production supply chain management lab product service division operates plant germany china finland uk u plant also serve center competence conse quently tend focus one product group small set product group laboratory balance manu factured goettingen beijing example pipette made helsinki souzhou site kit microbiological test produced stonehouse membranebased product manufactured goettingen capacity expanded sartorius invested creating additional production capacity number site reporting year new machinery enhanced process pipette tip manufacturing place since summer 2014 kajaani plant finland addition construction new laboratory instru ment production facility began october goettingen site two plant separate site goettingen combined new building part sartorius campus project calibration center prototype manufacturing unit training workshop also integrated sartorius invested efficient logistics like bioprocess solution division lab product service us logistics center sartorius along joint venture partner built goettingen shipping product supplying manufacturing oper ations future division deliver product customer asia centrally distribution hub suzhou china group management report discontinued operation 51 discontinued operation industrial technology order intake sale revenue industrial weighing division leading supplier following weak start fiscal 2014 industrial industrial weighing control equipment focus technology division recorded positive performance ing premium segment pharmaceutical year progressed order intake thus increased 83 food industry sartorius decided 2011 ex 1002 million 1080 million growth sale amine option including sale business revenue slightly less dynamic due timing effect high investment would necessary related completion contract whole sale ensure sustained positive development revenue industrial technology division rose division especially outside europe reporting 10 1032 million 1038 million thus year business therefore carved legal reached lower end guidance range 1 ly independent subgroup december 2014 4 rate change constant currency signed contract sell industrial technology division accordingly business reported europe region contributing highest share discontinued operation requirement ifrs around 65 division sale revenue international financial reporting standard 05 strong prioryear base sale reve nue asia pacific accounted around 24 key figure industrial technology industrial technology business 18 million 2014 20131 reporting year previous year figure attributable soft demand particularly order intake 1080 1002 beginning year review business expanded sale revenue 1038 1032 briskly north america generated around 9 underlying ebitda 129 103 division total sale region sale reve sale revenue 124 100 nue surged 171 rate change constant employee dec 31 707 705 currency 1 restated earnings reporting year industrial technology divi sion signficantly increased earnings positive product mix effect primarily contributing result therefore division underlying ebitda surged 249 103 million 129 million earnings margin improved accordingly 100 124 higher forecast 105 52 group management report annual financial statement sartorius ag note based hgb annual financial statement sartorius ag note based hgb retained profit sartorius ag key reference earnings value payment dividend shareholder whereas sartorius group financial statement sale revenue sartorius ag consists essentially drawn according international financial cost transfer affiliated company within group reporting standard ifrs annual financial management service rendered statement sartorius ag prepared applying rule regulation german commercial item operating expense includes consult code hgb ing expense 21 million related contract sell industrial technology division management report sartorius ag signed reporting year among expense group management report fiscal 2014 com bined hgb annual financial statement income investment 160 million relative sartorius ag combined management report 112 million 2013 concern dividend paid published simultaneously german federal french subsidiary sartorius stedim biotech sa gazette bundesanzeiger well sartorius mechatronics th based hamburg germany profit loss transfer agreement sartorius lab holding gmbh sartorius corporate business operation corporate strategy administration gmbh resulted receipt profit corporate management oversight 96 million compared 83 million 2013 overview business development sartorius ag exercised function net worth financial position strategic groupleading management holding entity sartorius group since beginning fiscal 2011 balance sheet total sartorius ag rose refer connection explanatory 1794 million reporting year 6918 million remark concerning business operation corporate increase primarily attributed con strategy corporate management oversight well clusion new syndicated loan agreement part overview business development presented agreement sartorius ag taken page 22 et seq combined management report financing entire group since transaction sartorius ag group borrowed fund also transferred company sartorius stedim biotech subgroup internal group loan agreement cash pooling account balance sheet structure sartorius ag reflects function management holding entity sartorius group fixed asset consist essentially financial asset reporting year amounted 4830 million previous year 4754 million accordingly fixed asset account 698 balance sheet total previous year 928 equity ratio decreased due increase balance sheet total 388 538 previous year group management report annual financial statement sartorius ag note based hgb 53 statement profit loss sartorius ag based total cost accounting method according section 275 subsection 2 hgb1 k 2014 2013 1 sale revenue 4285 2921 2 operating income 1726 333 6011 3254 3 employee benefit expense 3746 2992 4 depreciation amortization 262 240 5 operating expense 8663 4263 6 income investment 16013 11222 7 profit received profit loss transfer agreement 9604 8306 8 loss accepted profit loss transfer agreement 0 1474 12946 10559 9 earnings interest tax 18957 13813 10 interest similar income 507 471 11 interest similar expense 9933 6454 9426 5983 12 profit tax 9531 7830 13 income tax expense 837 4351 14 tax 24 31 813 4382 15 net profit period 10344 3448 16 profit brought forward 129027 142797 17 retained profit incl net profit period 139371 146245 1 hgb german commercial code 54 group management report annual financial statement sartorius ag note based hgb balance sheet sartorius ag according hgb1 k asset dec 31 2014 dec 31 2013 fixed asset property plant equipment 14527 7161 ii financial asset 468510 468253 483037 475414 b current asset trade receivables 206120 35493 ii cash hand deposit bank 689 296 206809 35789 c prepaid expense 1905 1109 691751 512312 equity liability dec 31 2014 dec 31 2013 equity subscribed capital 18720 18720 nominal value treasury share 1673 1673 issued capital 17047 17047 ii capital reserve 101453 101397 iii earnings reserve 10867 10867 iv retained profit incl net profit period 139371 146245 268738 275556 b provision 26941 23582 c liability 396072 210252 deferred tax liability 0 2922 691751 512312 1 hgb german commercial code group management report annual financial statement sartorius ag note based hgb 55 proposal appropriation profit risk opportunity executive board submit proposal opportunity risk affecting business annual shareholder meeting appropriate development sartorius ag management retained profit 13937014984 reported holding entity essentially equivalent sartorius ag year ended december 31 2014 sartorius group sartorius ag share risk follows investment subsidiary exposed proportion extent investment expedient feasible adopted countermeasure arranged balance sheet measure payment dividend reporting year cover discernible risk within 106 per ordinary share 903973936 sartorius ag potential damage net payment dividend worth financial position profitability 108 per preference share 920053836 unappropriated profit carried forward 12112987212 detailed opportunity risk report 13937014984 sartorius group provided page 56 62 de scription internal control risk management system page 68 70 research development detailed information research develop report material event ment activity sartorius group division given page 42 et seq 46 et seq please refer page 67 read report material event sartorius ag sartorius group employee forecast report sartorius ag employ staff disclosed pursuant section 285 7 hgb earnings trend sartorius ag depend substantially progress subsidiary hence sartorius group development sartorius group business discussed forecast report page 63 66 56 group management report opportunity risk report opportunity risk report every business activity entail opportunity risk planning medium longerterm opportunity managed skill tracked systematically part strategic planning done go long way determining future devel status opportunity management permanent opment company shareholder value manag fixture corporate management system mean ing risk opportunity sartorius aim identify also feature discussion decision use business opportunity systematically well making process toplevel management recognize evaluate risk early stage executive board supervisory board take measure counter possible unrealistic expect risk management eliminate key area opportunity presented risk rather approach intentionally appropriate reference made relevant section take certain measure risk business activity group management report order avoid order successful unlocking opportunity repetition risk presented section however endeavor important keep risk specific risk represent opportunity event contained within acceptable limit control develop opposite positive direction carefully reason discus opportunity section specific risk opportunity end sartorius single unit tasked identifying chapter managing opportunity risk instead pre fers make function integral component groupwide planning control system described area opportunity internal control system compliance department responsible development supplier pharmaceutical laboratory group risk management system including industry sartorius operates futureoriented organization respective reporting process highgrowth sector significant opportunity generated various market technology trend described detail section entitled managing opportunity sector condition outlook sector page 27 et seq page 63 et seq opportunity management center analysis target market sector environment well assessment rank company one glob assessment trend give strong al market leader many subsegments product indication future business opportunity area believe high quality product identification potential development strong brand recognition established customer context one key role relevant manag relationship give u strong opportunity continue er initially take place local rather extending market leadership corresponding central level marketfacing function division strategy growth opportunity strategic marketing product management initiative based discussed section individual division play leading role respect strategy bioprocess solution division central business development unit additionally begin page 24 section support area market monitoring data strategy lab product service division analysis implementation strategic project start page 25 part strategy review member group strict management process cost provides executive committee regularly meet manag opportunity increase profitability key er operational responsibility business target area respect include continued en development unit discus short medium hancements procurement chain ongoing longterm opportunity potential various busi effort optimize production present ness area subsequent step prioritizing page 68 opportunity evaluating business management perspective deriving strategic measure opportunity discussed context allocating resource proceed accordance presentation specific risk opportunity begin standardized decisionmaking process applies ning page 57 throughout group opportunity short term nature considered annual budget group management report opportunity risk report 57 risk management urgent reporting procedure place ensure new emerging significant risk opportunity management overall responsi net worth financial position profitability bility maintenance effective risk man identified estimated involving 25 million agement system ensuring comprehensive higher executive board sartorius ag receives consistent management material risk rest necessary detail without undue delay executive board coordinating developing system responsibility central internal control system compliance department super risk classification visory board sartorius ag monitor effective ness risk management system first level risk management relates four preparatory work necessary per main risk category defined sartorius external risk formed audit committee furthermore operating risk financial risk corporate govern carrying statutory audit mandate ance risk annual financial statement consolidated financial statement independent auditor examine wheth second level consists additional subcategories er early warning system place capable within main category legal risk pro prompt identification risk could put fu duction risk receivables risk organizational risk ture company jeopardy process also includes allocation functional category example supply chain sale distri risk management system risk reporting bution human resource accordance group structural organization heart risk management system sartorius group risk management handbook categorize risk according scale applies throughout entire group organization implication also perform specific evalua handbook includes definition frame tion risk assigned value work structural organization process risk maximum impact time risk analysis porting monitoring control word record maximum risk without consider effectiveness risk management system based ing probability occurrence effect risk internationally recognized coso standard mitigation measure also number source contain stipulation handling risk including article association rule procedure specific risk opportunity group company internal guideline groupwide risk reporting system form corner general macroeconomic risk stone internal risk communication object opportunity make possible address risk structured con tinuous manner document accordance nature various business area mean relevant statutory regulatory requirement sartorius whole insulated certain extent full force wider cyclical effect prescribed reporting process requires head macroeconomic effect little bearing central department managing director progress bioprocess solution division group company review risk situation within particularly relevant lab product service area responsibility ongoing basis division represent risk latter growth report finding every quarter new organiza context economic development prove tional unit joining consolidated group company positive expected turn additionally successively integrated reporting process stimulate stronger growth lab product service involves evaluating specific risk probability occurrence scale potential impact well ability foresee mitigate direct reporting case central risk management unit indirect effect risk broader sense example whenever defined threshold breached currency crisis natural disaster associated damage commercially significant critical infra structure limited 58 group management report opportunity risk report risk discussed section consider production risk opportunity probability occurrence low medium ing case occurrence significant manufacture large proportion sartorius group whole individual product belong core area technical group company expertise involve high level vertical integra tion example include filter laboratory balance product reusable fermenters bio supply chain risk opportunity reactor manufactured collaboration sup plier production risk supply chain extends way procure transferred external third party manu ment production sale distribution problem facture product also bear associated within sequence consequential effect risk capacity bottleneck overcapacity production including delay delivery global supply chain downtime excessive reject rate high level management system instituted throughout tiedup working capital contain reduce production process prevent problem risk planning production capacity carefully using largely minimizes associated risk analyzing versatile machine semiautomated individual work controlling operation involved strongly station flextime work schedule continu international alignment organization open ously monitoring production process moreover whole series opportunity various risk global manufacturing network enables u compensate opportunity encountered within supply capacity bottleneck shifting production chain explained detail regional plant regard probability occurrence concerning procurement risk opportunity risk described low risk happen occur significant individual group purchase wide range raw material compo company nents part service supplier conse quently exposed risk unexpected delivery consider opportunity various pro bottleneck price increase global supply duction facility able concentrate specific chain management system reduces risk ena production technology result enhance bling u monitor supervise procurement activi production operation greater efficiency tie moreover conduct regular supplier review ternational production network also make possible also use early warning system continued capitalize cost advantage offered indi increase number framework agreement con vidual site furthermore continuous improvement cluded safeguard supply supplier strate production simplifying process increas gically important raw material fiscal 2013 ing level automation help drive efficiency addition always maintain reserve inventory even higher strategic raw material work alternative supplier possible sale distribution risk opportunity present see low probability occurrence risk described risk happen occur use variety channel sell distribute likely limited significance product around world potential risk entailed sartorius group unexpected change demand structure growing price pressure noncompliance supply opportunity arise area procurement agreement concluded customer employ growth enables u increase order quanti targeted market analysis identify emerging demand tie thereby strengthen position trend individual segment early supplier increased globalization supplier pool time respond appropriately technical innova hold prospect purchasing favorable tions focus less pricesensitive sale term moreover also possibility market product validated production expanded purchasing activity international process biopharmaceutical industry reduce market leading u identify supplier special exposure risk growing price pressure product technical expertise could eventually minimized risk exposure area logis enhance competitive edge tic recent year setting using central warehouse optimize distribution logistics group management report opportunity risk report 59 area well probability risk occur quality requirement growing ring low medium according estimate stringent time least result regulato case occurrence significant ry pressure actually regard first fore sartorius group whole individual risk opportunity open group company new market prospect also challenging quality de mands represent considerable barrier entry opportunity arise area sale distribu potential new competitor provide stimulus tion increasing breadth product range technical innovation actively bioprocess lab segment put u respond position sell new product existing customer business relationship estab lished long term global presence rd risk opportunity provide opportunity moreover ongoing project strengthen direct sale especially lab devote considerable share resource segment also promise enhance sale prospect research development potential risk area may arise development result diverge market need exceeding planned development dead quality risk opportunity line unintentional transfer knowhow com petitors advanced project management intensive customer use sartorius product wide range rd controlling early involvement custom critical production process including manu er development process substantially limit facture pharmaceutical food chemical rd risk patent continuous tracking research development laboratory main technology competitor relevant u secure risk encountered area noncompliance technology position agreed quality criterion lead loss customer may made liable reason see low probability pre compensation claim employ rigorous quality sent risk described might occur check stateoftheart production method case could significant process cleanroom technology ensure sartorius group whole product satisfy stringent quality requirement manufacturing method pro hand rd sphere also offer num cesses subject constant review con ber potential opportunity intensive collabora tinuous improvement process moreover tion partner rank among global market refined appropriately requirement evolve leader field open opportunity successful completion host annual audit u jointly develop innovative product customer accreditation iso 9001 especially high level innovation area iso 13485 together document high level quality membrane technology well weighing technology achieved sartorius product process irrespec turn expertise specialist put u tive measure also maintain significant forefront global research development insurance coverage product liability risk present u opportunity turn tech sartorius established traceability system nical knowledge potential sale even enables u recall entire production batch imme stronger position market diately necessary minimize adverse conse quences event defect discovered product customer risk opportunity consider probability occurrence sartorius source key customer pharma risk described low case ceutical chemical food industry occurrence significant sartorius group search educational institution public whole individual group company sector customer usually relatively large organization existence time strong credit rating busi ness area highly diversified customer base group whole dependent individual key account significant degree factoring program additionally place keep 60 group management report opportunity risk report risk exposure trade receivables customer acquisition risk opportunity constant low level work continuously improve receivables management nature acquisition provide many opportunity sale growth extension product portfo present see low probability lio development new market contrast risk associated customer might occur purchase sale company part company case occurrence would likely lim entail number inherent risk incorrect ited significance sartorius group whole valuation assumption insufficient usage antici individual group company pated synergy effect prevent risk take various measure particular acquisition process performing standard due diligence competitive risk opportunity review addition involve external consultant expert purchase sale process early sartorius leading competitive position possible especially focus drafting transaction market competitor larger contract adequately counter risk u share status globally operating especially clause assuring specific characteristic company example include emd millipore pall contractual warranty guarantee provision mettlertoledo serve large number cu well agreement mechanism adjustment tomers highly regulated sector like pharma purchase price liability clause immediately ceutical food industry technology acquisition taken place integration barrier market entry substantially high phase initiated potential risk regard risk new competitor emerging low likewise detected early possible prevented furthermore global presence significantly miti minimized taking appropriate counteraction gate regional risk consider probability occurrence change competitive environment example risk described low case consolidation market pose opportu occurrence significant sartorius group nities risk sector find whole individual group company ongoing process change sartorius remains active participant made acquisition continuously recent year reinforce market personnel risk opportunity position open new potential synergy innovative technology group sartorius employ consider probability occurrence large number highly qualified people possible risk described low case scarcity required specialist represents oppor occurrence likely limited significance tunity well risk instance company sartorius group however cannot entirely ruled prof particularly good training retain risk might significant individual ing staff counter threat demo group company graphic change losing employee especially key position offering performance related remuneration model targeted continuing professional development option attractive social benefit continuous education training junior staff member within organization interesting people development opportunity success measure apparent low attri tion rate recent year many year sen iority people accumulate average employment contract certain case contain clause prohibiting move direct competitor reason regard probability risk occuring low risk happen occur likely limited importance sartorius group whole group management report opportunity risk report 61 financial risk opportunity anticipated net currency exposure foreign currency level make policy hedge global nature sartorius group operation 70 exposure advance following 18 mean business activity inevitably ex month hedging transaction set one group posed financial risk significant staff monitored another separate group aside risk associated group accounting exchange rate risk interest rate risk liquidity risk described addressed interest rate risk opportunity detail note consolidated financial statement vice versa financial risk concluded fixed interest agreement notably exchange rate risk interest rate risk portion outstanding loan eliminate risk balanced opportunity approximately equal posed variable interest payment however magnitude financial instrument outstanding reporting date subject interest based market rate consider probability occurrence almost twothirds currently covered risk described following low risk happen interest rate swap interest rate risk opportu occur significant sartorius group nities apply remainder monitor interest whole individual group company rate trend interest rate exposure constantly facility arrange additional hedging transaction consider necessary eco risk associated group accounting nomically advisable individual loan except general typical risk inherent accounting process specific risk concerning group liquidity risk opportunity accounting discernible typical accounting error connection example incorrect discre sartorius group actively manages liquidity central tionary decision measurement asset ly order check minimize liquidity risk liability use various common standardized optimize liquidity management within organization control mechanism integrated accounting use various long shortterm financial instru process ensures error recognized ments purpose corrected early stage syndicated credit facility place far sartorius ag sartorius stedim biotech subgroup exchange rate risk opportunity refinanced ahead schedule december 2014 based highly attractive market condition pre generate around half consolidated sale reve vailing time financing structure nue foreign currency twothirds total converted holding company group revenue u dollar currency pegged wide financing sartorius ag subsidiary financed u dollar positively negatively impacted primarily financing contract within group currency effect especially converting cur rencies balance sheet item profit loss item shortterm liquidity procurement also employ respectively largely compensate general risk various measure addition credit line resulting impact individual foreign curren accessed repaid short notice cies taken number measure besides number bilateral credit line place smaller hedging currency global production network scale individual group company furthermore thus enables u offset lion share sale reve use cash pooling agreement selected group nues received foreign currency within group company primary tool manage liquidity cost likewise incurred foreign currency within group example manufacture many product north american market locally therefore disadvantaged way competition regulatory risk u rival continuously monitor exchange rate net currency exposure ie propor role supplier biopharmaceutical indus tion foreign currency sale revenue try health care provider mean sartorius main settled cost use also affected underlying development derivative financial instrument notably spot area possibility regulatory authority fda forward swap transaction basis current emea adopting restrictive approach 62 group management report opportunity risk report approval new medication remains principal opportunity especially relation efficiency gain source risk context move would standardization harmonization business reduce number new pharmaceutical product process worldwide marketed would consequently downgrade future prospect sartorius medium term believe low probability occurrence risk mentioned case occurrence significant sartorius group environmental risk whole sartorius established environmental manage ment system encompasses integrated process risk division cover whole series environmen tally relevant regulation minimize environmental legal dispute proceeding could risk management system certified substantial negative impact group result compliance iso 14001 company relatively allowance made balance sheet large manufacturing site respective company cover cost potential proceeding organizational unit ensure particular site law regulation relating environmental protection observed technical insurance possibility limiting environmental risk identi fied ongoing basis taken insurance policy cover wide range risk possible economically advisa assess probability occurrence environ ble insurance policy include coverage mental risk low case occur liability business interruption transport material rence significant group company pecuniary damage risk provide com affected prehensive coverage legal cost independent department working conjunction external insurance broker regularly review nature risk opportunity extent insurance protection make adjustment necessary besides risk already described sartorius group exposed potential risk area sult pronounced dependence system assessment overall risk situation risk since errorfree operation essential outlook smooth functioning company business pro cesses reduce security risk continuously expedient feasible adopted countermeas enhancing implementing security guideline ures arranged balance sheet measure policy rule measure based reporting year cover discernible risk within requirement iso 27001 standard sartorius group potential damage german federal office information security bsi net worth financial situation profitability standard furthermore company existing application system checked potential judge probability occurrence risk risk regular external internal audit presented low case appropriate measure taken minimize risk occurrence significant sartorius group identified continuous alignment strategy whole individual group company business strategy tracking new technical development use advanced hardware thorough analysis entire risk situation software minimize risk inherent operation according current review discernible system environment new erp system risk present could jeopardize continued commissioned sartorius goettingen group existence group headquarters 2012 successively rolled group site around world starting 2014 similarly based current review conducting project continued focus discernible risk could jeopardize future controlling risk involved maintain existence group ing precautionary backup system implementa tion new system brings whole series group management report forecast report 63 forecast report future macroeconomic environment japan expect another year moderate expansion economic output 2015 according imf based forecast provided imf global indicates growth rate 08 2014 09 economy gain momentum 2015 growth forecast 38 33 2014 based large part anticipated economic progress u future exchange interest rate trend positive outlook imf caution subject though high level risk least connection expert assessment suggest 2015 another year geopolitical tension low base rate additional measure provision liquidity bond repurchase pro gram euro zone example also forecasted gdp growth rate 2014 mooted 38 38 13 13 31 31 08 08 66 66 forecast eurous dollar exchange rate 8 course 2015 range 110 euro u dollar 135 euro u dollar 6 source international monetary fund world economic outlook october 2014 reuters forex poll november 2014 4 2 outlook sector 0 global euro area u japan asia1 strong growth prospect pharmaceutical 1 asia china india asean5 indonesia malaysia philippine industry thailand vietnam future global pharmaceutical industry source international monetary fund driven large part constantly expanding aging global population increasing access imf expects rate economic growth healthcare emerging developing country u pick strongly 22 2014 general increase prevalence lifestyle 31 2015 fueled continued expansionary chronic disease new medication especially monetary policy ongoing recovery u targeting condition currently difficult real estate market treat also fuel significant growth expiry patent austerity measure cut healthcare euro zone expected register minor gain spending particular industrialized country economist predicting moderate growth 13 hand tend slow future growth 2015 2014 08 imf predicts even industry expansionary monetary policy adopted euro zone slight positive impact ger market researcher ims health forecasting many expected see growth 15 2014 14 overall growth 4 7 global economic activity france forecast pick pharmaceutical industry period 2014 2018 increase 10 compared 2014 04 italy saw economic output contract 02 expected register growth 08 2015 imf forecast asia region suggests 66 growth 2015 compared 65 prior year helped part development china economy expected expand 71 2014 74 growth economy india forecast increase 56 64 64 group management report forecast report u pharmaceutical market expected emerging country still driving growth post solid growth expansion pharmerging market contrast u pharmaceutical market world largest remain average around 8 11 per expected register growth 5 8 annum 2014 2018 period rapid growth average period 2014 2018 driven demographic trend expansion driven principally continuous also notably rising level state investment rollout state health insurance demographic change healthcare system increased private spending price increase especially among fastexpanding middle class thus share global pharmaceutical market accounted pharmerging market likely moderate growth europe japan increase next five year approxi mately 30 growth european japanese pharmaceutical market likely remain moderate 1 4 next year continuing austerity measure impact respective healthcare system pronounced longterm trend deliver better average growth biopharmaceutical industry global trend pharma market sector trend q aging population q average growth1 4 7 q patent expiry western country q increasing cost pressure eg q increasing population due healthcare reform improved access health care biopharma market developing economy q growing number chronic q average growth1 6 8 trend toward biotech civilization disease q continued market penetration approved indication technology trend singleuse technology q label expansion q higher yield efﬁciencies q doubledigit growth q personalized medicine cell cultivation q highest growth innovative q biosimilars q availability innovative segment eg bioreactors singleuse technology ﬂuid management q strong pipeline eg mabs q higher ﬂexibility change manufacturing system multipurpose 1 source ims global use medicine outlook 2017 2018 evaluate pharma world preview 2014 outlook 2020 june 2014 bioplan 10 th annual report april 2013 biotech sector still growing faster medication vaccine manufactured using biotech market whole method expected rise today figure around 22 23 approximately 26 peri expert forecast suggest biopharma segment od 2018 pharmaceutical market enjoying particularly strong growth year continue continued exceptional growth driven outperform market whole going forward part biopharmaceuticals already gained proportion sale revenue accounted approval increasing market penetration group management report forecast report 65 expanding range indication part whole series patent ims health report segment persistently strong research develop sale come known biosimilars ment pipeline proportion new development biobetters likely swell based biological manufacturing process partic u 10 billion 2020 ularly high around 40 expert expect biotechnology market whole expiry patent significant factor tradi grow around 6 8 average 2014 tional market likely increasing effect 2018 growth biotechnology market noting expiry biopharma growth market proportion global pharmaceutical sale revenue rx otc area biotechnology conventional production technology compared biotech share within top 100 product 21 45 52 2006 2013 20201 568bn 754bn 1065bn biotechnology conventional unclassified 1 2020 split biotech n45 avg 36bn conv n55 avg 27bn source evaluate pharma world preview 2014 outlook 2020 june 2014 publicsector research demand stabilizes slight growth chemical industry ongoing widespread reduction national budget european chemical industry council cefic ex likely affect overall level demand pects chemical industry europe expand public sector 2015 however according 15 2015 following moderate 20 increase frost sullivan important u market likely production 2014 slightly lower growth stabilize current year thus global demand attributed tailingoff inventorybuilding activity public sector may broadly flat 2015 source ims global use medicine outlook 2017 2018 ims searching terra firma biosimilars nonoriginal biologics market evaluate pharma preview 2013 2014 june 2013 2014 bioplan 10th annual report april 2013 2014 midyear report forecast analysis global market laboratory product cefic chemical industry benefit general economic recovery june 2014 66 group management report forecast report outlook 2015 sartorius division outlook 2015 incorporates potential op bioprocess solution division forecast portunities risk outlined annual report sale revenue full year 2015 rise signifi following forecast provided assump cantly assuming trend toward biomanufac tion economic activity relevant sector turing pharmaceutical increasing utilization trend develop described singleuse technology continue see page 64 et seq accordingly project sale revenue increase 5 8 relative strong com sartorius group parative base prior year also plan crease division underlying ebitda margin management expects sartorius group around 245 figure constant currency achieve significantly profitable growth year 2015 well thus anticipate fullyear sale lab product service division serf sector grow 4 7 group underlying ebitda whose dependency economic cycle varies therefore margin increase around 215 figure division partly depends general develop constant currency ment economy due strained public budget geopolitical risk outlook europe sur moreover 2015 planning invest around rounded exceptionally high level uncertainty 10 sale revenue investment include lab product service division expect multiyear project consolidate extend sale increase approximately 2 5 group headquarters goettingen well expand whole assuming economic momentum pick production capacity continue international slightly see page 63 view profitability rollout new erp system striving achieve underlying ebitda margin around 155 figure constant currency regard financial position forecast end 2015 ratio net debt underlying ebitda remain level 2014 year end provided target mentioned earlier achieved proceeds sale industrial technology help contribute decrease without possible change product portfolio considered group management report report material event 67 report material event sale industrial technology divsion japanese minebea co ltd partner development bank japan inc completed february 6 2015 become economically effec tive january 1 2015 cash proceeds resulting transaction total approximately 90 million 68 group management report description key feature internal control risk management system description key feature internal control risk management system relation group accounting process sec statement group bookkeeping external tion 289 subsection 5 section 315 subsection 2 reporting includes operational risk manage 5 german commercial code hgb ment involves activity transfer risk insurance company coverage damage liability risk arrangement definition element internal control suitable hedge limit currency interest rate risk risk management system sartorius group monitoring system operated sartorius group early groupwide detection risk internal control system sartorius ag potential jeopardize company continued exist sartorius group encompasses principle ence defined section 91 subsection 2 procedure measure adopted ensure organi german stock corporation law aktg efficacy zational implementation management decision early risk detection system sartorius main priority system relates sartorius ag group adapts promptly response relevant group accounting process make sure change circumstance assessed independ accounting effective costefficient formally ent group auditor accordance section 317 correct complies pertinent legal subsection 4 german commercial code hgb provision regular system review also carried verify system remains functional effective internal control system sartorius ag sartorius group consists combination pro cessintegrated nonprocessintegrated monitor use system ing measure processintegrated safeguarding measure subdivided turn organizational transaction relevance accounting measure four eye principle double recorded individual financial statement verification access restriction relation subsidiary sartorius ag using software system control measure manual target actual used worldwide process preparing check programmed plausibility check consolidated financial statement sartorius ag software used supervisory board case group company add supplementary information specifically audit committee sartorius ag individual financial statement create stand internal control system compliance unit ardized reporting package submitted group auditing department involved group company consolidated reporting sartorius group internal control system system sartorius ag consolidated financial state nonprocessintegrated audit activity ments prepared using consolidation rou tine consolidated reporting system independent group auditor auditing developed sartorius ag authority also play role control environment supplemented manual adaptation inhouse sartorius group nonprocess auditor independent group auditor sarto integrated audit activity particular review rius ag regularly verify reporting package consolidated financial statement inde submitted consolidated reporting system concur pendent group auditor audit indivi individual company financial statement dual financial statement sartorius group audit based case consol company included consolidated financial idation procedure necessary prepare consolidat statement constitute key nonprocessintegrated ed financial statement sartorius ag monitoring measure relation group consolidation investment elimination inter accounting process company payable receivables elimination intercompany revenue expense performed finance unit represents another important element using documented consolidated reporting internal control system analysis system component sartorius ag consolidated monthly report subsidiary financial statement including detail presented note developed using consolidated risk management system concentrate con reporting system also provides wide range text group accounting primarily risk mi analysis option group management report description key feature internal control risk management system 69 key supervision control activity ensure sartorius group accounting rule also govern proper reliable group accounting specific formal requirement placed consolidated financial statement include mandatory use internal control system measure designed standardized complete reporting package maintain proper reliable group accounting ensure group accounting department assist local unit transaction recorded full timely resolving complex accounting issue measur manner accordance applicable provision ing fair value ensure consistent accurate law article association addition porting consolidated financial statement measure ensure inventory taken properly asset liability recognized scope regulation group level also extends assessed reported appropriately consolidated central definition measurement rule para financial statement meter among factor additional data presentation external information note employee involved accounting process group management report also prepared aggre meet qualitative standard receive regular training gated group level duty responsibility clearly assigned dif ferent specialized unit company regional unit specific control activity performed ensure segregation duty foureyes principle proper reliable group accounting encompass ie review two individual strictly imple analysis applicable correction indi mented complex evaluation actuarial report vidual financial statement submitted sartorius company valuation purchase price allocation group company line report authored assigned specialized service provider involve independent auditor reporting package contain specially qualified inhouse staff ing error identified corrected group level basis large number control mechanism example control activity performed ensure already incorporated consolidated reporting proper reliable accounting include analysis system impairment test conducted centrally situation development reference specific specific cashgenerating unit known cgus key indicator separation administrative ex group perspective ensure consistent ecutive settlement approval function reduces standardized evaluation criterion applied possibility fraud organizational measure also intended record company groupwide manual company internal control system restructuring step change nature focusing company business process operation individual business area promptly drafted involving group financial auditor accurately group accounting finally internal contribute toward strengthening control system also ensures change ternal control ic system based current rule sartorius group economic legal environment manual combine icsrelevant requirement mapped new amended legal provision business process define one stand applied group accounting ardized document first time supple mented appropriate control necessary sartorius group accounting principle govern standard recognition measurement principle german nongerman company included qualifying statement sartorius consolidated financial statement addition general recognition principle internal control risk management system method rule applied statement finan enables complete recording processing evalu cial position statement profit loss note group ation companyrelated matter basis management report statement cash flow organizational control monitoring structure segment report established compli defined sartorius group well ance eu legislation primarily accurate presentation group accounting ifrs german commercial law 70 group management report description key feature internal control risk management system particular decision based personal judgment erro neous control criminal act circumstance impair efficacy reliability ternal control risk management system place cannot ruled however even application throughout group system adopted cannot provide absolute assurance accurate complete timely recording matter group accounting statement made relate solely subsidiary included consolidated financial statement sartorius ag whose financial business policy sartorius ag directly indirectly determine order obtain benefit activity group management report explanatory report executive board 71 explanatory report executive board disclosure pursuant section 289 subsec according mandatory announcement dated april 1 tions 4 section 315 subsection 4 german 2011 biorad laboratory inc 1000 alfred nobel drive commercial code hgb hercules california 94547 usa voting right biorad laboratory gmbh heidemannstr 164 composition issued capital limitation 80939 munich germany ascribed according sec voting right tion 22 subsection 1 sentence 1 1 german security trading act wphg hold 3001 2809299 sartorius ag capital stock total 18720000 vote voting right sartorius ag comprises 18720000 par value individual bearer share 9360000 ordinary share appointment dismissal executive board 9360000 nonvoting preference share member amendment article share certificate represents calculated proportion association 1 issued capital executive board member sartorius ag nomi right obligation associated share nated appointed well dismissed ac governed provision german stock cordance section 84 et seq german stock corporation law aktiengesetz abbreviated aktg corporation law aktg section 31 33 according company article association german codetermination law mitbestimmungsgesetz preference share entitled dividend payment abbreviated mitbestg amendment sartorius ag higher dividend payment ordinary article association regulated section 133 share amount equal 2 preference 179 german stock corporation law aktg share calculated proportion issued capital ie two euro cent per share case dividend power executive board issue share entitlement shall least 4 preference share calculated proportion issued capital ie subject approval supervisory board four euro cent per share apart case pro executive board authorized sell treasury share vided section 140 141 german stock held corporation including selling corporation law aktg preference share non channel stock exchange voting however grant right tendering offer shareholder proportion every shareholder entitled participation company provided share offered within scope acquiring com company hold 831944 ordinary share panies shareholding company return 840983 preference share entitle circumstance preemptive right company membership right shareholder excluded direct indirect equity ownership exceeding material agreement clause regulating 100 voting right event change control community heir consisting mr u baro sartorius ag two material agreement containing resident munich germany mr c franken resident clause regulating possible event change bovenden germany mr franken resident control one syndicated loan agreement concluded riemerling germany mr kc franken resident 2014 current volume 400 million goettingen germany mr k sartoriusherbst term december 2019 note resident northeim germany hold voting per loan schuldscheindarlehen placed 2012 centage approximately 501 sartorius ag volume 100 million maturity term five 4688540 vote according list attendee ten year respective clause customary annual shareholder meeting april 10 2014 market give participating lender op decedent horst sartorius ordered tion extraordinary termination event executed appointed executor prof change control dr dres hc arnold picot resident gauting germany exercise specified voting right circumstance beyond disclosure made pursuant discretion defined section 22 subsection 1 289 subsection 4 315 subsection 4 sentence 1 6 german security trading hgb exist known act wertpapierhandelsgesetz abbreviated wphg 72 group management report corporate governance report corporate governance report executive supervisory body sartorius ag remark concerning corporate governance guided action principle trans parent responsible corporate governance reporting year executive board executive board supervisory board report supervisory board dealt issue raised corporate governance pursuant article 310 revised version german corporate governance german corporate governance code code dated june 24 2014 change code essentially referred model table management board member remuneration declaration executive board implemented full extent furthermore su supervisory board sartorius ag concerning pervisory board reviewed whether compensation recommendation government executive board member appropriate commission german corporate taking account level compensation governance code pursuant 161 paid peer company compensation place german stock corporation law aktiengesetz within area company supervisory board determined executive board member executive board supervisory board declare remuneration appropriate full compliance achieved recommen dations made government commission target composition supervisory german corporate governance code published board defined 2010 continue apply german federal ministry justice official section electronic german federal gazette elektronischer woman make less 25 bundesanzeiger amended june 24 2014 supervisory board since last year declaration compliance issued independent member shall account less sartorius ag complied recommendation 25 supervisory board valid version government commission german corporate governance code full extent aim selecting candidate international experience international background goettingen december 16 2014 considered previously making appoint ments supervisory board supervisory board executive board upper age limit 70 time election taken consideration may waived exceptional case provided reservation suitability person pro posed election expedient interest company spite age limit prof dr dres hc dr joachim kreuzburg exceeded arnold picot company already meet target target proportion woman supervisory board somewhat higher proportion woman management position within sartorius group corporate governance statement accordance section 289a german commercial code hgb following present detail concerning mode operation executive board supervisory board governance measure employed company accordance section 289a german commercial code hgb group management report corporate governance report 73 mode operation executive board interest aim creating sustainable value supervisory board executive board provides supervisory board regular prompt detailed report writ sartorius ag company german law founded ten oral relevant corporate planning dual management system executive strategic development issue progress board supervisory board group business significant transaction dis independent competency cussed depth full supervisory board ac cordance rule procedure executive supervisory board comprises twelve member board rule procedure executive board defined german codetermination law mitbe additionally define legal transaction may stimmungsgesetz equal number share effected without approval supervisory holder representative employee representative board executive board supervisory board supervisory board monitor advises execu work closely together spirit mutual trust tive board management company detail management supervision company member supervisory board provided chapter executive board supervisory board page 154157 shareholder shareholder meeting supervisory board established four committee sartorius ag shareholder exercise right executive task committee audit committee company shareholder meeting shareholder conciliation committee nomination meeting held least year within first committee executive task committee audit eight month fiscal year shareholder committee conciliation committee four meeting decides matter member equal number shareholder responsible law representative employee representative executive task committee audit committee hold shareholder register due time may attend regular meeting conciliation committee shareholder meeting shareholder una nomination committee meet necessary ble participate shareholder meeting person may arrange vote cast bank executive task committee carry preparatory shareholder union proxy ap work resolution issue addressed pointed sartorius ag bound follow meeting supervisory board also look instruction issued different proxy preparation appointment including choice muneration employment contract condition member executive board audit committee assist supervisory board performance risk management supervisory function chairperson audit committee independent member supervi conscientious management commercial risk key sory board detailed knowledge extensive principle good corporate governance sartorius ag experience application accounting standard group disposal enterprisewide internal control system pro companyspecific reporting control system fessional practice conciliation committee meet designed facilitate recording assessment majority required connection appoint management commercial risk system ment member body authorized repre developed adapted continuously condition sent company legal purpose reached evolve executive board notifies supervisory nomination committee comprises representative board regularly existing risk development shareholder function propose audit committee concerned particular suitable candidate supervisory board monitoring following accounting process latter election proposal submitted annual including reporting efficacy internal con shareholder meeting information trol system risk management internal auditing individual meeting held reporting year system compliance independent statutory supervisory board committee given audit detail risk management presented report supervisory board page 1214 risk opportunity report executive board sartorius ag currently consists three member board full responsibility action managing company latter 74 group management report corporate governance report transparency statement prepared executive board au dited independent auditor elected sartorius ag place great importance disclosing annual shareholder meeting approved consistent complete information promptly infor supervisory board mation economic position group new development consequently released regularly agreed independent auditor without delay becomes known order inform notify supervisory board directly participant capital market interested potential disqualification bias issue mate member public large annual report rial finding incident identified audit firsthalf financial report quarterly report also encompasses corporate governance published within timeframes specified porting duty pursuant section 161 german purpose current development material event stock corporation law aktiengesetz publicized press release appropriate ad hoc announcement information usually made available german english simultaneously code conduct published via suitable medium internet central corporate culture sartorius ag chief recurring event publication understanding always conduct business annual shareholder meeting annual report sustainable manner compatible pertinent interim report listed financial cal economic environmental social imperative endar may viewed time group uniform code conduct applies across entire website group order ensure action con sistent throughout organization code conduct applies equally group share trading activity supervisory people whether member executive executive board member board managing director manager employee establishes defined standard formulated help user receive report applicable successfully navigate ethical legal challenge mandatory disclosure requirement purchase everyday operation interest employ sale share sartorius ag related financial ee company breach code instrument made member executive conduct investigated internal con board supervisory board person trol system compliance department established management responsibility related party purpose cause eliminated supervisory board chairman prof dr dres hc arnold information given sustainability picot hold approximately 501 ordinary report pp 86 et seq company internet share issued company capacity execu website wwwsartoriuscom tor estate horst sartorius otherwise member executive board supervisory board holding share financial instrument subject mandatory reporting requirement supervisory board executive board directly indirectly exceeds 1 share issued company accounting independent statutory audit consolidated financial statement consolidat ed interim financial statement prepared ac cordance international financial reporting standard ifrs applied within eu annual financial statement sartorius ag prepared accordance german commercial law german commercial code hgb con solidated financial statement annual financial group management report remuneration report 75 remuneration report 1 main feature remuneration plan consolidated net profit hand executive board multiyear component depend value monetary sum ascribed executive board mem ber beginning year general fixed remuneration full supervisory board responsible establish consolidated net profit ing remuneration paid member execu tive board sartorius ag total value subordinate target basis assessment remuneration executive board member reflects consolidated net profit noncontrolling scope responsibility executive board terest excluding amortization impairment value member concerned executive board member intangible asset due business combination personal performance company economic situa pursuant ifrs 3 target achievement assessing tion sustainable progress addition extent annual variable remuneration particular year amount remuneration typical review based average taken considered taking account peer company period three fiscal year beginning partic remuneration structure place area ular year review smooth amount company similar company remuneration paid partial payment amounting 50 comprised fixed variable component target achievement first fiscal year reviewed annually ensure remains respective average period effected appropriate variable remuneration component payment result partial payment paid addition fixed base salary represent offset remuneration component fixed approximately half total remuneration exclud variable total target achievement ing pension commitment fringe benefit determined third fiscal year average case 100 target achievement period cap component provided well variable remuneration phantom stock plan variable portion remuneration contains issue shadow share called phantom component paid annually deter stock executive board member treated mined multiyear performance assessment owner certain number share sartori category component making one u ag without however entitled receive half target achievement possible dividend development value phan tom stock linked development sarto annually paid variable remuneration rius share increase decrease share price taken account later value portion variable remuneration paid phantom stock assessed based share price annually based following weighted compo time equivalent paid provided nents sale revenue order intake underlying ebitda associated condition met phantom stock ratio net debt ebitda minimum target cannot traded entail share sub achievement required component scription right amount paid depends degree target achieved supervisory according sartorius phantom stock plan board defines setting individual subordinate executive board member credited beginning target cap provided variable component every year phantom stock unit valued paid agreed monetary sum value phantom stock paid entire annual tranche b variable remuneration based multiyear assessment payment requested earliest period four year later eight year one hand weighted component determined multiyear assessment depend degree executive board member entitled receive target achieved supervisory board payment phantom stock unit share defines setting subordinate target constituted price time payment request appre 76 group management report remuneration report ciated least 75 per year relative time old age invalidity well form phantom stock assigned share price survivor benefit surviving spouse child performed tecdax comparative index decedent phantom stock plan rule subsequent change parameter used comparative stock valuation member turned 65 shall considered amount paid capped maximum 25 regular age limit member shall auto time share price time phantom stock matically entitled receive benefit assigned based case actual annual tranche concerned remuneration component assignment phantom stock payment monetary equivalent depend mean value cal remuneration system provides supervisory culated average price class board sartorius ag discretion may grant sartorius ag share closing auction xetra executive board member special compensation based trading frankfurt stock exchange last member exceptional performance 20 day trading previous year last 20 day trading prior submission payment request serf compensate shortterm early termination executive board duty fluctuation share price event early termination executive payment phantom stock blocked four board duty employment contract executive week preceding scheduled publication date board member provide severance capped quarterly preliminary yearend result 20 maximum two annual salary day trading stock exchange following actual publication quarterly preliminary year end result blackout period intended fringe benefit prevent executive board member profiting insider knowledge beyond remuneration component stated member executive board entitled use company car reclaim expense incurred pension commitment business travel covered accident insur ance insurance fringe benefit according company remuneration policy insurance provides application deductible executive board member sartorius ag receive excess amount required law performancerelated benefit commitment defined benefit plan reappointed first time addition including basic pension sharebased payment commitment provide executive board member make contribution variable earn rule remuneration policy executive board ings company match contribution member provide transfer sartorius bonus amount executive board member may ag share compensation member exception choose receive defined benefit form policy rule made december 2014 dr retirement pension old age onetime kreuzburg granted entitlement receive payment cover member retirement pension sharebased remuneration due third extension old age invalidity well form survi appointment member executive vors benefit surviving spouse child board chairman ceo please refer decedent section 2 chapter beyond commitment executive board member additionally entitled former company pen sion scheme receive performancebased retirement benefit based salary german federal civil servant classified grade 10 salary class b ministry official according federal civil service remuneration act bundesbesoldungsgesetz benefit paid form retirement pension group management report remuneration report 77 2 remuneration executive board subject holding period end member reporting year november 10 2019 dr kreuzburg leave company prior november 11 2017 2014 total remuneration active service request entitlement granted said share provided executive board member totaled transfer shall lapse entirety dr kreuzburg 7767 k relative 2501 k 2013 aggre leaf company november 11 2017 gate total 1424 k accounted nonperformance november 11 2019 request half related component 2013 1346 k 6343 k entitlement granted said share shall lapse performancerelated component 2013 1155 k share already transferred entitle performancerelated component include ments lapsed shall returned company transfer share agreed december 2014 remuneration component included granted dr kreuzburg actually possible total remuneration fair value grant date grant november 11 2015 earliest share respective fair value derived therefore yet granted furthermore number share granted price part pension commitment executive class share grant date amount board member pension service cost totaling 4950 k considering agreed condition 503 k reporting year expensed following amount resulting december 16 2014 210 k prior year spread employee benefit expense full vesting period plan fiscal 2014 amount according executive board remuneration policy 56 k accordingly recognized employee nonperformancerelated component paid benefit expense resulting grant share year granted variable remuneration com ponents based annual performance assessment determined consolidated annual financial statement approved therefore accounted paid following year variable remuneration component based multiyear per formance assessment accrue period lasting three least four year thus paid two earliest three year respective reporting year ended minimum target achievement cap provided variable remuneration component third term dr kreuzburg member executive board chairman ceo expire november 10 2015 resolution supervisory board december 16 2014 dr kreuzburg reap pointed member executive board chairman ceo term november 11 2015 november 10 2020 due dr kreuzburgs excel lent performance developing company since start tenure executive board november 11 2002 company wished continue successful cooperation despite alternative offer made new remuneration agreement therefore provides 25000 ordinary share 25000 preference share company shall transferred supplementary compensation component dr kreuzburg sharebased payment subject rule ifrs 2 deemed granted upon resolution approved supervisory board december 16 2014 follow ing basic structure agreed upon transfer share granted shall effected time determined dr kreuzburg earlier november 11 2015 however share granted shall 78 group management report remuneration report total remuneration executive board pursuant 314 subsec 1 6 german commercial code hgb executive board total dr joachim kreuzburg jörg pfirrmann reinhard vogt k 2014 2013 2014 2013 2014 2013 2014 2013 fixed remuneration 1375 1298 675 635 290 275 410 388 fringe benefits1 49 48 18 19 15 13 16 16 fixed remuneration 1424 1346 693 654 305 288 426 404 annually paid variable remuneration2 759 548 373 268 160 116 226 164 variable remuneration multiyear component consolidated net profit 3 years3 289 282 141 136 62 62 86 84 phantom stock plan 48 years4 345 325 169 159 73 69 103 97 share granted 4 4950 0 4950 0 0 0 0 0 variable remuneration 6343 1155 5633 563 295 247 415 345 total remuneration 7767 2501 6326 1217 600 535 841 749 1 amount contributed insurance totaling 263 k 2013 235 k included refer executive body company sartorius group allocated individual insurees 2 recognized amount corresponds actual target achievement 3 recognized amount corresponds actual target achievement plan fiscal year ended ie 2014 consolidated net profit 2012 2014 2013 consolidated net profit 20112013 4 fair value grant date share granted dr kreuzburg fiscal 2014 derived number share granted 25000 ordinary share 25000 preference share respective price stock exchange grant date 100 98 resp due sharebased payment arrangement expected dividend included measurement share part remuneration component based consolidated net profit three consecutive fiscal year executive board member receives partial compensation payment 50 respective target achievement first fiscal year review total target achievement deter mined third fiscal year final payment effected deducting particular partial payment already made amount partial payment made total end reporting year shown follows 2014 2013 k k balance jan 1 fiscal year 306 310 partial payment deducted 150 160 partial payment effected 146 156 balance dec 31 fiscal year 302 306 group management report remuneration report 79 3 disclosure sharebased payment 2014 2013 k k employee benefit expense recognized profit executive board total 617 539 loss connection sharebased payment phantom stock unit 561 539 shown follows share granted 56 0 dr joachim kreuzburg 330 260 phantom stock unit 274 260 share granted 56 0 jörg pfirrmann 121 121 phantom stock unit 121 121 share granted 0 0 reinhard vogt 166 158 phantom stock unit 166 158 share granted 0 0 disclosure phantom stock unit fair value granted fair value jan 1 year fair value number end yearend change phantom price particular dec 31 dec 31 paid value stock unit assignment year 2013 2014 fiscal 2014 fiscal 2014 status k k k k k dr joachim kreuzburg paid tranche 2010 8715 1578 138 344 0 344 0 2014 tranche 2011 5165 2662 138 333 344 0 11 exercisable tranche 2012 4416 3312 146 344 365 0 21 exercisable tranche 2013 2289 6936 159 175 224 0 49 exercisable sum tranche previous year 20585 581 1196 933 344 81 tranche 2014 2008 8403 169 0 193 0 24 exercisable total sum tranche 22593 750 1196 1126 344 105 jörg pfirrmann paid tranche 2010 3334 1578 53 132 0 132 0 2014 tranche 2011 2348 2662 63 152 156 0 4 exercisable tranche 2012 1937 3312 64 147 160 0 13 exercisable tranche 2013 990 6936 69 76 97 0 21 exercisable sum tranche previous year 8609 249 507 413 132 38 tranche 2014 863 8403 73 0 83 0 10 exercisable total sum tranche 9472 322 507 496 132 48 reinhard vogt paid tranche 2010 4754 1578 75 187 0 187 0 2014 tranche 2011 3193 2662 85 206 212 0 6 exercisable tranche 2012 2699 3312 90 210 223 0 13 exercisable tranche 2013 1397 6936 97 107 137 0 30 exercisable sum tranche previous year 12043 347 710 572 187 49 tranche 2014 1220 8403 103 0 117 0 14 exercisable total sum tranche 13263 450 710 689 187 63 80 group management report remuneration report 4 pension commitment retirement plan executive board member furthermore earlier pension agreement granted provides old age disability pension dr kreuzburg provides receive monthly dr kreuzburg old age pension pension 70 basic salary german federal messrs pfirrmann vogt cover pension civil servant classified grade 10 salary class b benefit contribution amounting one percent ministry official according federal civil service pensionable income pensionable remuneration act bundesbesoldungsgesetz bonus paid reinsurance policy benefit respective version applicable full year contribution dr kreuzburg 10 service 5 full pension vested messrs pfirrmann vogt 14 respective full pension reached 20 year pensionable income equal fixed remuner arrangement pension surviving dependent ation executive board member elect convert basically provide widow pension 60 portion salary accrued retirement benefit orphan pension child amounting 20 paying contribution reinsurance pension policy sartorius match paying correspond ing additional benefit contribution reporting projected pension payment present value date amount matched company 5 pension obligation past service cost shown pensionable bonus earned dr kreuzburg 7 following table earned messrs pfirrmann vogt pensionable bonus comprised respective oneyear variable remuneration respective multiyear remuneration based consolidated net profit amount retirement benefit sartorius pay later executive board member surviving dependent dependent turity payment insurance policy accrued maturity date including policyholder bonus earned insurance company executive board member acquire right reinsurance policy sartorius shall solely vested right time projected pension present value obligation ifrs current service cost ifrs payment k pa 31122014 31122013 2014 2013 dr joachim kreuzburg 214 2091 1241 174 166 jörg pfirrmann 82 221 158 53 44 reinhard vogt 20 268 0 276 0 total 316 2580 1399 503 210 group management report remuneration report 81 5 disclosure required german tainable maximum minimum remuneration corporate governance code dcgk variable remuneration component line requirement dcgk lit 425 june 2014 following table show benefit granted year 2014 including fringe benefit dr joachim kreuzburg jörg pfirrmann reinhard vogt benefit granted 2014 2014 2014 2013 2014 2014 2014 2013 2014 2014 2014 2013 k min max min max min max fixed remuneration 675 675 675 635 290 290 290 275 410 410 410 388 fringe benefits1 18 18 18 19 15 15 15 13 16 16 16 16 total 693 693 693 654 305 305 305 288 426 426 426 404 annually paid variable remuneration1 0 405 338 318 0 174 145 138 0 246 205 194 variable remuneration multiyear component consolidated net profit 2014 201420161 0 203 169 0 87 73 0 123 103 consolidated net profit 2013 201320151 159 69 97 phantom stock plan 2014 holding period 201420172 0 422 169 0 181 73 0 256 103 phantom stock plan 2013 holding period 201320162 159 69 97 share granted2 0 4950 4950 0 0 0 0 0 0 0 0 0 total 693 6673 6318 1289 305 747 595 563 426 1051 836 792 postemployment benefit 174 174 174 166 53 53 53 44 276 276 276 0 total remuneration 867 6847 6492 1455 358 800 648 607 702 1327 1112 792 1 recognized amount 100 target achievement 2 fair value grant date inflow various remuneration component reporting year shown following table dr joachim kreuzburg jörg pfirrmann reinhard vogt benefit received 2014 2013 2014 2013 2014 2013 k fixed remuneration 675 635 290 275 410 388 fringe benefits1 18 19 15 13 16 16 total 693 654 305 288 426 404 annually paid variable remuneration1 373 268 160 116 226 164 variable remuneration multiyear component consolidated net profit 2014 201420161 141 62 86 consolidated net profit 2013 201320151 136 62 84 phantom stock plan 2014 holding period 201420172 344 132 187 phantom stock plan 2013 holding period 201320162 249 0 0 share granted2 0 0 0 0 0 0 total 1551 1307 659 466 925 652 postemployment benefit 174 166 53 44 276 0 total remuneration 1725 1473 712 510 1201 652 1 amount equal actual target achievement 2 paid transferred fiscal year 82 group management report remuneration report 6 main feature remuneration plan 2014 2013 supervisory board k k prof dr dres hc arnold picot remuneration supervisory board member defined chairman article association sartorius ag comprises total remuneration 265 262 fixed remuneration meeting attendance fee reim fixed remuneration 120 120 bursement outofpocket expense member serving compensation committee work 24 24 chairperson vice chairperson supervisory board meeting attendance fee 29 14 receive higher fixed remuneration remuneration sartorius weighing technology gmbh goettingen 0 13 total remuneration sartorius member chairperson supervisory board commit stedim biotech subgroup 92 91 tee entitled receive additional annual fixed remuneration sartorius stedim amount meeting attendance fee reim biotech gmbh goettingen 38 38 bursement outofpocket expense amount remuneration sartorius stedim apply relation nomination committee biotech sa aubagne 54 53 committee pursuant section 27 subsection 3 german codetermination law mitbestg 2014 2013 k k 7 remuneration dr dirk basting supervisory board member total remuneration 46 46 fixed remuneration 40 40 2014 2013 meeting attendance fee 6 6 k k remuneration supervisory board member 2014 2013 total remuneration 926 888 k k fixed remuneration 600 600 annette becker1 compensation committee work 80 80 total remuneration 46 46 meeting attendance fee 154 104 fixed remuneration 40 40 remuneration sartorius weighing technology gmbh goettingen 0 13 meeting attendance fee 6 6 total remuneration sartorius stedim biotech subgroup 92 91 remuneration sartorius stedim 2014 2013 biotech gmbh goettingen 38 38 k k remuneration sartorius stedim biotech sa aubagne 54 53 uwe bretthauer1 total remuneration 82 70 fixed remuneration 40 40 compensation committee work 16 16 meeting attendance fee 26 14 2014 2013 k k michael dohrmann1 total remuneration 46 46 fixed remuneration 40 40 meeting attendance fee 6 6 group management report remuneration report 83 2014 2013 2014 2013 k k k k dr lothar kappich manfred zaffke1 march 1 2014 total remuneration 46 46 vice chairman fixed remuneration 40 40 total remuneration 103 0 meeting attendance fee 6 6 fixed remuneration 67 0 compensation committee work 13 0 meeting attendance fee 23 0 2014 2013 k k petra kirchhoff 2014 2013 k k total remuneration 46 46 fixed remuneration 40 40 gerduwe boguslawski1 feb 28 2014 meeting attendance fee 6 6 total remuneration 21 110 fixed remuneration 13 80 performancerelated remuneration 3 16 2014 2013 meeting attendance fee 5 14 k k karoline kleinschmidt1 1 employee representative declared donate total remuneration 45 46 supervisory board remuneration foundation han fixed remuneration 40 40 böckler stiftung according guideline german trade union association meeting attendance fee 5 6 beyond supervisory board remuneration 2014 2013 employee representative employee within k k sartorius group receive compensation prof dr gerd krieger related service supervisory board total remuneration 66 58 fixed remuneration 40 40 compensation committee work 8 8 8 remuneration former managing director meeting attendance fee 18 10 2014 2013 k k 2014 2013 remuneration former managing k k director prof dr thomas scheper remuneration former managing director member executive total remuneration 46 46 board well surviving fixed remuneration 40 40 dependent 405 394 meeting attendance fee 6 6 retirement benefit pension obligation former managing director member executive board well surviving dependent 6768 7065 2014 2013 k k prof dr klaus trützschler total remuneration 68 66 fixed remuneration 40 40 compensation committee work 16 16 meeting attendance fee 12 10 84 group management report remuneration report sustainability report 86 sustainability report sustainability sartorius sustainability sartorius sustainability one core value based sustainable approach important corporate culture sartorius founded primary u comply legal ethical standard manu commercial mission offer attractive product facture product environmentally responsible solution customer entail way consider environmental impact highly innovative achieving maintaining developing product innovation similarly hr strategic operational excellence sus policy aim protect right interest em tainably believe mean taking broadbased ployees actively utilize develop poten longterm view business includes social tial global workforce sartorius help shape ecological consideration take responsibil regional environment around site worldwide ities toward various stakeholder seriously employer customer believe longterm relation deliver benefit party involved sartorius elected make defined relevant performance indicator sustainability responsibility chief executive supplementary financial indicator used officer recognition overarching importance assessing impact commercial activity company economy environment employee society indicator designed great care ensure incorporate far dimension sustainability possible expectation demand important stakeholder customer employee sup plier investor community operate society whole survey employee economic customer regular meeting investor f method use track stakeholder eo success u loyee co e v l p mp view priority l e ntia glo acti l te ian ba po ce able corpo sartorius conduct reporting activity line tain ra u anagement guideline global reporting initiative gri e ensure transparency facilitate ready compari e u c tio n l ctiv p r ti n son sustainability report published annually r ese rc h n y ble ctio n c n r cie part group annual report reporting period l ai g c b ili produ u st fiscal year unless otherwise indicated em ibu ti na l ty n g ec ployeerelated data cover sartorius company f sus including discontinued operation indus oci r oje trial technology data include 31 p n pr al c t f ica l io f e n r l g ovum employee u startup allpure acquired ar ra st f h e e c inn r r u c ius tu duc 2014 environmental indicator encompass sit e r e pro production company unless otherwise indicated coverage rate based total head count amount 765 data gathered internal ly addition data consumption used provided utility company report externally audited sustainability report sustainable corporate management 87 sustainable corporate management compliance legal ethical standard global compact company categorically reject form forced compulsory child labor explicitly activity based corporate value sus expects supplier act integrity tainability openness enjoyment value dealing competitor supplier customer govern interact customer business aim work trusting partnership relevant partner investor every day well employee representative body work together within company time corporate value guide u direction remuneration paid sartorius regular work intend develop company ing hour overtime compensation hour future worked excess contract regular work schedule either meet additional variable remuner sartorius conduct business compliance ation component applies exceeds industry standard legal regulation individual country andor legal minimum wage level vari globally accepted ethical standard action follow able component linked progress principle responsible corporate governance company attainment personal target de control focused sustainable value added fined employee line manager annual cludes compliance legal groupinternal regu target agreement lations consideration stakeholder interest transparent corporate communication appropriate risk management proper accounting auditing employee survey confirms key issue sartorius complies stipulation recom mendations german corporate governance global employee survey conducted 2013 yielded code recent version published june 24 aboveaverage score whole sartorius 2014 information topic given spondents especially satisfied role corporate governance report page 72 task manager nature cooperation within company finding also sartorius operates global compliance system intend confirmed continuing professional development ed ensure member executive body opportunity advancement important manager employee comply legal regula employee topic therefore one tions code internal guideline systematically focal point hr activity reporting year raise awareness relevant compliance issue among people prevent misconduct financial loss damage image internal control sys applying different perspective tems compliance department responsible inter nal auditing corporate security environmental workforce reflects diversity market management data protection risk management anti business region customer served interna corruption export control tional operation take care assembling team ensure different perspective experi sartorius code conduct sartorius anti ences contributed people combine productively corruption code set expand minimum similarly aim achieve mix nationality standard legally compliant ethical behavior gender age group filling management sartorius code conduct help employee act vacancy december 31 2014 583 ethically accordance law daily group employee employed outside germany work provision specific rule conduct represents yearonyear increase 17 percent counter corruption binding employee age point half company manager employee around globe complete train originated outside germany proportion woman ing course deal ethically legally total workforce decreased slightly 350 problematic situation whistleblower portal 346 2014 proportion woman hold telephone hotline enable employee supplier cu ing post two tier management immediately tomers partner report dubious conduct executive board increased worldwide 200 223 regard making management sartorius adheres principle united nation team even international increasing universal declaration human right interna proportion woman managerial position tional labor organization ilo united nation significant priority medium term 88 sustainability report sustainable corporate management sartorius employed 163 people reporting period finding developing talented young staff registered disabled 133 germany 25 france sartorius enjoys reputation attractive employer evidenced among indicator large number applicant respond job adver developing potential tisements provide extensive range infor employee worldwide mation company applicant career section website employee attach great importance continuing professional development offering sartorius offer young people rigorous initial profes corresponding program wide range field sional training germany group provides train many year made particular effort 2014 ing education total 22 different make international strand hr development profession eight workstudy program sartorius work even stronger improved training availa total 157 trainee student em ble locally south american site example ployment december 31 2014 reporting date set electronic platform internal job yearonyear increase eight people 111 advertisement site usa globally male 46 female two trainee disability developing structured talent management system previous year large proportion trainee improving support option help employee entered continuing employment company working outside field away successfully completing final examination home site temporarily permanently con tinue professional personal development sartorius run foreign exchange program trainee enable interest gaining interna annual performance review held em tional experience spend number week ployee manager provide forum discus specific group site another country part training development opportunity well target per option offered addition standard tech formance sartorius conduct annual performance nical program promising young individual sartori review worldwide line set criterion u also opportunity prepare specific future role highly practical work sartorius fill management vacancy within study program natural science business rank help junior manager build administration management skill specific project directly related company business sartorius company regularly avail eu funding pro also provides separate development program gram including marie curie scheme young experienced management staff designed refer scientist leonardo da vinci scheme inter ence management guideline program national vocational education enable intern help strengthen common management culture take part variety training initiative intern aubagne site example opportunity particularly rd scientist engineer sartorius attend master business administration offer structured expert career path complement course offered kedge business school mar traditional management career program seille alliance enhances visibility expert internally externally build staff loyalty reporting international sartorius scholarship program year together expert introduced meanwhile support talented student graduate refinement program scientific technical discipline finan cially also provision mentor sartorius college offer employee diverse within organization technically range training continuing personal develop personally program intended attract appro ment opportunity number different language priately qualified young people global help improve linguistic methodological skill growth market organization enhance specialist course targeted onthejob training international project activity sartorius pas essential skill expertise sustainability report sustainable corporate management 89 certified vocational training workstudy freedom flexibility work program sartorius germany sartorius set employee demanding task del vocational study program offered german chamber egates responsibility early stage also commerce industry ihk give freedom arrange daily work recognized profession commerce recognition desire flexible working event manager arrangement allow better balance industrial business administrator work family life working time model give office management assistant employee german site option arrange application specialist working hour flexibly example system integration specialist flextime parttime work teleworking sartorius warehouse logistics specialist group 314 people 50 employee part warehouse operator time employment reporting year recognized profession natural science germany represents increase 06 per skilled chemistry technician centage point 2013 figure sartorius al physic laboratory assistant ready garnered number award family chemical laboratory assistant friendly policy recognized profession skilled trade skilled technical job mechatronics engineer electronics technician automation technology culture open dialog electronics technician equipment system milling machine operator sartorius seek maintain culture open industrial mechatronics engineer constructive dialog employee share construction technician formation financial progress strategic skilled machine plant operator plant technician objective change within company technical product designer promptly regularly internal notice news certified production technician letter employee magazine machine tool technician process technician specific relationship employee workstudy program employer vary region region bachelor art business administration sartorius always work together relevant bachelor engineering electrical electronic employee representative body spirit mutual engineering information technology confidence involvement employee man bachelor engineering physical engineering technology agement operational level germany governed bachelor engineering precision machinery provision including german codetermination bachelor engineering production technology law mitbestg german work constitution bachelor science biotechnology bachelor science information technology act betrvg employee germany represented bachelor science business information management system total twelve work council 17 work agreement concluded german site 2014 cover matter health incentive system apply good 90 employee health protection safety sartorius operates corporate health management policy covering physical psychosocial element health order enhance employee performance motivation reduce cost associated illness special action day sport opportunity held different site raise health awareness among employee senior manager ger many access annual medical checkup selected partner clinic advisory travel service introduced 2014 assist sartorius employee business trip international deployment event medi cal emergency accident security threat example 90 sustainability report sustainable corporate management sartorius strives improve working condition strong cooperation supplier continuously bring reduction job related medical condition risk health poten sartorius maintains broad product range pur tial cause industrial accident company also chase correspondingly diverse range material provides regular employee training occupational use manufacturing operation service provider health safety environmental protection supplier contribute value creation continuously adapt job safety work organization expect supplier service provider comply condition line applicable law regula internationally recognized social environ tions example provision guidance mental standard respect law uphold issued german occupational health safety tenet fair competition formalized agency corresponding requirement code conduct supplier service provider sartorius stand 68 accident recorded sartorius worldwide ardized procurement channel worldwide reporting year led 1411 day missed great contract awarded transparent process majority accident minor nature complies current regulation reporting date company recorded 56 workrelated accident largest production site goettingen sartorius total approximately 6000 supplier previous year 36 18 occurred com service provider worldwide cost purchase pany premise rather employee com consumed purchased service amounted mute home work review reporting year 1459 million equates 16 effectiveness accident prevention measure sale revenue please refer note regularly reference accident analysis statement financial position page 130 sartorius operates high level vertical integration accident statistic 2014 material change 2014 2013 workrelated accident 68 77 day missed due accident 1411 1270 accident rate1 64 78 accident severity2 1323 1285 1 workrelated accident per million working hour 2 number day lost due work accident per million working hour sustainability report ecological sustainability 91 ecological sustainability sustainable manufacturing sustainable product sartorius supply product pharmaceutical food key longterm financial success sartorius chemical manufacturer research de design manufacturing process conserve velopment laboratory high level product quality source offer customer product delivery reliability critical customer efficient safe also provide environmental strictly regulated industry company em benefit planning operation look ploy rigorous quality check advanced manufac yond immediate use resource turing method process ensure stand entire life cycle product including used intended product comply customer process supplier also required requirement highly regulated sector con meet specification green approach cerned pose risk health safety tracea sartorius seek grow business without bility system make possible recall entire commensurate increase consumption natural production batch immediately event defect resource made formal objective discovered product various level specific environmental risk requiring provision emission monitoring accordance set identified reporting year greenhouse gas protocol sartorius recording greenhouse gas emission high standard quality line greenhouse gas ghg protocol since environmental protection 2013 accordingly considers report co2 equivalent co2eq emission co2 sartorius certified internationally recog gas relevance climate change nized standard quality iso 9001 environ currently report direct emission relevance cli mental protection iso 14001 two management mate change caused production site scope 1 system ensure comply quality require energy indirect emission arise course ments manufacture product power generation external energy supplier prudent use resource avoid scope 2 greenhouse gas emission environmental risk tagelswangen employ associated manufacture precursor around 40 people one manufactur product distribution operation scope 3 ing site certified compliance moment assessed main production site iso 9001 quality standard iso 14001 environmen singleuse bag aubagne considering tal management system introduced three phased integration scope 3 greenhouse gas company goettingen hamburg beijing emission bangalore site pipette production site kajaani finland suzhou china operate energy management system specified iso 50001 singleuse product manufacturing operation goettingen nearby guxhagen site manufacture equipment system biopharmaceutical production energy man agement system first certified 2014 rele vant local organizational unit ensure compliance applicable law regulation international site sartorius established working group incor porating representative number different country improve harmonize process across three area action environment health safety 92 sustainability report ecological sustainability greenhouse gas emission sartorius group efficient use energy developed follows 2014 sartorius adapting negative consequence energy consumption greenhouse gas climate change endeavoring reduce green 2014 2013 house gas emission associated business op erations energy efficiency one main area total energy consumption mwh 103858 86301 targeting connection accounting ap electricity strom 52785 50242 proximately 59 total energy consumption natural gas 47808 32746 largest site goettingen play key role effort fuels1 2009 2685 adoption advanced technology including energy source 1256 628 energyefficient combined heat power chp plant total greenhouse gas emission compressed air center controlling production co2eq2 29110 31083 3 equipment brought reduction annual carbon scope 1 9462 7937 dioxide emission around 5600 metric ton intelli scope 2 19648 23146 gent control system pave way annual energy key indicator saving 1300 mwh second chp plant co2eq emission per employee 63 75 cut emission additional 400 metric co2eq emission per sale revenue ton carbon dioxide year came online 2014 tmio 327 350 measure enabled u break link 1 diesel generator tween consumption output goettingen site 2 co2eq calculated hawk university applied science result overall energy consumption art goettingen using gabi analytical software increased much slower rate sale revenue package greenhouse gas emission last year energy management sys 3 scope 1 emission excluding fuel consumption vehicle pool tem make possible identify additional energy saving potential specific area scope 2 emission consumption electricity account almost 75 company total continue improve existing production process emission represent main source emission building international site order relevance climate change sartorius reduce resource consumption increasing pro quarter attributed largely combustion portion renewable energy source energy mix fossil fuel scope 1 key aspect effort especially new build solar energy meet around 3 total scope 1 2 3 emission aubagne site energy requirement yauco site example assessed according bilan carbone method guxhagen tagelswangen site developed french environment energy photovoltaic plant make use geo management agency ademe result 2013 thermal energy recent year analyzed show business workrelated travel employee account around sartorius supply various market directly 22 environmental footprint raw production facility case work mini terials obtained sartorius supplier make mize business travel example making greater approximately 19 significant use videoconferencing measure source co2 include freight transport 18 avoid emissionsgenerating transport operation packaging 10 site drawn plan ac staff travel tion reduce co2 emission based finding minimizing water consumption solvent emission occur principally filter production goettingen yauco site rinsing process follow precipitation amounted 516 metric ton reporting year bath procedure filter membrane production share total carbon figure relevance largest consumer water sartorius modern cast term greenhouse gas emission taken ing machine help make water use efficient account calculating co2eq measure possible sartorius operates waste water treatment plant company premise goettin gen bangalore beijing site interest sustainable water management new building sustainability report ecological sustainability 93 yauco consumes around 85 less fresh water ever leaving premise enables u simultane conventional factory thanks part intelligent ously close material cycle minimize transport concept use rain water requirement reduce water consumption volume waste water produced thanks result water consumption research development moreover 2014 2013 able reduce relative quantity sol 3 vent required membrane manufacture total water consumption 330956 310797 water consumption per employee 3 72 75 switched delivery polypropylene waste water m3 use manufacture injectionmolded component biochemical oxygen demand bod1 metric ton 201 177 required singleuse product sack silo reduce consumption polythene packaging 1 contaminated waste water excludes waste water sanitary facility sartorius little scope use recycled plastic due safety regulation applying product however use small amount material return recyclable material certain functional component balance instance sartorius endeavor reduce waste volume employ waste separation system help ensure recyclable material recycled reduce environmentally compatible infrastructure proportion waste sent landfill development waste sartorius new build plant expansion com pleted comply local legislation regulation 2014 2013 land use production facility utilize dedicated total quantity waste metric ton 3614 4101 industrial area away nature conservation area waste reuserecycling green space maintain extensive green space metric ton 2018 2273 within site avoiding unnecessary artificial waste disposal ground covering prevent water entering soil metric ton 1596 1828 generally believe activity material quantity waste per employee impact biodiversity remain acutely aware metric ton 078 099 special sensitivity biodiversity hot spot recycling rate 56 55 tunisia puerto rico site located however take care act accordingly yauco site example expanded 2012 become sartorius applies relevant regulation environ main production logistics facility mentally compatible reuse recycling force north american market meet stringent u around world electronic product standard sustainable environmentallycompatible balance laboratory equipment en resourcefriendly construction production sures material heavy precious metal building yauco actually achieved platinum status recovered reuse rather landfilled leed u certification system green sartorius site germany using elec building making sartorius first pharmaceutical tronic signature system hazardous waste item industry supplier world receive award example caustic solution oil since 2010 advanced building technology often exceeds ensures generation disposal hazardous requirement national environmental protection waste product documented digitally regulation site traced full proportion waste count hazardous waste recorded germany corresponding figure 2014 524 metric ton avoidance environmentally problematic material organic solvent sartorius need manufac turing membrane filter cartridge recovered sartorius employ material management system recycled goettingen facility account check raw material used ensure solvent use solvent reprocessing comply applicable environmental plant site solvent used recovered health safety regulation pertinent regulation fed back production operation without context include directive restriction 94 sustainability report ecological sustainability use certain hazardous substance electrical ucts example requires around 80 less water electronic equipment rohs regulation 30 less energy equivalent process using registration evaluation authorisation predominantly reusable solution using singleuse striction chemical reach europe well solution make smaller production unit similar standard around world safety data ducing manufacturing space required 30 sheet product safety notice instruction consequently shrinking energy material consump user manual reliably inform customer hazard tion well research confirmed ous material contained product cannot energy consumption associated sterilization replaced steadily reducing amount cleaning material process based singleuse leadcontaining solder used production elec product around half conventional processes1 tronic component circuit board time sartorius able implement corresponding although singleuse product clear environmen rohs regulation full 2014 us tal benefit term energy water consumption leadfree solder use generate waste however consistent reuse recycling significantly im sartorius classified three raw material type prove environmental performance ultrapure plas critical manufacture product chemical tic use manufacture various singleuse product production filter membrane plastic contain around 80 90 energy pure singleuse product stainless steel reusable crude oil thus valuable secondary raw mate bioreactors system began phased introduc rial high energy content polymer example tion indicator boughtin raw material 2013 mean reused fuel heat sartorius procured 3448 metric ton chemical power generation reporting year 2013 2995 metric ton cor responding figure plastic report integrated solution sartorius flexact prod first time 2014 1157 metric ton uct line combine fundamental environmental advantage singleuse technology bene fit lower material consumption due reduced sustainable product innovation need permanently installed system versatile central control unit example used effort improve environmental performance number different biopharmaceutical process product production method begin early development stage aim increase use technical refinement membrane filter renewable raw material reduce packaging enabled sartorius slash consumption ultrapure whenever done without compromising water wetting rinsing membrane safety functionality sartorius also collaborates 95 improved filter waste less highlyvaluable industrial academic partner connec protein solution due significantly lower tion currently exploring possibility including absorption enabling pharmaceutical manufacturer sourcing polymer membrane capsule simultaneously reduce resource consumption con renewable recycled raw material siderably obtain higher yield sartorius process monitoring control technol highperformance product improve customer ogy also reduces material consumption help environmental footprint prevent defective batch sartorius service analyzes customer process round identifies area singleuse product becoming increasingly wide harboring potential economic environmental im spread manufacture innovative effective provements pharmaceutical essentially due 1 economic advantage offer singleuse product source sinclair lindsay l etal environmental impact also completely eliminate resourceintensive disposable technology biopharm int november 2 2008 httpwwwbiopharmservicescomdocsenvironmentimpactdis cleaning process ultrapure water associated posablespdf rawlings b pora h environmental impact wastewater processing required conventional singleuse reusable bioprocess system bioprocess int steel glass equipment study confirm single february 2009 18 25 use product made plastic far superior com plex reusable system consumption energy water chemical product life cycle typical industrial manufacturing process monoclo nal antibody using predominantly singleuse prod sustainability report contributing society 95 contributing society business operation many positive effect goettingen group headquarters site progress city community longstanding member local logistics network based great majority measurement valley business association home sartorius many year often one alliance small midsize measurement technology largest private employer customer company established boost local economy area especially main manufacturing site also involved local climate protection initia consequently play significant role increasing tive reduce co2 emission collaborate growth purchasing power sartorius part goettingens georgaugust university industri ners actively involved shaping economic al partner several goettingen high school social environment around site company also feature among sponsor internationally help make region operates renowned goettingen handel festival city liter attractive current future employee alike aturherbst fall literature festival men team providing financial support project sphere local basketball club bg göttingen currently education culture social affair sport play germany top division also made dona tion support local childrens cancer charity social outreach activity targeting area beyond elternhilfe für da krebskranke kind 2014 home region concentrate field linked core business promoting research education yauco sartorius supporting public school supporting event scientific community remain university many year award around 20 chief priority scholarship annually pupil student low income family also sponsored equipment sport group charity performance support contributing regional economic development breast cancer research 2014 many sartorius production facility among goettingen guxhagen aubagne yauco alliance research site located small mediumsized city educational institution community rank important employer region group headquarters site university promoting academic excellence interdisciplinary city goettingen example largest private communication key aspect longterm alli employer area 2000 employee ances research educational institution company also major force local economy florenz sartorius prize created recognize rural region surrounding nearby guxhagen standing academic achievement awarded twice aubagne yauco mediumsized city year best class faculty economic population around 40000 provide attractive science goettingens georgaugust university job 550 350 people respectively site also sartorius provides financial support around 20 support additional job local service provider outstanding student seven different university supplier every year involvement german federal government deutschlandstipendium local subsidiary involved alongside repre national scholarship program also support sentatives political industrial social sphere international graduate school metrology initiative make region competitive brunswick germany concentrate connection issue directly indirectly affect company operation sartorius site aubagne many year infrastructure logistics environmental protection collaborating highlyregarded school uni education make priority longterm coopera versities including école nationale supérieure de tion reliable partnership maintain open technologie de biomolécules bordeaux support constructive dialog various local stake education training biotechnology engineer holder group notify promptly full business administrator help young graduate activity development touching upon area make start career sartorius also award two concern several example goettingen scholarship every year hong kong especially yauco presented highachieving young geologist biologist 96 sustainability report contributing society chemist university hong kong chinese university hong kong hong kong university science technology french muscular dystrophy association afm téléthon charity working several year received christmas donation 80000 sartorius used help fund research rare nervous system muscle disorder development gene stem cell therapy company also provided laboratory equipment worth 50000 support goettingen experi mental laboratory young people xlab supporting event scientific community sartorius regularly take part symposium conven tions annual conference event scientific community primarily involving bioprocess industry addition maintaining longterm alliance scientific institution supported international regional annual conference usbased parenteral drug association pda interna tional society pharmaceutical engineering ispe 2014 example ispe independent notfor profit association dedicated employee education information sharing across pharmaceutical industry worldwide sartorius also involved symposium presented chinese academy inspection quarantine caiq whose area expertise include quality assurance lab sustainability report gri g4 index 97 gri g4 index gri g4 indicator description page supplementary detail general standard disclosure strategy analysis g41 executive board statement concerning relevance 86 httpwwwsartoriusenenkonzern sustainability sartorius uebersartoriuscorporatesocial g42 description key impact risk 5662 responsibility opportunity organizational profile g43 name organization 22 g44 primary brand product service 4450 g45 location organization headquarters 22 g47 nature ownership legal form 22 g48 market served 2829 g49 scale organization 3139 g410 employee profile total number employee 3638 g411 percentage total employee covered collective 89 bargaining agreement g412 description supply chain 44 48 90 g413 significant change reporting period 22 regarding organization size structure ownership supply chain g414 precautionary principle 60 92 g415 commitment voluntary initiative 87 g416 active membership 95 identified material aspect boundary g417 entity included 86 g418 definition report content 86 g419 material aspect 86 g420 aspect boundary within organization 86 g421 aspect boundary outside organization 86 g422 restatement reporting relevant g423 change scope aspect boundary relevant stakeholder engagement g424 list stakeholder 86 g425 selection stakeholder 86 g426 stakeholder engagement 8687 8990 9596 g427 result stakeholder engagement 86 98 sustainability report gri g4 index report profile g428 reporting period 86 g429 previous report 86 g430 reporting cycle 86 g431 contact point question regarding report back cover content g432 gri content index 9798 g433 external assurance externally audited governance g434 governance structure governance body 6874 86 91 responsibility economic environmental social performance ethic integrity g456 code conduct 87 specific standard disclosure category economic g4en3 energy consumption within organization 9192 g4en4 energy consumption outside organization 92 g4en6 reduction energy consumption 9192 g4en10 percentage total volume water recycled 92 reused g4en15 direct greenhouse gas emission scope 1 9192 g4en16 energy indirect greenhouse gas emission scope 2 9192 g4en17 indirect greenhouse gas emission scope 3 determined g4en22 total water discharge quality destination 92 g4en23 total weight waste disposal method 93 g4en25 hazardous waste 94 g4en27 impact mitigation environmental impact 9394 product service g4en28 percentage product sold packaging determined material reclaimed g4en30 significant environmental impact transport 92 operation category social g4la1 total number new hire employee turnover 36 38 g4la4 minimum notice period regarding operational 89 change g4la8 health safety topic covered agreement 89 trade union g4la10 program skill management lifelong 8889 learning g4la12 diversity equal opportunity 37 8788 g4hr5 child labor 87 g4hr6 forced compulsory labor 87 g4hr10 supplier human right assessment 90 g4so4 anticorruption policy 87 g4so8 compliance 87 g4so9 supplier assessment impact society 90 category economic g4ec1 economic performance 3138 g4ec7 indirect economic impact 9596 consolidated financial statement note 100 consolidated financial statement note statement profit loss comprehensive income statement profit loss comprehensive income 2014 2013 note k k sale revenue 10 891168 791559 cost sale 11 461551 406957 gross profit sale 429617 384602 selling distribution expense 11 200224 181630 research development expense 11 50413 47710 general administrative expense 11 58280 49688 operating income expense 12 5489 4402 earnings interest tax ebit 126188 109976 financial income 13 3360 2004 financial expense 13 33256 16585 financial result 29897 14581 profit tax 96291 95395 income tax 14 32378 29294 profit tax continuing operation 63913 66101 profit tax discontinued operation 33 4530 4538 net profit period 68443 70639 attributable equity holder sartorius ag 48524 52424 noncontrolling interest 19919 18215 earnings per ordinary share basic diluted 15 284 307 continuing operation 257 280 discontinued operation 027 027 earnings per preference share basic diluted 15 286 309 continuing operation 259 282 discontinued operation 027 027 consolidated financial statement note statement profit loss comprehensive income 101 statement comprehensive income 2014 2013 k k net profit period 68443 70639 cash flow hedges1 2295 2681 income tax cash flow hedge 688 563 net investment foreign operation 5697 1432 income tax net investment foreign operation 1709 429 currency translation difference 23044 9168 item may reclassified profit loss net tax 17449 6047 actuarial gain loss defined benefit obligation 14355 1733 income tax actuarial gain loss 3985 267 item reclassified profit loss net tax 10370 2000 comprehensive income tax 7079 4047 total comprehensive income 75522 66592 attributable equity holder sartorius ag 53024 49393 noncontrolling interest 22499 17199 1 amount reclassified statement profit loss listed section 31 note consolidated financial statement integral part statement 102 consolidated financial statement note statement financial position statement financial position note dec 31 2014 dec 31 2013 k k noncurrent asset goodwill 16 382438 378995 intangible asset 16 168638 169435 property plant equipment 17 254936 229538 financial asset 7736 7731 asset 715 995 deferred tax asset 18 21891 26374 836354 813068 current asset inventory 19 145941 138956 trade receivables 20 140365 138893 financial asset 21 11755 15843 current tax asset 11045 14108 asset 10550 8574 cash cash equivalent 40559 51877 asset classified held sale 33 75878 0 436093 368252 1272447 1181320 note dec 31 2014 dec 31 2013 k k equity equity attributable sartorius ag shareholder 397957 367632 issued capital 22 17047 17047 capital reserve 23 87044 86988 reserve retained earnings 23 293866 263597 noncontrolling interest 24 99121 82618 497078 450251 noncurrent liability pension provision 25 61182 54265 provision 26 7259 8594 loan borrowing 27 359875 349226 finance lease liability 27 18790 19599 financial liability 27 49608 41814 deferred tax liability 18 29755 35657 526468 509156 current liability provision 28 8880 9884 trade payable 29 90497 84435 loan borrowing 11106 26167 finance lease liability 2304 2025 financial liability 29 78789 72680 current tax liability 11056 8902 liability 29 15687 17821 liability associated asset classified held sale 33 30583 0 248901 221914 1272447 1181320 yearearlier figure restated final purchase price allocation acquisition tap biosystems section 9 consolidated financial statement note statement cash flow 103 statement cash flow 2014 2013 k k profit tax 103927 101508 financial result 29647 14800 earnings interest tax ebit 133574 116308 depreciation amortization intangible tangible asset 54905 47728 increase decrease provision 734 345 income tax paid 32320 37258 gross cash flow operating activity 155425 127123 increase decrease receivables 23942 12730 increase decrease inventory 13981 8669 increase decrease liability 12186 2464 net cash flow operating activity 129688 103260 net cash flow operating activity continuing operation 125689 97000 net cash flow operating activity discontinued operation 3999 6260 capital expenditure 86144 56006 proceeds disposal fixed asset 900 1682 payment 3262 1884 net cash flow investing activity 81982 56207 payment acquisition consolidated subsidiary business operation net cash acquired 4291 45090 net cash flow investing activity acquisition 86273 101297 net cash flow investing activity continuing operation 82637 99059 net cash flow investing activity discontinued operation 3636 2238 interest received 421 367 interest paid financial charge 13985 12528 dividend paid shareholder sartorius ag 17217 16195 noncontrolling interest 5117 4664 gross cash flow financing activity 35899 33020 change noncontrolling interest 144 10 loan borrowing raised 138010 143909 loan borrowing repaid 144201 100606 net cash flow financing activity 41945 10293 net cash flow financing activity continuing operation 41945 10293 net cash flow financing activity discontinued operation 0 0 net increase decrease cash cash equivalent 1470 12256 cash cash equivalent beginning period 51877 39549 net effect currency translation cash cash equivalent 3090 72 less cash cash equivalent discontinued operation 15879 0 cash cash equivalent end period 40559 51877 104 consolidated financial statement note statement change equity statement change equity equity attribut foreign able cash flow currency sartorius non issued capital hedging pension retained translation ag share controlling total k capital reserve reserve reserve earnings reserve holder interest equity balance jan 1 2013 17047 86988 3087 11890 247443 2118 334383 70048 404431 net profit period 0 0 0 0 52424 0 52424 18215 70639 comprehensive income tax 0 0 1734 1956 674 7395 3031 1016 4047 total comprehensive income 0 0 1734 1956 53098 7395 49393 17199 66592 dividend 0 0 0 0 16195 0 16195 4663 20858 change equity 0 0 0 0 51 0 51 35 86 balance dec 31 2013 jan 1 2014 17047 86988 1353 9934 284397 9513 367632 82619 450251 net profit period 0 0 48524 48524 19919 68443 comprehensive income tax 0 0 821 9430 2565 17316 4500 2579 7079 total comprehensive income 0 0 821 9430 45960 17316 53024 22499 75523 sharebased payment 0 56 0 0 0 56 56 dividend 0 0 0 0 17217 17217 5117 22334 purchase price liability forward non controlling interest 0 0 0 0 5243 5243 1816 7059 change non controlling interest 0 0 0 0 225 225 1046 1271 change equity 0 0 0 0 520 0 520 110 630 balance dec 31 2014 17047 87044 2174 19364 307602 7802 397957 99121 497078 dividend paid per share follows 2014 2013 per share total per share total k k dividend ordinary share 100 8528 094 8016 dividend preference share 102 8689 096 8178 17217 16195 consolidated financial statement note note financial statement 105 note financial statement 1 general information consolidated financial statement prepared euro unless otherwise specified amount sartorius ag listed joint stock corporation estab disclosed thousand euro abbreviated k lished according german law highest case sum figure given level parent company sartorius group report may precisely equal stated total corporation recorded german commercial percentage may exact due rounding register district court goettingen hrb 1970 headquartered weender landstrasse 94108 executive board scheduled submit consol goettingen federal republic germany idated financial statement february 24 2015 supervisory board sartorius group organizes business two divi sion bioprocess solution lab product ser 2 sale industrial technlologies division vice bioprocess solution division sartorius leading international supplier product sartorius ag signed contract december 19 2014 technology manufacture medication japanese minebea group partner vaccine biological basis socalled biopharma development bank japan inc sell industrial ceuticals part total solution provider strate technology division intec latter gy bioprocess solution division offer biopharmaceutical industry product portfolio group sale important milestone cover nearly process step industry manu mediumterm strategy focus two core facture encompass cell culture medium division bioprocess solution lab product cultivation cell bioreactors various size cell service offer higher growth earnings po propagation different technology filter tential intec unlock potential however bag cell harvesting purification concen high degree focus investment tration way filling required proceeds sale intec divi sion strengthen financing potential lab product service division focus labor expansion core business atories research quality assurance sector pharmaceutical biopharmaceutical company pending sale intec division resulted academic research institute serf cu application ifrs 5 noncurrent asset held tomers chemical food industry divi sale discontinued operation thus sion portfolio cover instrument consumables disclosure intec division discontinued oper laboratory use example sample prepara ation therefore expense income tion standard application industrial operation disclosed item profit tax technology division formerly industrial weighing discontinued operation asset liability classified asset held sale since attributable operation reported item december 2014 see also section 33 asset held sale liability associated asset classified held sale respectively compliance 315a subsection 1 ger statement financial position disclosure man commercial code hgb conjunction art note financial statement accordingly refer 4 regulation ec 16062002 europe continuing operation unless otherwise specified parliament council dated july 19 2002 oj prioryear disclosure statement profit l243 p 1 consolidated financial statement loss correspondingly adjusted line sartorius group year ended december 31 rule ifrs 5 contrast amount reported 2014 prepared according ifrs ifric statement financial position reclassified standard interpretation international accounting standard board iasb required applied european union available following site httpeceuropaeuinternal_marketaccountingias index_enhtm 106 consolidated financial statement note note financial statement 3 effect new revised firsttime application ifrs 10 11 12 2014 financial reporting standard result material impact special purpose entity associate jointly controlled compared yearearlier consolidated financial entity ifrs 12 led disclosure con statement following new amended accounting solidated financial statement see section 24 standard obligatorily applied first time following revised accounting standard inter pretations generally required applied ifrs 10 consolidated financial statement first time result material im pact consolidated financial statement ifrs 11 joint arrangement amendment ia 32 financial instrument ifrs 12 disclosure interest entity presentation offsetting financial asset financial liability amendment ia 27 separate financial statement amendment ifrs 10 11 12 transition amendment ia 28 investment associate amendment ia 36 recoverable amount joint venture disclosure nonfinancial asset ifrs 10 contains new definition term amendment ia 39 novation derivative control must considered determining continuation hedge accounting company included consolidated finan cial statement ifrs 11 establishes rule standard interpretation revision financial reporting entity interest amendment following page yet ap arrangement controlled jointly ie joint plied consolidated financial statement arrangement ifrs 12 combine disclosure obliga reporting year yet adopted tions interest subsidiary joint arrangement eu application obligatory associate unconsolidated structured entity 2014 one standard consolidated financial statement note note financial statement 107 applicable endorsement financial standard interpretation title year eu commission standard amendment ia 19 employee contribution february 1 20151 yes annual improvement ifrss 20102012 various cycle issued dec 2013 february 1 20151 yes annual improvement ifrss 20112013 various cycle issued dec 2013 january 1 20151 yes investment entity applying amendment ifrs 10 ifrs 12 ia 28 consolidation exception january 1 2016 sale contribution asset amendment ifrs 10 ia 28 investor associate joint venture january 1 2016 accounting acquisition interest amendment ifrs 11 joint operation january 1 2016 ifrs 14 regulatory defferral account january 1 2016 amendment ia 1 disclosure initiative january 1 2016 amendment ia 16 ia 41 agriculture bearer plant january 1 2016 clarification acceptable method amendment ia 16 ia 38 depreciation amortization january 1 2016 equity method separate financial amendment ia 27 statement january 1 2016 annual improvement ifrss 20122014 various cycle issued sep 2014 january 1 2016 ifrs 15 revenue contract customer january 1 2017 ifrs 9 financial instrument january 1 2018 interpretation ifric 21 levy june 17 20141 yes 1 application mandatory adopted eu commission standard require earlier compulsory application process measuring potential impact scope consolidated financial statement standard interpretation consolidated financial statement sartorius group pro consolidated financial statement sartorius ag gress according current audit review status include annual financial statement major group anticipate overall significant im company controlled directly indirectly pact consolidated account arising sartorius ag term ifrs 1 consolidated fi application new amended standard nancial statement controlling interest exists following criterion met presently firsttime application planned reporting period standard interpreta power ie investor must existing right tions amendment enter force give current ability direct relevant activity investee respect latter return 4 significant accounting policy exposure right variable return investee basis preparation ability use power way significantly consolidated financial statement group affect investees return based principle historical cost acquisi tion construction production exception investees included consolidated finan item disclosed fair value financial asset cial statement time sartorius ag held trading available sale derivative subsidiary acquire control longer included time control transferred entity outside group 108 consolidated financial statement note note financial statement subsidiary included basis annual certain defined loan granted longterm basis financial statement reporting period group applies principle net investment parent company using uniform group recognition foreign operation foreign currency translation measurement method difference resulting loan recognized comprehensive income according ia 2132 intragroup asset liability equity income expense cash flow relating transaction exchange rate major currency tween member group eliminated full euro considered follows consolidation yearend exchange average annual rate exchange rate business combination 2014 2013 2014 2013 usd 121410 137910 132881 132806 business combination measured according gbp 077890 083370 080619 084938 acquisition method identifiable asset acquired chf 120240 122760 121466 123105 group well liability contingent liabili jpy 14523000 14472000 14030709 12958904 tie assumed recorded fair value date inr 7671900 8536600 8106162 7793433 combination cny 753580 834910 818674 816496 significant acquisition purchase price alloca tion generally carried assistance independent thirdparty valuation specialist sale revenue valuation based information available acquisition date revenue derived selling product rendering service recognized sale expense directly related business combination operational revenue recognized operat reported profit period ing income sale recognized statement profit loss significant risk reward ownership good transferred foreign currency translation customer company retains neither continuing managerial effective control good sold subsidiary annual financial statement prepared amount revenue cost incurred foreign currency translated pursuant incurred measured reliably sufficiently ia 21 effect change foreign exchange probable economic benefit associated rate accordance concept functional transaction flow company currency foreign subsidiary regarded inde pendent subdivision sartorius group item statement financial position translated functional cost exchange rate reporting date income expense item converted average rate general operating expense assigned translation difference resulting use dif individual function according functional area ferent exchange rate item statement corresponding profit cost center expense financial position statement profit loss relating crossfunctional initiative project recognized comprehensive income assigned respective functional cost based shareholder equity appropriate allocation principle individual financial statement consoli item cost sale report cost product dated company transaction foreign currency sold acquisition cost merchandise sold translated functional currency com besides directly imputable expense raw pany exchange rate date transac material supply employee benefit expense tion monetary asset liability denominated energy expense cost sale also includes foreign currency translated closing rate overhead allocated manufac reporting date gain loss foreign currency turing area corresponding depreciation transaction recognized profit loss amortization consolidated financial statement note note financial statement 109 selling distribution expense pertain par income tax ticular cost sale marketing organi zation distribution advertising market research current income tax determined based respective local taxable income period local research development cost comprise cost tax rule addition current income tax may research product process development insofar clude adjustment uncertain tax payment tax capitalized amortization capital refund period yet assessed ized development cost also indicated item deferred tax asset liability determined based item general administrative expense primarily temporary difference carrying comprises employee benefit expense cost amount tax base asset liability material general administrative area including difference consolidation addition loss carryforwards tax credit considered profit loss item cannot allocated measurement based tax rate expected one functional area mentioned recognized effective period asset realized operating income expense essen liability settled change deferred tax asset tially include effect currency translation dis liability reflected income tax except posal fixed asset allowance trade receivables change recognized comprehensive income extraordinary expense income grant relat directly equity ed expense recognized income reasonable assurance condition principle tax rate tax rule used tached grant complied enacted substantively enacted grant received reporting date deferred tax asset recognized extent probable taxable profit level relevant tax authority available borrowing cost utilization deductible temporary differ ences loss carried forward borrowing cost expensed incurred unless directly attributable acquisition construc tion production qualifying asset goodwill fore part cost asset asset deemed qualified asset period least 12 month goodwill represents future economic benefit required ensure intended arising asset acquired business combination state ready use sale individually identified separately recognized according ia 36 goodwill acquired business combination may amortized rather must tested annually impairment soon indication asset impairment purpose impairment testing goodwill must allocated acquirer cashgenerating unit cgus cgu represents lowest level within entity goodwill monitored internal management purpose may larger segment 110 consolidated financial statement note note financial statement intangible asset amortization intangible asset based fol lowing period useful life intangible asset acquired stated cost less accumulated regular amortization calculated software 2 10 year according straightline method useful life customer relationship technology 5 15 year intangible asset period capitalized development expense 4 6 year asset expected contribute directly indirectly 10 year cash flow entity brand name indefinite period cost incurred within scope development new product method capitalized internally property plant equipment generated intangible asset following criterion met item property plant equipment reported cost subject depreciation depreciated technical feasibility completing intangible scheduled straightline method applied asset available use sale depreciation reported consolidated financial statement intention complete intangible asset use sell grant related asset generally deducted cost asset ability use sell intangible asset depreciation fixed asset based following demonstration intangible asset period useful life generate probable future economic benefit building 15 50 year availability adequate technical financial machinery 5 15 year resource complete development factory office equipment 3 13 year use sell intangible asset ability measure reliably expenditure impairment intangible tangible asset tributable intangible asset devel opment book value carrying amount property plant equipment intangible asset examined capitalized development cost essentially cover whether indication asset might cost allocated staff involved rd impaired pursuant ia 36 impairment asset raw material supply outside service indication asset impaired directly attributable overhead recoverable amount asset estimated recoverable amount asset cashgenerating internally generated intangible asset may unit higher fair value less cost sell capitalized development cost recognized asset cgu value use event expense period incurred individual asset recoverable amount cannot cost research activity reported expense estimated recoverable amount asset cash period incurred generating unit cgu estimated estimated recoverable amount asset cgu go book value carrying amount carrying amount must reduced recoverable amount cause asset impairment removed book value asset cgu credited newly estimated recoverable amount however book value increase limited value asset cgu would asset impairment loss would assessed previous financial year consolidated financial statement note note financial statement 111 lease inventory must evaluated lower amount cost net realizable value net realizable lease considered agreement whereby lessor value represents estimated selling price conveys lessee return payment series ordinary course business less estimated cost payment right use asset agreed completion estimated cost necessary period time according ia 17 lease classi marketing sale distribution inventory fied either operating lease finance lease risk exist risk reduced shelf life finance lease lease transfer substantially result storage period limited usability invento risk reward incidental ownership ries marked accordingly asset lease designated operating lease trade receivables group lessee finance lease amount equal fair value leased asset lower trade receivables reported present value minimum lease payment discernible risk covered book value trade recognized asset statement financial receivables receivables approximate position simultaneously recognized financial fair value considering maturity date credit liability inception lease mini risk determining recoverability trade receiv mum lease payment essentially consist finance ables group considers change credit charge reduction outstanding liability quality date credit originally granted leased asset depreciated straightline basis reporting date period expected useful life shorter lease term construction contract group lessor finance lease sale revenue equal net investment lease lease construction contract contract specifically nego receivable recognized leasing rate group tiated construction asset combina receives also apportioned finance tion asset closely interrelated charge reduction liability according interdependent term design technology effective interest method function ultimate purpose use outcome construction contract estimated operating lease lease rate paid reliably revenue constructiontype project lessee recognized expense lease generally recognized percentageof rate received lessor recognized income completion method based percentage cost respectively leased asset continues recog date compared total estimated contract cost nized lessor statement financial position expected loss construction contract im fixed asset mediately recognized expense cumulative work contract cost contract result inventory exceeds advance payment received construc tion contract recognized receivables raw material supply including merchandise amount due customer contract reported inventory average cost prin balance deduction advance payment received ciple finished good work progress reported negative obligation construction contract cost conversion cost includes direct cost recognized liability amount due allocated material customer appropriate portion production material han dling overhead general administrative expense fixed asset normal depreciation amortiza tion rate provided expense caused production 112 consolidated financial statement note note financial statement provision pension similar obligation financial liability group mainly comprise loan bank trade payable finance lease payable pension provision similar obligation recog derivative financial instrument negative fair nized consolidated financial statement value sartorius group accordance actuarial principle ia 19 employee benefit stipulates projected financial instrument initially recognized unit credit method method measurement fair value transaction cost directly attributable addition known pension life expectancy acquisition issue financial instrument expected cash value method take account future recognized determining carrying amount salary pension increase financial instrument measured fair value profit loss financial asset liabil actuarial gain loss recognized ities subsequently measured according cate comprehensive income directly equity pension gory assigned cash cash reserve according ia 19r standard equivalent availableforsale financial asset loan receivables financial liability measured amor tized cost financial asset liability classified provision held trading provision recognized liability third party incurred outflow resource cash cash equivalent probable amount obligation reasonably estimated amount recognized group considers highly liquid investment provision represents best estimate obliga less three month maturity date tion end reporting period provision acquisition cash cash equivalent main term maturity one year ly comprise check cash hand deposit bank discounted present value expenditure cash cash equivalent measured cost expected settle obligation end reporting period investment provision regularly reviewed adjusted fur ther information becomes available circumstance investment nonconsolidated subsidiary associ change provision warranty cost based ate security measured cost expected value reflect past experience active market exists share security fair value asset cannot reliably restructuring provision set connection measured program materially change scope business performed segment business unit man ner business conducted case loan receivables restructuring expense include termination benefit due termination employment lease financial asset classified loan receivables well compensation payment due agree measured amortized cost less impairment loss ments supplier dealer restructuring provi application effective interest method im sion recognized group detailed pairment loss trade receivables formal plan either commenced imple recognized using separate allowance account ment announced financial instrument financial instrument contract give rise financial asset one entity financial liabil ity equity instrument another entity financial asset mainly include cash cash equivalent availableforsale financial asset trade loan receivables derivative financial instrument positive fair value consolidated financial statement note note financial statement 113 financial liability noncurrent asset disposal group held sale discontinued operation financial liability except derivative financial instrument measured amortized cost using according ifrs 5 noncurrent asset disposal effective interest method group must classified held sale carrying amount recovered principally sale transaction rather continuing use derivative financial instrument case asset disposal group available immediate sale present condition sale derivative financial instrument foreign cur highly probable sale considered highly probable rency exchange contract interest rate swap con appropriate level management committed tract measured fair value derivative financial plan sell asset active program locate instrument classified held trading unless buyer complete plan already initi designated hedging instrument ated offer sell asset disposal group hedge accounting applied change fair value reasonable price made sale expected derivative financial instrument recognized recognized completed within twelve month either profit loss case hedge date classification unlikely comprehensive income significant change plan made plan withdrawn cash flow hedge noncurrent asset disposal group classified held sale measured lower effective portion change fair value carrying amount fair value less cost sell derivative instrument designated cash flow hedge asset longer depreciated amortized recognized comprehensive income ineffective portion recognized immediately component entity disclosed discontin financial result amount accumulated equity ued operation either disposed reclassified net income period classified held sale hedged item affect net income represents separate major line business geographical area operation statement cash flow part single coordinated plan dispose statement cash flow cash flow present separate major line business geographical area ed according allocation operating activity operation investing activity financing activity subsidiary acquired exclusively view resale instance cash flow operating activity determined using indirect method ie expens e without effect payment added profit 5 critical accounting judgment key tax income without effect pay source estimation uncertainty ments subtracted cash flow financing activity composed primarily change equity preparation consolidated financial addition repayment loan statement management us estimate assump tions based best knowledge current future situation period however actual result may differ estimate estimate assumption therefore revised regular basis impact change immediately recog nized statement profit loss period 114 consolidated financial statement note note financial statement addition group management exercise judgment intangible asset defining accounting treatment specific transac tions existing standard interpretation capitalization selfconstructed intangible asset explicitly treat accounting problem concerned includes certain level estimate assumption eg evaluation technical feasibility assumption estimate primarily concern fol development project expected market prospect lowing fact determination useful live business combination trade receivables accounting acquisition requires certain estimate allowance doubtful account involves signifi assumption made especially concerning cant management judgment review individual fair value intangible asset property receivables based individual customer creditworthi plant equipment acquired liability assumed ness current economic development well acquisition date well useful life analysis historical bad debt portfolio basis intangible asset property plant equipment acquired employee benefit provision pension measurement largely based projected cash obligation flow difference expected actual cash flow may material impact future obligation pension postemployment group result benefit determined accordance actuarial valuation valuation rely key assumption including discount rate expected salary increase impairment asset mortality rate discount rate assumption determined reference yield highquality impairment test conducted certain event lead fixedinterest corporate bond appropriate duration assumption asset might impaired currency end reporting period case carrying amount asset com pared recoverable amount higher due changing market economic condition net realizable value value use cal underlying key assumption may differ actual culation value use generally based dis development may lead significant change counted cash flow method use cash flow pension obligation postemployment benefit projection five year projection take obligation account past experience represent manage ments best estimate future sale revenue difference recognized full directly cost development cash flow planning equity period occur without af period extrapolated using individual growth rate fecting profit loss sensitivity analysis see key assumption management based section 25 pension employee benefit provision determination value use include estimated growth rate weighted average cost capital tax rate estimate material impact respective value ultimately amount impairment carrying amount exceeds recoverable amount impairment loss recognized consolidated financial statement note note financial statement 115 provision contingent liability 6 operating segment contingent asset according ifrs 8 operating segment identifi provision recognized legal constructive cation reportable operating segment based obligation exist respect third party management approach ie segment end reporting date determine defined analogously internal control amount obligation certain estimate porting structure entity therefore area sumptions applied including evaluation activity considered operating segment probability obligation occur business activity may result revenue expense amount cost incurred typically significant operating result regularly reviewed uncertainty involved determination entity chief operating decision maker execu provision related onerous contract warranty cost tive board sartorius ag discrete financial closure business location asset retirement obliga formation available internal reporting tions legal proceeding result classification intec division discontinued operation division called bioprocess solution lab product service con income tax sidered operating segment group operates various tax jurisdiction underlying ebitda key performance indicator therefore must determine tax position respec operating segment group ebitda corre tive local tax law tax authority view sponds earnings interest financial result complex subject different interpreta tax depreciation amortization underlying tions taxpayer local tax authority ebitda mean ebitda adjusted extraordinary item connection extraordinary item ex deferred tax asset recognized de penses income exceptional ductible temporary difference unused tax loss onetime nature accordingly distort sustaina extent probable future taxable ble profitability segment material profit available deductible impact net worth financial position earn temporary difference unused tax loss ings group example item restruc utilized future development uncertain turing expense large group project proceeds partly beyond management control assumption loss disposal sale transfer necessary estimate future taxable profit financial asset property plant equipment well period deferred tax asset provided recurrent nature recovered apart recognition measurement estimate revised period method reportable segment conform sufficient evidence revise assumption man general group accounting principle agement considers probable portion deferred tax asset cannot realized correspond intersegment receivables payable internal ing valuation allowance taken account transfer price set price corresponding would agreed upon external third party particular situation given framework condition essentially price calculated applying costplusmargin method resale price method combination two method method determining internal transfer price documented promptly continuously maintained volume inter segment receivables payable immaterial segment asset segment liability report ed regular basis chief operating decision maker therefore part segment report 116 consolidated financial statement note note financial statement sale revenue underlying ebitda k 2014 2013 2014 2013 bioprocess solution 615643 517792 145625 118896 lab product service 275525 273767 41199 43393 total continuing operation 891168 791559 186824 162289 reconciliation profit tax depreciation amortization 52328 45817 extraordinary effect 8308 6497 earnings interest tax ebit 126188 109976 financial result 29897 14581 profit tax continuing operation 96291 95395 depreciation amortization capital expenditure k 2014 2013 2014 2013 bioprocess solution 34895 30126 42686 30601 lab product service 17763 15691 38234 30014 total continuing operation 52659 45817 80920 60615 geographical information particular company location sale revenue reported according customer location noncurrent european region includes market western asset correspond property plant equipment eastern europe north american region well intangible asset group affiliate comprised u marketplace canadian allocated various region goodwill market japan china australia south korea india resulting reverse acquisition stedim among country allocated associated intangible asset regionally allocated asia pacific region market segment pri france marily consists latin america africa fiscal 2014 prior year none custom following applies regional key figure er accounted 10 sale revenue regional allocation noncurrent asset refers sale revenue noncurrent asset k 2014 2013 2014 2013 europe 421128 393455 740323 721054 germany 128221 118992 291273 266487 france 61949 59385 344669 348947 north america 241559 182359 35583 28191 usa 240801 174725 35581 28182 asia pacific 201008 183824 28360 27630 china 61051 49019 11663 11637 market 27473 31921 1747 1094 group 891168 791559 806012 777968 consolidated financial statement note note financial statement 117 7 scope consolidation ownership consolidated parent sartorius ag goettingen germany company x sartorius stedim biotech sa aubagne france along subsidiary 743 x europe sartorius stedim belgium nv vilvoorde belgium 1000 x sartorius stedim nordic herlev denmark 1000 x distribo gmbh goettingen germany 260 sartorius stedim biotech gmbh goettingen germany 1000 x sartorius stedim plastic gmbh goettingen germany 1000 x sartorius stedim system gmbh guxhagen germany 1000 x sartorius stedim uk ltd epsom uk 1000 x sartorius stedim lab ltd stonehouse uk 1000 x tap biosystems group ltd royston uk 1000 x tap esop management ltd royston uk 1000 x tap biosystems phc ltd royston uk 1000 tap biosystems ltd royston uk 1000 automation partnership cambridge ltd royston uk 1000 x sartorius stedim fmt sa aubagne france 1000 x sartorius stedim france sa aubagne france 1000 x sartorius stedim financière sa aubagne france 1000 sartorius stedim aseptics sa lourdes france 1000 x sartorius stedim ireland ltd dublin ireland 1000 x sartorius stedim italy spa florence italy 1000 x sartorius stedim netherlands bv rotterdam netherlands 1000 x sartorius stedim austria gmbh vienna austria 1000 x sartorius stedim poland sp z oo kostrzyn poland 1000 x ooo sartorius icr st petersburg russia 1000 sartorius stedim switzerland ag tagelswangen switzerland 1000 x sartorius stedim spain sa madrid spain 1000 x sartorius stedim hungaria kft budapest hungary 1000 north america sartorius stedim filter inc yauco puerto rico 1000 x sartorius stedim north america inc wilmington delaware usa 1000 x allpure technology llc new oxford pennsylvania usa 500 x asia pacific sartorius stedim australia pty ltd dandenong south victoria australia 1000 x sartorius stedim biotech beijing co ltd beijing china 1000 x sartorius stedim shanghai trading co ltd shanghai china 1000 x sartorius stedim india pvt ltd bangalore india 1000 x sartorius stedim japan kk tokyo japan 1000 x sartorius korea biotech co ltd seoul south korea 1 490 x sartorius stedim malaysia sdn bhd kuala lumpur malaysia 1000 x sartorius stedim singapore pte ltd singapore 1000 x market sartorius stedim bioprocess sarl mhamdia tunisia 1000 x 118 consolidated financial statement note note financial statement ownership consolidated europe sartorius belgium nv vilvoorde belgium 1000 x sartorius nordic herlev denmark 1000 x sartorius weighing technology gmbh goettingen germany 1000 x sartorius corporate administration gmbh goettingen germany 1000 x si weendeverwaltungsgmbh goettingen germany 1000 x siv weende gmbh co kg goettingen germany 1000 x si grone 1verwaltungsgmbh goettingen germany 1000 x siv grone 1 gmbh co kg goettingen germany 1000 x swt treuhand gmbh goettingen germany 1000 x sartorius lab holding gmbh goettingen germany 1000 x sartorius lab instrument gmbh co kg goettingen germany 1000 x sartorius uk ltd epsom uk 1000 x sartorius biohit liquid handling oy helsinki finland 1000 x sartorius france sa dourdan france 1000 x vl finance sa aubagne france 1000 x sartorius ireland ltd dublin ireland 1000 x sartorius italy srl florence italy 1000 x sartorius netherlands bv rotterdam netherlands 1000 x sartorius austria gmbh vienna austria 1000 x sartorius poland sp z oo kostrzyn poland 1000 x ooo sartogosm st petersburg russia 1000 ooo biohit st petersburg russia 1000 x sartorius spain sa madrid spain 1000 x sartorius hungaria kft budapest hungary 1000 sartorius intec belgium bvba vilvoorde belgium 1000 x sartorius mechatronics th gmbh hamburg germany 1000 x sartorius mechatronics cd gmbh co kg aachen germany including sartoriusverwaltungsgmbh 1000 x sartorius industrial scale gmbh co kg bovenden germany 1000 x sartorius industrial weighing verwaltungs gmbh bovenden germany 1000 x sartorius intec uk ltd epsom uk 1000 x sartorius intec france sa le ulis france 1000 x sartorius intec italy srl muggiò italy 1000 x sartorius intec netherlands bv rotterdam netherlands 1000 x sartorius intec austria gmbh vienna austria 1000 x sartorius intec poland sp z oo kostrzyn poland 1000 x sartorius mechatronics switzerland ag tagelswangen switzerland 1000 x sartorius intec spain sl madrid spain 1000 x north america sartorius north america inc wilmington delaware usa 1000 x sartorius corporation wilmington delaware usa 1000 x sartorius canada inc mississauga canada 1000 x consolidated financial statement note note financial statement 119 ownership consolidated asia pacific sartorius australia pty ltd dandenong south victoria australia 1000 x denver instrument beijing co ltd beijing china 1000 x sartorius scientific instrument beijing co ltd beijing china 1000 x sartorius shanghai trading co ltd shanghai china 1000 x biohit biotech suzhou co ltd shanghai china 1000 x sartorius hong kong ltd kowloon hong kong 1000 x sartorius weighing india pvt ltd bangalore india 1000 x biohit biotech system india pvt ltd chennai india 1000 x sartorius japan kk tokyo japan 1000 x sartorius malaysia sdn bhd kuala lumpur malaysia 1000 x sartorius singapore pte ltd singapore 1000 x sartorius korea ltd seoul south korea 1000 x sartorius thailand co ltd bangkok thailand1 490 x sartorius industrial weighing equipment beijing co ltd beijing china 1000 x sartorius mechatronics india pvt ltd bangalore india 1000 x sartorius intec kk tokyo japan 1000 x sartorius mechatronics philippine inc makati city philippine 1000 market sartorius argentina sa buenos aire argentina 1000 sartorius brasil ltda são paulo brazil 1000 sartorius de méxico sa de cv naucalpan mexico 1000 1 company sartorius korea biotech sartorius thailand included scope consolidation due contractual agreement see section 24 company marked nonconsolidated january 1 2014 difference resulting table included scope consoli initial consolidation deducted dation figure minor importance retaining earnings assessing actual net worth financial position profitability sartorius group sale revenue total asset nonconsolidated com 8 statement cash flow panies taken whole approximately 1 group figure associate joint venture statement cash flow show impact cash consolidated company identified x inflow outflow cash cash equivalent fully consolidated group cash flow classified operat ing investing financing activity according fiscal 2014 material change ia 7 statement cash flow capital voting share right company listed respect prior year context cash equivalent asset converted cash within short term generally following company included first within three month amount considered time fiscal 2014 scope consolidation statement cash flow primarily includes cash hand bank balance similar item equal sartorius intec poland sp z oo amount reported statement financial sartorius poland sp z oo position sartorius stedim poland sp z oo well allpure technology llc acquired april 2014 company poland consolidated group financial statement due polish company minor importance consolidated 120 consolidated financial statement note note financial statement 2014 group received grant related asset purchase price allocation business final connection purchase construction ized end 2014 following table compare production facility puerto rico amount final purchase price allocation preliminary 41 million cash inflow reported allocation measured 2013 payment cash flow investing activity final purchase preliminary following noncash transaction concluded price purchase price allocation allocation reflected statement cash flow k k intangible asset 15945 22105 addition fixed asset related financial property plant 6960 lease amounted 485 k 2014 3057 k equipment 6989 2013 inventory 6442 3681 trade receivables 7254 7610 asset 816 748 9 business acquisition cash cash equivalent 2846 2846 deferred tax net 2155 3475 acquisition tap biosystems group plc provision 208 208 loan borrowing 7413 7413 december 2013 sartorius acquired british com liability 18474 14963 pany tap biosystems group plc company primari net asset acquired 12013 17920 ly specializes design development small scale multiparallel fermentation system addition purchase price 33050 33050 company array product cover automated cell goodwill 21037 15130 culture system bioprocessing benchtop equipment biotech application acquisition sartorius stedim biotech intangible asset identified within scope extended current bioprocess solution portfolio purchase price allocation measured essentially fermentation business multiparallel mini comprised technology acquired customer bioreactors range 15 milliliter 250 milli relationship liter tap portfolio stand gain substantial market penetration based sartorius greater sale goodwill disclosed represents asset strength global reach well benefit separately identifiable recognized synergy related product sartorius generate economic benefit expansion group fluid management cell culture medium group portfolio strengthened position business relevant biopharmaceutical market named among benefit acquisition bring goodwill may amortized corre sponding effect taxable income purchase price paid cash acquisition related cost 04 million included 2013 operating expense statement profit loss consolidated financial statement note note financial statement 121 acquisition allpure technology llc goodwill disclosed represents asset separately identifiable recognized april 25 2014 sartorius subgroup generate economic benefit expansion sartorius stedim biotech acquired 5001 stake group portfolio strengthened position u startup allpure technology llc price relevant biopharmaceutical market u 6 million purchase price paid cash named among benefit goodwill expected latter company based new oxford pennsylvania taxdeductible full usa operating market four year 2013 earned revenue around u 3 million sartorius stedim biotech group elected 25 employee allpure specializes singleuse recognize amount noncontrolling interest component biopharmaceutical application level prorated share net identifiable provides product complementary sar asset partial goodwill method torius group portfolio bioprocess solution segment reporting year company acquired earned sale revenue approximately 3 million slight share allpure remaining former ly positive annual profit reason er also transferred sartorius 2022 material effect group financial statement latest exact time acquisition well since allpures initial consolidation may 1 2014 purchase price depend future business perfor mance entity purchased corresponding transaction cost 02 million disclosed liability disclosed financial liability operating expense present value expected future payment 71 million liability initially recognized retained earnings according ia 3223 subsequent measurement recognized profit loss financial result overall preliminary purchase price allocation follows preliminary purchase price allocation k intangible tangible asset 2068 inventory 468 trade receivables asset 307 cash cash equivalent 41 provision liability 484 net asset acquired 2400 5001 1200 purchase price 4332 goodwill 3132 noncontrolling interest 1200 122 consolidated financial statement note note statement profit loss note statement profit loss 10 sale revenue 11 functional cost sale revenue broken operating statement profit loss prepared according segment geographical market according function expense method also known customer location consists following cost sale expense allocated spective functional area production sale lab distribution research development well bioprocess product general administration total expense incurred solution service total 2014 k k k functional area material employee bene fit represented follows germany 72357 55864 128221 country 543285 219662 762947 615643 275525 891168 raw material supply lab item consists following bioprocess product solution service total 2013 k k k 2014 2013 k k germany 63120 55872 118992 country 454672 217895 672566 purchase consumed 213911 192262 517792 273767 791559 cost purchased service 46273 20898 260184 213160 amount 135 million earned affiliated company 2013 156 million addition com employee benefit expense pany earned sale revenue 68 million discontinued operation 2013 63 million sum item broken follows approximately 65 million earned providing service 2013 55 million 2014 2013 k k wage salary 264938 227748 social security 51850 46276 expense retirement benefit pension 6816 4142 323604 278165 consolidated financial statement note note statement profit loss 123 12 operating income expense 13 financial result 2014 2013 2014 2013 k k k k currency translation gain 15043 14362 interest similar income 118 176 income decrease allowance bad debt 1451 3353 affiliated company 0 39 income release use income derivative provision liability 3742 1855 financial instrument 105 899 income grant 2223 2292 financial income 3136 929 income 9666 7160 financial income 3360 2004 operating income 32125 29023 interest similar expense 11533 9901 extraordinary expense 8308 6497 currency translation loss 10692 13836 affiliated company 0 6 allowance bad debt 1834 1730 expense derivative financial instrument 13270 2993 expense 5802 2558 interest pension operating expense 26636 24621 retirement benefit 1624 1591 financial charge 6830 2100 operating income financial expense 33256 16585 expense 5489 4402 29897 14581 item reported income grant discloses expense derivative financial instrument e grant expense essentially related research sentially include effect connection disso development project recognized lution hedging relationship consequence come soon sufficiently reliable indication refinancing see section 27 necessary prerequisite met income fiscal 2014 includes income 14 income tax cell culture medium business well income con nection service provided discontinued 2014 2013 operation k k current income tax 32665 29009 extraordinary item fiscal 2013 2014 essential deferred tax 286 285 ly incurred various strategic group project 32378 29294 integration acquisition cost matter principle domestic income tax calculated 300 estimated taxable profit fiscal 2014 income generated outside germany taxed particular rate valid cor responding country considering german average tax rate impact tax legislation expected tax rate group roughly 30 following table describes difference tax expense expected income tax expense reported particular financial year 124 consolidated financial statement note note statement profit loss 2014 2013 15 earnings per share k k expected tax rate 30 30 according ia 33 earnings per share earnings per share class must determined separately expected tax expense 28887 28618 case higher dividend entitlement cur difference group average income tax rate 5160 2518 rently two euro cent preference share must effect loss taken account undiluted earnings per share interest carried forward basic eps calculated basis number temporary difference share outstanding period diluted earn deferred tax accrued 1825 378 ings per share diluted eps calculated taxfree income tax cause option conversion right credit 1708 1021 exercised sartorius share regard share expense deductible subscription right granted executive board tax purpose 1686 2002 member december 16 2014 change adjustment previous year 2938 932 computed result withholding similar tax 2044 1748 treasury share may included calculating 1866 90 average number share outstanding 32378 29294 2014 2013 effective tax rate 336 307 ordinary share basis calculating basic earnings per ordinary share item effect loss interest carried net profit minority interest k 24190 26141 forward temporary difference continuing deferred tax accrued include negative ef operation k 21923 23870 fects due lack foreseeability future taxable discontinued profit well opposite positive effect operation k 2266 2270 use interest loss carried forward weighted average number deferred tax asset yet recognized share outstanding 8528056 8528056 basic earnings per ordinary share 284 307 continuing operation 257 280 discontinued operation 027 027 preference share basis calculating basic earnings per preference share net profit minority interest k 24335 26283 continuing operation k 22070 24015 discontinued operation k 2264 2268 weighted average number share outstanding 8519017 8519017 basic earnings per preference share 286 309 continuing operation 259 282 discontinued operation 027 027 consolidated financial statement note note statement financial position 125 note statement financial position 16 goodwill intangible asset integration business division bioprocess solution lab product goodwill service respective positioning total solu tions provider regard segment goodwill1 cashgenerating unit thus goodwill distributed k segment follows gross book value jan 1 2013 358095 currency translation 597 dec 31 2014 dec 31 2013 change scope consolidation k k acquisition 21497 bioprocess solution 329725 324243 gross book value dec 31 2013 378995 lab product service 52713 52279 amortization impairment loss industrial technology 0 2473 jan 1 2013 0 382438 378995 currency translation 0 amortization impairment loss 2013 0 amortization impairment loss dec 31 2013 0 impairment test conducted fiscal 2014 mea net book value dec 31 2013 378995 sure recoverable amount basis value use particular cashgenerating unit cash gross book value jan 1 2014 378995 flow forecast consider previous experience currency translation 2801 generally based current projection ex change scope consolidation acquisition 3146 ecutive board period three five year reclassification held sale 2504 bioprocess solution division calculation gross book value dec 31 2014 382438 based average terminal growth rate 25 amortization impairment loss fiscal year 2018 terminal growth rate jan 1 2014 0 derived market expectation forecast currency translation 0 mediumterm growth rate high upper single amortization impairment loss 2014 0 digit range biopharmaceutical market targeted amortization impairment loss division major growth driver dec 31 2014 0 among others aging population increase net book value dec 31 2014 382438 population improved access pharmaceutical market emergingmarket country well 1 yearearlier figure adjusted account final currently ongoing paradigm shift towards utiliza purchase price allocation tap biosystems tion singleuse product manufacture biopharmaceuticals lab product service item reported goodwill amount division terminal growth rate 15 used 382438 k 2013 378995 k capitalized dif fiscal year 2018 ference asset resulting capital consolidation extent also cover asset deal discount rate cashgenerating unit corre crease fiscal 2014 refers acquisition spond weighted average cost capital wacc pure technology llc see section 9 goodwill recognized follows atrributable intec reclassified accordance ifrs 5 according ia 36 goodwill may 2014 2013 amortized scheduled basis rather must tax tax tax tax tested annually impairment bioprocess solution 84 65 88 68 lab product service 91 67 98 71 industrial technology 99 71 126 consolidated financial statement note note statement financial position fiscal 2014 impairment test result recognition impairment loss even realistic change basic assumption upon mea surement value use based would result carrying amount cashgenerating unit exceeding value use upon classification intec division discontinued operation criteri testing reclassified goodwill impairment must applied according fair value less cost sell reporting date need recognize impairment loss based expected selling price intangible asset patent license technology capitalized similar customer development payment right brand name relationship cost account total k k k k k k gross book value jan 1 2013 72044 14887 112762 55672 192 255557 currency translation 356 0 522 40 0 919 change scope consolidation acquisition 6904 0 7414 1656 0 15974 capital expenditure 11237 0 0 9338 66 20641 disposal 7679 0 0 27 0 7706 transfer 121 0 0 0 28 93 gross book value dec 31 2013 82271 14887 119653 66599 230 283640 amortization impairment loss jan 1 2013 30551 413 38204 29353 0 98521 currency translation 200 0 131 184 0 349 amortization impairment loss 2013 6486 411 9381 7456 0 23735 disposal 7677 0 0 27 0 7704 transfer 2 0 0 0 0 2 amortization impariment loss dec 31 2013 29163 824 47453 36764 0 114205 net book value dec 31 2013 53108 14063 72200 29835 230 169435 consolidated financial statement note note statement financial position 127 patent license technology capitalized similar customer development payment right brand name relationship cost account total k k k k k k gross book value jan 1 2014 82271 14887 119653 66599 230 283640 currency translation 1215 1 599 233 0 2046 change scope consolidation acquisition 1478 0 437 134 0 2049 capital expenditure 14217 0 0 14955 257 29429 disposal 1556 0 0 67 122 1746 transfer 167 0 0 0 96 71 reclassification held sale 2674 0 0 9273 0 11947 gross book value dec 31 2014 95118 14885 120689 72581 269 303542 amortization impairment loss jan 1 2014 29163 824 47453 36764 0 114204 currency translation 435 1 77 48 0 559 amortization impairment loss 2014 8510 412 9732 10108 0 28762 disposal 1549 0 0 0 0 1549 transfer 0 0 0 0 0 0 reclassification held sale 894 0 0 6177 0 7071 amortization impairment loss dec 31 2014 35664 1235 57262 40743 0 134904 net book value dec 31 2014 59454 13650 63427 31838 269 168638 brand name acquired stedim transaction fiscal 2014 development cost 14955 k book value 10779 k considered indef 2013 9338 k recognized asset fig inite useful life foreseeable limit ures also include discontinued operation capi period expected generate net cash talized development cost essentially covered cost inflow company integration allocated project staff involved stedim brand sartorius stedim biotech rd effort raw material supply outside ser brand separate measurement relevant cash flow vice directly attributable overhead internally possible however recoverability generated intangible asset amortized according brand name intangible asset acquired straightline method useful life within scope business combination considered nexthigher level cash amortization intangible asset allocated generating unit cgu ie bioprocess solution corresponding function statement profit division loss capitalized development cost amortization disclosed research development cost brand name acquired conjunction biohit liquid handling business limited period fiscal 2014 impairment expense 25 million useful life estimated ten year average recognized capitalized development cost 2013 0 million customer relationship obtained part acquisition stedim likewise constitute material intangible asset attributable intec division intangible asset book value customer reclassified according ifrs 5 relationship amounted 405 million 2013 459 million year ended december 31 2014 remaining period useful life eight year 128 consolidated financial statement note note statement financial position 17 property plant equipment factory office payment land building technical equipment account machinery construction improvement equipment equipment progress total k k k k k gross book value jan 1 2013 177334 114780 108741 10343 411198 currency translation 2026 1117 1211 43 4397 change scope consolidation 5565 1221 202 0 6988 capital expenditure 4720 12114 12561 12816 42212 disposal 416 2585 9267 106 12374 transfer 646 3743 1285 5422 251 gross book value dec 31 2013 185823 128156 112311 17588 443878 depreciation impairment loss jan 1 2013 51990 72421 78288 0 202699 currency translation 389 655 773 0 1817 depreciation impairment loss 2013 5977 7649 10361 6 23993 disposal 214 1911 8752 0 10877 transfer 0 13 356 0 342 depreciation impairment loss dec 31 2013 57363 77491 79480 6 214340 net book value dec 31 2013 128460 50665 32831 17582 229538 factory office payment land building technical equipment account machinery construction improvement equipment equipment progress total k k k k k gross book value jan 1 2014 185823 128156 112311 17588 443878 currency translation 4504 2094 1955 98 8651 change scope consolidation 5 23 316 16 360 grant related asset 4060 0 0 0 4060 capital expenditure 4353 8413 10844 31516 55127 disposal 747 4879 10437 435 16497 transfer 3548 5259 871 9775 97 reclassification held sale 354 6479 7947 0 14779 gross book value dec 31 2014 193072 132588 107915 39008 472584 depreciation impairment loss jan 1 2014 57363 77491 79480 6 214340 currency translation 811 1272 1170 0 3253 depreciation impairment loss 2014 6407 8790 10944 2 26143 disposal 710 5230 9799 0 15739 transfer 0 1 21 6 26 reclassification held sale 245 3727 6352 0 10325 depreciation impairment loss dec 31 2014 63627 78596 75422 2 217647 net book value dec 31 2014 129446 53992 32493 39006 254936 depreciation included statement profit capitalized property plant equipment include loss according use asset cost sale asset held finance lease amounting selling distribution expense research devel 18457 k 2013 19023 k cost acquisition opment expense administrative expense asset total 21397 k 2013 20562 k operating expense fiscal 2014 rental payment amounting 2014 year material impairment 118 million 2013 102 million made loss plant property equipment recognized set leased operating lease consolidated financial statement note note statement financial position 129 18 deferred tax deferred tax asset deferred tax liability dec 31 2014 dec 31 2013 dec 31 2014 dec 31 2013 k k k k intangible asset 994 6494 23486 28594 tangible asset 0 0 6695 4777 inventory 4706 3882 974 2281 receivables current asset 1179 963 345 959 provision 12247 9703 0 0 liability 3711 3827 0 575 gross amount 22837 24869 31500 37186 taxable loss carried forward 5326 6861 0 0 tax nondistributed earnings subsidiary 0 0 4527 3827 offset 6272 5356 6272 5356 21891 26374 29755 35657 deferred tax asset deferred tax liability reporting date group unused tax loss deferred tax liability connection intangi amount carried forward 28 million 2013 ble asset refer asset acquired business combina around 34 million deducted future tax tions consequently mainly linked customer able profit deferred tax amount reported relationship approx 13 million 2013 approx 21 million loss concerning remaining loss company taxable temporary difference carried forward deferred tax amount recog 147 million 2013 113 million respect nized lack foreseeability future investment subsidiary deferred tax liability taxable profit 45 million 2013 38 million recognized temporary difference include deferred tax asset approximately 4 million 2013 holding tax realization liability around 3 million relate company reported expected within foreseeable future temporary loss year review earlier difference conjunction retained earnings porting year loss carried forward report subsidiary amount 154 million 2013 ed asset assumed taxable profit 174 million deferred tax liability measured would available future unused realization foreseeable planned tax loss deductible temporary difference retained earnings distributed offset would subject taxation rate 5 ger many addition foreign withholding tax might addition group unused interest carry incurred determination tax effect would entail forward german company group unreasonable expense effort amount 7 million 2013 8 million deferred tax asset considered carryforwards fiscal 2014 previous year tax effect reporting year today stance use yielded reporting derivative financial instru sufficiently probable remaining amount ments recognized outside statement profit carried forward loss according ia 39 rule hedge accounting deferred tax asset recognition actuarial gain loss recognized comprehen sive income likewise amount current income tax incurred net investment foreign operation recognized comprehensive income deferred current income tax recognized directly equity disclosed follows table 130 consolidated financial statement note note statement financial position 2014 2013 trade receivables reported k k discernible risk covered allowance recog cash flow hedge 688 563 nized based past experience actual credit actuarial gain loss loss please refer section 12 concerning ex defined benefit obligation 3985 267 penses income resulting allowance net investment foreign reported statement profit loss operation 1709 429 book value trade receivables receiv total 6382 725 ables approximate receivables fair value due short term 19 inventory within scope implementing factoring pro gram retained part risk essentially credit dec 31 2014 dec 31 2013 risk associated asset carrying k k amount continuing involvement stood raw material supply 45241 45813 25 million end fiscal 2014 2013 work progress 41327 33068 25 million associated liability finished good 31 million 2013 31 million total amount merchandise 57497 58227 original asset 319 million 2013 payment account 1876 1848 291 million 145941 138956 reporting year valuation allowance developed follows dec 31 2014 dec 31 2013 k k 2014 2013 gross amount inventory 159660 152144 k k writedowns 13720 13188 valuation allowance net amount inventory 145941 138956 beginning year 7714 10101 increase fiscal year 2387 2006 derecognition 20 current trade receivables consumption 1179 580 recovery amount dec 31 2014 dec 31 2013 previously impaired 2159 3590 k k currency translation difference 200 222 trade receivables third party 129201 124136 reclassification held sale 1147 0 amount due customer contract work 2076 7767 valuation allowance end year 5816 7714 receivables non consolidated affiliate 9088 6989 trade receivables 140365 138893 business area group carry long term construction contract limited extent customerspecific contract recognized application ia 11 construction contract based percentage completion method reporting year contract revenue 12423 k earned 2013 21901 k aggregate amount cost incurred profit loss recognized project progress reporting date 17426 k 2013 29938 k project advance pay ments 17613 k 2013 25551 k recorded consolidated financial statement note note statement financial position 131 following table show maturity structure sartorius ag exercised authority granted receivables past due impaired annual shareholder meeting june 21 2000 repurchase treasury share amount 16082 k dec 31 2014 dec 31 2013 pursuant 71 subsection 1 8 german k k stock corporation law aktg according ia 32 130 day 18874 14832 treasury share deducted equity capital 3190 day 11023 11489 reserve 91180 day 2218 5351 181360 day 1004 855 share held particular currency 360 day 251 639 future acquisition company october 27 total 33370 33165 2000 reporting date 831944 ordinary share repurchased average price 1127 840983 preference share average price 798 corresponds portion 1673 89 trade receivables 33370 k past due capital stock fiscal 2013 treasury share reporting date 2013 33165 k valuation purchased share deducted company allowance made material issued capital capital reserve change creditworthiness debtor could expected would pay amount outstanding trade receivables yet due 23 reserve financial asset written indication impairment capital reserve 21 asset capital reserve include amount generated previous year beyond nominal amount dec 31 2014 dec 31 2013 sartorius ag issued share within scope k k purchase treasury share see 14464 k derivative financial deducted capital reserve instrument 120 4303 miscellaneous fiscal 2014 capital reserve increased 56 k financial asset 11635 11540 due use share part sharebased pay financial asset 11755 15843 ments see section 32 detail provided remuneration report 22 issued capital cash flow hedging reserve sartorius ag capital stock divided 9360000 bearertype ordinary share 9360000 nonvoting amount recognized comprehensive income preference share calculated par value part effective hedgeing relationship trans 100 according company article asso ferred cash flow hedging reserve particular ciation preference share entitled dividend fluctuation fair value interest payment higher dividend payment currency hedge well respective tax effect ordinary share amount equal 20 preference share calculated proportion issued capital ie two euro cent per share case pension reserve dividend entitlement shall least 40 preference share calculated proportion issued actuarial gain loss defined benefit plan capital ie four euro cent per share share commitment including respective tax effect paid full included pension reserve 132 consolidated financial statement note note statement financial position 24 noncontrolling interest condensed statement profit loss comprehensive income sartorius stedim biotech subgroup headquartered aubagne france account majority non 2014 2013 controlling interest sartorius group latter k k hold approximately 75 capital share 85 sale revenue 683524 588378 voting right subgroup following sub profit tax 105112 94445 sidiaries account noncontrolling interest income tax 31378 26970 amount net profit period 73734 67474 comprehensive income sartorius korea biotech based seoul south korea tax 8131 3470 sartorius thailand located bangkok total comprehensive income 81865 64004 49 share capital company consolidated due available call option exercised time comparable contractual arrangement condensed statement cash flow allpure technology llc new oxford usa 5001 2014 2013 k k 2014 2013 k k net cash flow operating activity 111312 90107 cumulative noncontrolling interest dec 31 net cash flow investing activity acquisition 46813 73408 sartorius stedim biotech 92668 78781 net cash flow 6453 3838 financing activity 84208 8010 99121 82618 net increase decrease profit loss allocated cash cash equivalent 19709 8689 noncontrolling interest cash cash equivalent sartorius stedim biotech 18625 16980 beginning period 35605 27807 1294 1235 net effect currency translation cash cash 19919 18215 equivalent 2648 891 dividend paid non cash cash equivalent controlling interest end period 18544 35605 sartorius stedim biotech 4716 4322 401 341 5117 4663 25 pension employee benefit provision following summarized financial information refers sartorius stedim biotech group defined contribution plan company group defined condensed statement financial position contribution plan frequently form govern mentbacked retirement insurance country dec 31 2014 dec 31 2013 percentage company pay social security k k contribution national insurance contribution noncurrent asset 630593 612503 oldage retirement benefit cannot reliably deter current asset 276166 260912 mined fiscal 2014 amount 215 million 906758 873415 recognized defined contribution plan 2013 188 million remaining group company equity 538512 481838 noncurrent liability 138662 233685 current liability 229584 157891 906758 873415 consolidated financial statement note note statement financial position 133 defined benefit plan following parameter used french company pension provision similar obligation recognized consolidated financial statement 2014 2013 sartorius group accordance actuarial prin discount rate 180 350 ciples actuarial gain loss shown directly future salary increase 300 300 comprehensive income according future pension increase 200 200 vised ia 19r standard actuarial loss transferred pension reserve essentially resulted change discount rate totaled 30295 k 2013 15895 k amount reported statement profit loss statement comprehensive income amount 52745 k 2013 46757 k relates consist following particular net amount pension provision retirement pension plan germany provision 2014 2013 based direct commitment defined bene k k fit pension plan commitment em service cost 1207 1561 ployees earn benefit year service rendered net interest cost 1722 1672 company pension benefit generally component defined funded asset substantial portion benefit cost recognized profit loss 2929 3233 provision relate sartorius ag case return plan asset excl obligation measured pertain general pension interest 3 32 plan allgemeine versorgungsordnung employ actuarial gain loss 14352 1700 ee whose employment commenced prior january 1 component defined 1983 one hand individual com benefit cost recognized mitments active former executive board mem comprehensive income 14355 1733 bers executive exist form performance total defined benefit cost 17284 1500 based postemployment benefit plan assumed discount factor reflect interest rate paid reporting date prime corpo statement profit loss current service rate industrial bond matching maturity cost disclosed according assignment em denominated relevant currency corpo ployees respective function rate bond available matching longterm maturity insufficiently available match net amount present value included con ing interest rate determined extrapolation solidated statement financial position arising group obligation respect defined benefit measurement postemployment benefit obliga plan follows tions german group company based following actuarial assumption dec 31 2014 dec 31 2013 k k 2014 2013 present value obligation 67176 60908 discount rate 190 350 fair value plan asset 5994 6643 future salary increase 300 300 net liability 61182 54265 future pension increase 200 200 134 consolidated financial statement note note statement financial position defined benefit obligation plan asset 2014 2013 2014 2013 k k k k present value plan asset jan 1 6643 6063 obligation jan 1 60908 61547 interest income 165 138 current service cost 1535 1561 return plan asset excl past service cost 328 0 interest 3 32 interest cost 1887 1810 actuarial gain loss 12 9 actuarial gain loss 14340 1709 group contribution currency translation payment 824 595 difference 287 397 employee contribution 205 194 retirement benefit paid currency translation reporting year 3031 2566 difference 202 94 employer contribution 487 0 employer contribution 564 536 employee contribution 194 194 contribution plan contribution plan participant 459 391 participant 411 391 reclassification held reclassification held sale 1404 0 sale 10093 0 change 0 14 change 578 77 plan asset dec 31 5994 6643 present value obligation dec 31 67176 60908 composition plan asset actuarial gain loss defined benefit obligation allocated follows plan asset essentially consist insurance contract insurance company germany switzerland 2014 2013 amount 09 million held local bank k k security subsidiary south korea experience adjustment 1052 412 change demographic sensitivity analysis assumption 154 78 change financial increase decrease actuarial assumption assumption 13137 1365 would following impact defined total 14343 1700 benefit obligation year ended december 31 2014 demographic assumption change life expectancy 1 year 1 year effect 1696 1726 financial assumption change discount rate 100 bps 100 bps effect 11597 9143 change future salary increase 50 bps 50 bps effect 827 882 change future pension increase 25 bps 25 bps effect 1701 1785 consolidated financial statement note note statement financial position 135 present value defined benefit obligation maturity analysis year ended december 31 2013 undiscounted cash flow defined benefit demographic assumption obligation allocated maturity follows change life expectancy 1 year 1 year effect 1299 1389 dec 31 2014 dec 31 2013 financial assumption k k change discount rate 100 bps 100 bps 1 year 2853 2557 effect 8425 6757 15 year 11005 11893 change future salary 610 year 16531 16293 increase 50 bps 50 bps 10 year 83272 84992 effect 543 574 change future pension increase 25 bps 25 bps effect 1370 1432 weighted average duration defined benefit obligation 159 year 2013135 year sensitivity analysis presented might fiscal 2015 payment 26 million defined representative actual change defined benefit plan commitment expected 2013 benefit obligation unlikely change 26 million cover contribution plan asset assumption would occur isolation one another payment retirement benefit furthermore present value defined benefit obligation calculated using method applied calculating defined benefit obligation liability recognized statement financial position projected unit credit method 26 noncurrent provision payment employee early retirement plan total k k k balance jan 1 2013 5878 3850 9728 currency translation 0 395 395 consumption 1975 335 2310 reversal utilization 64 737 801 addition 1457 916 2373 balance dec 31 2013 5296 3298 8594 payment employee early retirement plan total k k k balance jan 1 2014 5296 3298 8594 currency translation 0 37 37 consumption 1998 219 2217 reversal utilization 0 1630 1630 addition 1437 1917 3354 reclassification held sale 285 593 878 balance dec 31 2014 4450 2809 7259 noncurrent provision comprise mainly provision employee anniversary bonus obligation partial retirement type early retirement plan arise mainly german group company 136 consolidated financial statement note note statement financial position early retirement plan partial retirement plan noncurrent provision reported present permit employee work parttime 3 5 value reporting date discount interest rate year reach actual retirement age employee early retirement plan provision accrued company anniversary according ia 19r treatment severance pay 03 2013 08 fiscal 2014 effect ments earned future period must recog compounding noncurrent provision including nized profit loss active employee effect change interest rate 01 million respective remaining period service 2013 01 millon ia 19 rule require actuarial gain loss well past service cost bonus company anniversary generally obligation recognized income granted employee accumulated seniori expense statement profit loss tie 20 25 30 40 year cover additional special vacation well relatively small sum money 27 noncurrent liability loan borrowing finance lease liability balance non balance non dec 31 2014 current dec 31 2013 current k k k k loan borrowing 370980 359875 375393 349226 finance lease liability 21094 18790 21624 19599 392074 378665 397017 368825 financing sartorius group consists various approximately 60 million factoring program element largely renewed reporting volume 500 million year benefit attractive market environ ment increase flexibility noncurrent liability major pillar financing syndicated credit line 400 million concluded december 2014 dec 31 2014 dec 31 2013 maturity term five year new financing k k arrangement sartorius replaced two syndicated derivative financial credit line ahead schedule consolidated instrument 6765 7049 financing within group liability 42843 34765 total 49608 41814 additional component company financing note loan schuldscheindarlehen placed 2012 volume 100 million maturity derivative financial instrument represent fair five ten year value interest rate swap agreement addition several longterm loan totaling around noncurrent liability essentially include 100 million available expand company liability payment remaining purchase price production capacity among project acquisition lonzas cell culture medium busi ness liability connection non beyond component company diverse controlling interest allpure see section 9 working capital guaranteed credit line totaling consolidated financial statement note note statement financial position 137 28 current provision warranty total k k k balance jan 1 2013 3783 4945 8727 currency translation 103 220 323 change scope consolidation 208 0 208 consumption 552 1714 2266 reversal utilization 518 4135 4653 addition 1997 6194 8191 balance dec 31 2013 4815 5069 9884 warranty total k k k balance jan 1 2014 4815 5069 9884 currency translation 155 193 349 change scope consolidation 0 0 0 consumption 1153 1319 2472 reversal utilization 1738 673 2411 addition 3047 1352 4398 reclassification held sale 636 232 868 balance dec 31 2014 4489 4390 8880 measuring provision recognizable obligation based past business trans action past event uncertain timing amount recognized provision recognized result legal constructive obligation respect third party provision essentially include pending loss onerous contract uncertain obligation concerning employee benefit 138 consolidated financial statement note note statement financial position 29 current liability 30 financial obligation contingent asset liability trade payable financial obligation conjunction oper ating lease consist following dec 31 2014 dec 31 2013 k k dec 31 2014 dec 31 2013 payment received k k account order 33864 17366 operating lease trade payable third due within one year 9082 11112 party 56387 66339 due within 2 5 year 12127 18431 payable participation 85 411 due thereafter 2309 2522 payable non consolidated subsidiary 160 320 trade payable 90497 84435 31 financial instrument financial risk financial liability general information dec 31 2014 dec 31 2013 k k section give overview impact finan cial instrument financial statement derivative financial instrument 6555 106 sartorius group provides additional information personnelrelated liability 39079 31217 item contain financial instrument 33156 41357 statement financial position financial liability 78789 72680 derivative measured fair value determined according markingtomarket method recognized mathematical method used fair value based market data available liability time value derivative calculated reflect estimate market condition dec 31 2014 dec 31 2013 k k end year tax social security 13197 15335 2490 2485 liability 15687 17821 consolidated financial statement note note statement financial position 139 class financial instrument following table compare carrying amount fair value category financial instrument reconcile item statement financial position carrying carrying amount fair value amount fair value category acc ia 39 dec 31 2014 dec 31 2014 dec 31 2013 dec 31 2013 k k k k financial investment available sale 6067 6067 6294 6294 financial asset loan receivables 1669 1669 1437 1437 financial asset noncurrent 7736 7736 7731 7731 trade receivables loan receivables 140365 140365 138893 138893 receivables asset loan receivables 11635 11635 11540 11540 derivative financial instrument held trading 13 13 0 0 derivative financial instrument hedging instrument 107 107 4303 4303 financial asset current 11755 11755 15843 15843 cash cash equivalent loan receivables 40559 40559 51877 51877 financial liability loan borrowing cost 370980 380859 375393 377796 finance lease liability ifrs 7 21094 24221 21624 21308 financial liability trade payable cost 56632 56632 67070 67070 trade payable ifrs 7 33864 33864 17366 17366 trade payable 90497 90497 84435 84435 derivative financial instrument held trading 8957 8957 785 785 derivative financial instrument hedging instrument 4363 4363 6370 6370 financial liability financial liability cost 77114 80187 76122 82082 financial liability ifrs 7 37964 37964 31217 31217 financial liability 128398 131471 114494 120454 aggregate carrying amount financial instrument ia 39 category shown following table dec 31 2014 dec 31 2013 k k availableforsale asset 6067 6294 loan receivables 194228 203748 held trading asset 13 0 financial liability cost 504726 518586 held trading liability 8957 785 140 consolidated financial statement note note statement financial position fair value hierarchy net result financial instrument fair value financial instrument de net gain loss various category termined basis market information avail financial instrument presented following able reporting date allocated table one three level fair value hierarchy accordance ifrs 7 2014 2013 k k level 1 financial instrument calculated availableforsale asset 1166 0 basis price quoted active market identical loan receivables 3626 5215 asset liability level 2 financial instrument financial asset calculated basis input factor liability held trading 779 1113 derivable observable market data basis financial liability cost 185 1719 market price similar instrument level 3 finan cial instrument calculated basis input factor cannot derived observable market net result availableforsale financial asset data essentially comprised dividend capital gain loss equity investment non equity investment measured acquisition consolidated subsidiary cost financial asset possible determine fair value reliably due absence active mar net result borrowing receivables primarily kets applies mainly share nonconsolidated includes effect currency translation change subsidiary assumed carrying amount valuation adjustment correspond fair value reporting date net result financial asset liability held financial instrument recognized fair trading primarily comprised change value reporting date exclusively derivative market value derivative financial instrument form forward contract interest rate interest income expense instrument swap measured basis quot ed exchange rate market yield curve taking net result liability measured acquisition cost counterparty risk account level 2 mainly consists effect currency translation fair value disclosed financial liability total interest income expense financial recognized amortized cost especially liability asset liability recognized fair bank related note loan schuldschein value profit loss follows darlehen measured basis market interest rate curve according zero coupon 2014 2013 method taking current indicative credit spread k k account level 3 interest income 413 655 interest expense 13781 10567 allpure liability required disclosed amount present value expected purchase price payment noncontrolling interest company present value derived expected allpure sale revenue exercise date riskadjusted discount rate presented fair value remaining financial asset liability disclosed approximate carrying amount account predominantly short term maturity consolidated financial statement note note statement financial position 141 capital management management exchange rate risk sartorius group capital managed order group exposed currency risk approximate maximize earnings company stakeholder ly onethird sale revenue generated u dol optimizing ratio equity liability lars currency linked u dollar ensure group company operate lesser extent foreign currency premise goingconcern principle time sartorius global manufacturing network enables company offset lion share sale reve financial liability described section 27 nues received foreign currency within group regarded managed capital furthermore cost likewise incurred foreign currency cash cash equivalent well equity capital portion sale revenue foreign currency main settled cost ie net currency exposure resulting currency translation goal financial risk management hedged large extent derivative financial struments hedging strategy generally provides treasury management unit group cen hedging remaining net currency exposure 15 trally focused sartorius corporate administration year ahead hedging measure regularly reviewed gmbh centralized treasury management unit adapt expected exchange rate fluctuation performs service company sartorius group coordinate access national interna using forward contract concluded end tional financial market addition treasury reporting date secure right simultaneous management unit monitor control financial risk ly create obligation sell established foreign essentially entail currency interest rate currency amount exercise date specific liquidity risk exchange rate euro independently exchange rate actually valid date profit sartorius group strives minimize impact loss resulting difference current currency interest rate risk using derivative finan previously established exchange rate gener cial instrument hedging transaction con ally measured income expense state trolling carried different staff member ment profit loss moreover group internal auditing department regularly monitor use financial instru addition structured hedge socalled target profit ments trading derivative financial instrument forward used optimize hedging transaction done hedging purpose transaction secure right create obligation swap agreed amount foreign currency corresponding euro amount fixed exchange rate several target date long profit resulting exchange transaction exceed contractually defined limit reporting date company forward contract total volume u 82 million 2013 76 million hedge risk fluctuation eur usd exchange rate furthermore japanese yen total volume 260 million 2013 1450 million hedged forward exchange transaction 300 million form target profit forward end reporting date 142 consolidated financial statement note note statement financial position december 31 2013 fair value currency volume maturity k forward contract usd 16500000 q1 2014 1031 usd 25500000 q2 2014 850 usd 24500000 q3 2014 765 usd 9500000 q4 2014 14 usd 76000000 2660 forward contract jpy 400000000 q1 2014 931 jpy 250000000 q2 2014 169 jpy 400000000 q3 2014 271 jpy 400000000 q4 2014 272 jpy 1450000000 1644 december 31 2014 fair value currency volume maturity k forward contract usd 29000000 q1 2015 1839 usd 20000000 q2 2015 1160 usd 17000000 q3 2015 1075 usd 9000000 q4 2015 442 usd 7000000 q1 2016 108 usd 82000000 4624 forward contract jpy 130000000 q2 2015 55 jpy 130000000 q3 2015 30 jpy 260000000 85 target profit forward jpy 150000000 q4 2015 16 jpy 150000000 q4 2015 16 jpy 300000000 32 derivative financial instrument measured annual profit tax would time acquisition cost fair value subse 14 million 2013 04 million currently quent reporting date change value disclosed figure vice versa u dollar would derivative financial instrument recognized appreciated 5 euro resulting statement profit loss reporting date impact annual profit tax would derivative financial instrument serve hedge 16 million 2013 04 million im cash flow risk qualified hedging rela pact equity 61 million 2013 56 million tionship exists based criterion ia 39 impact include effect group inter valuation adjustment portion determined company loan partially compensated effective hedge recognized compre effect currency reserve translation hensive income ineffective portion gain loss recognized financial result change swiss franc chf would primari ly affected measurement liability recorded fiscal 2014 amount 4256 k 2013 4303 chf resulting acquisition lonza cell recognized comprehensive income culture medium business 2012 increase de ineffective portion 252 k recognized crease chf rate 5 would effect result period amount 4303 k 19 million 17 million respectively classified reporting year equity measurement statement profit loss 2013 1725 k disclosed operating income 2013 expense concerning exchange rate u dollar euro following sensitivity provide estimated impact u dollar would depreciated 5 euro equity would 56 million higher 2013 51 million actually reported consolidated financial statement note note statement financial position 143 interest risk management ing relationship meet requirement cash hedge accounting according requirement refinancing arrangement implemented ia 39 valuation adjustment portion december 2014 entire sartorius group determined effective recognized financed exclusively sartorius ag us comprehensive income ineffective portion internal group loan ensure financing gain loss recognized financial result group company hedging relationship dissolved due placement former syndicated loan amount loan predominantly taken 74 million reclassified reporting year variable interest rate sartorius group exposed comprehensive income statement interest rate risk control interest rate risk profit loss earlier year amount group concluded interest rate hedge form 11 million recorded comprehensive interest swap cover part loan income standing variable interest rate result group receives particular variable interest rate following table provides overview inter valid market pay fixed interest rate est hedging contract available reporting date interest hedge transaction concluded serve hedge interest rate risk effective hedg hedged volume hedged volume hedged fair value fair value dec 31 2014 dec 31 2013 end term interest rate dec 31 2014 dec 31 2013 instrument k k k k swap 170000 140000 sept 15 mar 16 183 289 4732 5346 forward swap 80000 110000 aug 18 mar 19 168 202 3959 1702 8691 7049 reporting date december 31 2014 swap 41 million amount 18 mil volume variable interest loan around lion would recorded annual profit 220 million hedging volume next five effect comprehensive income year 80 million 170 million approxi conjunction market valuation financial mately half twothirds company exposure struments used hedging effective hedging interest rate risk hedged 2013 debt relationship exist 2013 46 million 260 million v hedging volume 110 million 140 million decrease base interest rate 0 used measure sensitivity declining interest financial instrument held reporting rate condition corresponding impact date sensitivity analysis yield following result profit tax would 05 million market interest rate would 10 per 06 million previous year additionally centage point higher would impact impact 49 million compre 23 million resulting variable interest hensive income loan 2013 21 million opposite effect would yielded valuation interest rate 144 consolidated financial statement note note statement financial position liquidity risk management following table show liquidity analysis financial liability excluding derivative form contractually agreed undiscounted cash flow based condition reporting date carrying amount cash flow dec 31 2013 dec 31 2013 1 year 1 5 year 5 year k k k k k loan borrowing 375393 407376 30910 313524 62943 finance lease 21624 40387 3002 8168 29217 trade payable 67070 67070 67070 0 0 liability excluding derivative 76122 86160 41357 16292 28511 financial liability 540209 600993 142339 337983 120671 carrying amount cash flow dec 31 2014 dec 31 2014 1 year 1 5 year 5 year k k k k k loan borrowing 370980 398592 96319 201119 101154 finance lease 21094 39482 2472 9819 27191 trade payable 56632 56632 56632 0 0 liability excluding derivative 77114 86448 34271 23069 29108 financial liability 525821 581154 189695 234006 157453 carrying amount cash flow derivative shown follows carrying amount cash flow dec 31 2013 dec 31 2013 1 year 1 5 year 5 year k k k k k interest rate swap 7155 10370 3264 6942 164 derivative 7155 10370 3264 6942 164 carrying amount cash flow dec 31 2014 dec 31 2014 1 year 1 5 year 5 year k k k k k gross fulfilment forward contract 4617 4652 4511 141 payment obligation 63565 5765 payment claim 59054 5624 net fulfilment interest rate swap 8703 11629 3488 8141 0 derivative 13320 16281 12510 8423 0 group control liquidity risk maintaining credit line additional facility bank selling ceivables within scope factoring program continuously tracking forecasted actual cash flow managing maturity profile financial asset liability consolidated financial statement note note statement financial position 145 credit line credit line credit line credit line used unused k dec 31 2013 1 year 1 5 year 5 year interest rate dec 31 2013 dec 31 2013 syndicated credit line 445000 15000 430000 0 variable 245000 200000 note loan variable schuldscheindarlehen 100000 0 49500 50500 fixed 100000 0 variable bilateral credit line 80400 61650 12500 6250 fixed 30393 50007 total 625400 76650 492000 56750 375393 250007 credit line credit line credit line used unused k dec 31 2014 1 year 1 5 year 5 year interest rate dec 31 2014 dec 31 2014 syndicated credit line 400000 0 400000 0 variable 160000 240000 note loan variable schuldscheindarlehen 100000 0 78500 21500 fixed 100000 0 variable bilateral credit line 171441 70016 12500 88925 fixed 110980 60461 total 671441 70016 491000 110425 370980 300461 explained section 27 group essentially 32 sharebased payment financed syndicated loan note loan schuldscheindarlehen agreement within sartorius group sharebased payment group required comply standard financial exist form socalled phantom stock unit key ratio covenant context ratio sartorius ag stock option plan sartorius net debt underlying ebitda may greater stedim biotech sa 325 400 respectively fiscal 2014 group achieved ratio net debt underlying socalled phantom stock virtual option ebitda 17 compared 20 2013 ratio share sartorius ag specifically company include company discontinued operation based phantom stock plan credit member ex current information available company ecutive board gec beginning every year considers unlikely would comply phantom stock unit valued agreed mone covenant tary sum phantom stock option may exer cised earlier four year sum credited certain condition risk associated spect performance sartorius ag share financial instrument met executive board member exercise option number phantom stock unit granted evalu reporting date sartorius group ated current stock exchange price amount exposed significant risk volatility paid capped 25 time grant price share price vested portion sharebased pay detail please refer remuneration ments linked directly price development port fair value phantom stock unit sartorius stock measured using blackscholes model disclosed follows significant risk financial instrument discernible 146 consolidated financial statement note note statement financial position fair value number yearend fair value phantom yearend stock unit dec 31 2014 dec 31 2013 paid component longterm incentive effect k k k tranche 2010 16803 0 663 663 tranche 2011 10706 712 691 0 tranche 2012 9052 748 701 0 tranche 2013 4676 458 358 0 tranche 2014 4760 458 0 0 45997 2376 2413 663 fiscal 2014 expense relating granting share granted price class share valuation phantom stock unit 626 k 2013 grant date ordinary share 100 preference 539 k prior year phantom stock unit share 98 amount 4950 k due exercisable reporting date phan sharebased payment arrangement expected dividend tom stock unit granted reporting year 4091 included measurement unit fair value 345 k grant date share considering agreed condition amount attributable member executive board resulting december 16 2014 spread detail phantom stock unit please refer employee benefit expense full vesting remuneration report integral part period plan fiscal 2014 amount 56 k group management report accordingly recognized employee benefit expense resulting grant share resolution supervisory board december detail please refer remuneration report 16 2014 dr kreuzburg reappointed member executive board chairman ceo stock option plan staff sartorius term november 11 2015 november 10 stedim biotech group relate share sartorius 2020 due dr kreuzburgs excellent performance stedim biotech sa various stock option plan developing company since start tenure outstanding exercisble reporting date executive board november 11 2002 shown follows company wished continue successful coopera tion despite alternative offer dec 31 2014 dec 31 2013 made new remuneration agreement pro outstanding vides 25000 ordinary share 25000 prefer beginning period 23642 24642 ence share company shall transferred granted period 0 0 supplementary compensation component dr forfeited period 0 0 kreuzburg sharebased payment subject exercised period 15642 1000 rule ifrs 2 deemed granted expired period 0 0 upon resolution approved supervisory outstanding end board december 16 2014 remuneration com period 8000 23642 ponent included total remuneration exercisable end fair value grant date share respec period 8000 23642 tive fair value derived number consolidated financial statement note note statement financial position 147 various stock option plan summarized follows number number date share number option general number option subject annual initial subscribed number granted target number shareholder date number director total share perfor benefi meeting board share director number subscrip subscribed exercisable mance ciaries authorized granted executive benefi tion price fiscal dec 31 dec 31 valid plan approval subscribed executive concerned ciaries 2013 2013 2013 option june 23 2000 july 23 2004 140000 0 0 19 923 1000 15642 0 2 june 10 2005 sept 15 2005 127500 0 0 15 1887 0 5000 0 1 june 10 2006 nov 10 2006 35000 0 0 2 2951 0 3000 0 1 total 302500 0 0 36 1000 23642 0 4 number number date share number option general number option subject annual initial subscribed number granted target number shareholder date number director total share perfor benefi meeting board share director number subscrip subscribed exercisable mance ciaries authorized granted executive benefi tion price fiscal dec 31 dec 31 valid plan approval subscribed executive concerned ciaries 2014 2014 2014 option june 23 2000 july 23 2004 140000 0 0 19 923 15642 0 0 0 june 10 2005 sept 15 2005 127500 0 0 15 1887 0 5000 0 1 june 10 2006 nov 10 2006 35000 0 0 2 2951 0 3000 0 1 total 302500 0 0 36 15642 8000 0 2 sartorius stedim biotech share purchase option 33 disclosure discontinued operation allocated employee director subgroup plan inactive since result comprehensive strategic analysis 2006 new stock option issued since company business area executive board sarto time option exercised reporting year rius ag already decided 2011 review various based average share price 13290 option industrial technology division date exercise share option still outstand included possibility selling business 2013 ing reporting date statement fi 2014 necessary initial action taken spin nancial position exercisable november 9 division separate legal entity december 2016 latest fair value service per 19 2014 sartorius signed contract sell entity formed measured reference fair value japanese company minebea ltd partner option date allocation using bino development bank japan reason mialtype mathematic model fair value thus intec division reported discontinued operation measured recognized employee benefit ex consolidated financial statement pense spread full vesting period plan need record impairment loss based meas provided stock option entitlement actual urement intec disposal group lower ly acquired carrying amount fair value less cost sell cash received exercise option sartorius stedim biotech share disclosed cash cash equivalent offsetting item non controlling interest reported equity 148 consolidated financial statement note note statement financial position asset liability intec division financial asset allocated loan reporting date december 31 2014 shown receivables category financial liability follows financial liability cost dec 31 2014 deferred tax asset discontinued operation k relate primarily temporary difference carry noncurrent asset ing amount intangible asset goodwill goodwill 2504 intangible asset 4876 pension provision reported consist defined property plant equipment 4455 benefit obligation 10091 k plan asset financial asset 287 amount 1404 k please see section 25 infor asset 47 mation measurement parameter deferred tax asset 7955 20124 earnings attributable shareholder current asset sartorius ag discontinued operation inventory 11905 follows trade receivables 24777 financial asset 262 2014 2013 k k current tax asset 1963 asset 968 cash cash equivalent 15879 sale revenue 103826 103213 55754 expense 94309 95539 asset classified held sale 75878 operating income expense 2131 1342 earnings interest noncurrent liability tax ebit 7386 6332 pension provision 8689 financial result 250 219 provision 878 profit tax 7636 6113 deferred tax liability 60 income tax 3106 1575 9627 profit tax current liability discontinued operation 4530 4538 provision 868 trade payable 9931 financial liability 5076 transaction date close reporting date current tax liability 2067 subsequent measurement fair value less cost sell liability 3014 yield impairment loss 20956 liability associated asset classified held sale 30583 consolidated financial statement note disclosure 149 disclosure consolidated financial statement prepared number employee goingconcern basis table show average workforce employed exemption option provided 264 subsection 3 fiscal year german commercial code hgb applied annual financial statement reported sartorius 2014 2013 lab holding gmbh sartorius weighing technology bioprocess solution 3469 3151 gmbh sartorius corporate administration gmbh lab product service 2066 1893 based goettingen germany year ended continuing operation 5535 5044 december 31 2014 industrial technology 708 741 total 6243 5785 exemption option provided 264 b german commercial code hgb used annual financial statement reported sartorius mechatronics cd gmbh co kg aachen germany siv weende gmbh co kg goettingen auditor fee germany siv grone 1 gmbh co kg goettingen germany sartorius lab instrument gmbh co kg fiscal 2013 2014 following fee goettingen germany sartorius industrial scale curred group auditor deloitte gmbh co kg goettingen germany year touche gmbh ended december 31 2014 2014 2013 k k material event reporting date audit 473 436 certification sale industrial technology divsion verification service 98 157 japanese minebea co ltd partner tax consultation service 57 97 development bank japan inc completed service 82 146 february 6 2015 become economically effec 710 836 tive january 1 2015 cash proceeds resulting transaction total approximately 90 million certification verification service include audit review fee 98 k 2013 102 k declaration according 314 subsec 1 8 firsthalf financial report pursuant 37w german commercial code hgb german security trading act wphg declaration prescribed 161 german stock corporation law aktg submitted december 16 2014 made available share holder sartorius ag company website wwwsartoriuscom member supervisory board executive board member supervisory board executive board listed end section 150 consolidated financial statement note disclosure related company person total remuneration executive board supervisory board member shown following group company included consolidated table financial statement carry business activity transaction related party relationship defined 2014 2013 ia 24 particular concern transaction k k nonconsolidated subsidiary associate total remuneration generally concluded according customary executive board market term detail transaction completed fixed remuneration 1375 1298 reporting year balance outstanding fringe benefit 49 48 reporting date provided relevant total 1424 1346 section note financial statement annually paid variable remuneration 759 548 specifically section 10 20 variable remuneration multi year component according ia 24 related person consolidated net result 3 year 289 282 responsible planning management control phantom stock plan 48 year 345 325 reporting entity particular person include share granted 4950 0 member executive board super total 6343 1155 visory board sartorius ag particular total remuneration 7767 2501 person include member executive board supervisory board sartorius ag reporting year total remuneration supervi partial payment multiyear variable remuneration sory board member 926 k 2013 888 k executive board member executive board 7767 k 2013 2501 k remuneration former managing director mem 2014 2013 bers executive board surviving de k k pendent 405 k 2012 394 k pension balance jan 1 fiscal year 306 310 obligation former managing director partial payment deducted 150 160 member executive board surviving partial payment effected 146 156 dependent totaled 6768 k 2013 7065 k balance dec 31 detail remuneration please refer remu fiscal year 302 306 neration report integral part com bined group management report beyond supervisory board remuneration employee repre 2014 2013 sentatives employee within sartorius k k group receive compensation related remuneration supervisory service supervisory board board member total remuneration 926 888 fixed remuneration 600 600 compensation committee work 80 80 meeting attendance fee 154 104 remuneration sartorius weighing technology gmbh goettingen 0 13 total remuneration sartorius stedim biotech subgroup 92 91 remuneration sartorius stedim biotech gmbh goettingen 38 38 remuneration sartorius stedim biotech sa aubagne 54 53 consolidated financial statement note disclosure 151 proposal appropriation profit supervisory board executive board submit proposal annual shareholder meeting appropriate retained profit 13937014984 reported sartorius ag year ended december 31 2014 follows payment dividend 106 per ordinary share 903973936 payment dividend 108 per preference share 920053836 unappropriated profit carried forward 12112987212 13937014984 goettingen february 23 2015 sartorius aktiengesellschaft executive board 152 consolida ted financiall statement note declaration executive board declaration executtive board declare best know wledge tthe consolidatedd financial staatements fiscal 2014 p sent truee fair vieew acctual net worrth p financial sittuation profitability group accordance acccounting staandards used preparing hese statement also certify tthe b progress group business including busin es performancee situuation represented acccu rately thee group manaagement report materrial respect andd present important opportunitties risk f groupss future deveelopment duriing fiscal yeear goettingen february 23 2015 sartorius akktiengesellschaaft executivve board dr joachim kreuzburg jörg pfirrmaann reinhard voogt consolidated financial statement note independent auditor report 153 independent auditor report audited consolidated yearend financial state audit cover assessment annual financial ments consist consolidated statement statement company included consoli profit loss along statement compre dated financial statement definition scope hensive income statement financial position consolidation accounting consolidation statement cash flow statement change principle applied significant estimate made equity note financial statement well executive board well evaluation management report integrated group overall presentation consolidated yearend management report sartorius aktieng financial statement group management esellschaft germany prepared fiscal year port believe audit provides reasonable january 1 december 31 2014 preparation basis opinion consolidated financial statement group management report according international audit result objection financial reporting standard ifrs applied eu according commercial according assessment based information rule additionally applied conformance obtained audit consolidated finan 315a subsection 1 german commercial code cial statement sartorius aktiengesellschaft hgb responsibility executive board goettingen conform ifrs parent corporation sartorius aktiengesellschaft applied eu commercial rule responsibility express opinion con additionally applied compliance 315a sub solidated financial statement group man section 1 hgb present fairly material agement report based audit respect net worth financial position earn ings group group management report conducted audit accordance 317 hgb consistent consolidated financial statement taking account principle proper auditing provides overall true fair view established german institute independent group situation accurately present oppor auditor institut der wirtschaftsprüfer prin tunities risk future development ciples require plan perform audit obtain reasonable assurance misrep hanover germany february 23 2015 resentations infraction material impact presentation net worth financial posi deloitte touche gmbh tion earnings consolidated financial state ments consideration accounting principle applied group management report determining audit focus information busi ness activity economic legal background group well expectation possible error henning scharpenberg dr christian meyer taken account within scope audit auditor auditor effectiveness accountingrelated internal control system well evidence supporting amount disclosure made consolidated financial statement group management port predominantly examined test basis 154 consolidated financial statement note executive board supervisory board executive board supervisory board fiscal 20141 executive board supervisory board dr rer pol joachim kreuzburg prof dr dres hc arnold picot diplingenieur graduate engineer ceo diplkaufmann graduate business administration chairman corporate strategy operation legal affair university professor compliance corporate communication chairman born april 22 1965 executive director institute information resident hanover germany organization management faculty economics member since november 11 2002 ludwig maximilian university munich germany sprecher spokesman may 1 2003 resident gauting germany november 10 2005 chairman since november 11 2005 manfred zaffke appointed november 10 2020 diplvolkswirt graduate political economist vice chairman jörg pfirrmann first authorized representative german diplökonom graduate economist metalworker union ig metall southern executive labor relation lower saxonyharz region northeim germany finance human resource general administration resident osterode harz germany born november 30 1972 resident noertenhardenberg germany dr dirk basting member since july 24 2009 diplchemiker graduate chemical engineer appointed july 23 2017 resident fort lauderdale florida usa reinhard vogt annette becker industriekaufmann industrial business manager personalfachkauffrau hr specialist marketing sale service chairwoman employee council born august 4 1955 sartorius corporate administration gmbh resident dransfeld germany goettingen germany member since july 24 2009 chairwoman group employee council appointed july 23 2019 sartorius ag goettingen germany resident goettingen germany uwe bretthauer diplingenieur graduate engineer chairman employee council sartorius lab instrument gmbh co kg goettingen germany resident goettingen germany michael dohrmann feinmechaniker precision engineer chairman employee council sartorius stedim biotech gmbh goettingen germany resident reinhausen germany dr lothar kappich diplökonom graduate economist managing director ece projektmanagement gmbh co kg hamburg germany 1 information required pursuant sec 285 10 resident hamburg germany german commercial code hgb consolidated financial statement note executive board supervisory board 155 committee supervisory board petra kirchhoff executive task committee diplvolkswirtin graduate political economist prof dr dres hc arnold picot chairman vice president corporate communication manfred zaffke since march 1 2014 investor relation gerduwe boguslawski february 28 2014 sartorius corporate administration gmbh uwe bretthauer goettingen germany prof dr gerd krieger resident goettingen germany audit committee karoline kleinschmidt prof dr klaus rüdiger trützschler chairman diplsozialwirtin graduate social economist manfred zaffke since march 1 2014 secretary german metalworker union ig metall gerduwe boguslawski february 28 2014 district management lower saxony uwe bretthauer saxonyanhalt hanover germany prof dr dres hc arnold picot resident hanover germany conciliation committee prof dr gerd krieger prof dr dres hc arnold picot chairman rechtsanwalt lawyer manfred zaffke since march 1 2014 honorary professor heinrichheine university gerduwe boguslawski february 28 2014 duesseldorf uwe bretthauer resident duesseldorf germany prof dr gerd krieger prof dr thomas sheper nomination committee diplchemiker graduate chemical engineer prof dr gerd krieger university professor head institute prof dr dres hc arnold picot technical chemistry dr lothar kappich leibnitz university hanover germany resident hanover germany prof dr klaus rüdiger trützschler diplwirtschaftsmathematiker graduate business mathematician diplmathematiker graduate mathematician resident essen germany gerduwe boguslawski diplsozialwirt graduate social manager vice chairman february 28 2014 german metalworker union ig metall south ern lower saxonyharz region northeim germany resident hoeckelheim germany 1 information required pursuant sec 285 10 german commercial code hgb 156 consolidated financial statement note executive board supervisory board position held member executive board1 december 31 2014 dr rer pol joachim kreuzburg jörg pfirrmann présidentdirecteur général ceo board director sartorius stedim biotech sa france2 sartorius ireland ltd ireland2 supervisory board sartorius stedim ireland ltd ireland2 sartorius stedim biotech gmbh germany sartorius corporation usa2 vice chairman2 sartorius canada inc canada2 board director sartorius stedim nordic denmark2 sartorius north america inc usa2 sartorius nordic denmark2 sartorius stedim north america inc usa2 sartorius uk ltd uk2 sartorius stedim filter inc puerto rico2 sartorius stedim uk ltd uk2 sartorius japan kk japan2 sartorius shanghai trading co ltd china2 sartorius stedim japan kk japan2 sartorius stedim shanghai trading co ltd china2 denver instrument beijing co ltd china2 sartorius stedim biotech beijing co ltd china2 sartorius scientific instrument beijing co ltd china2 management committee sartorius hong kong ltd china2 sartorius france sa france2 sartorius stedim lab ltd uk2 comité exécutif executive committee comité exécutif executive committee sartorius stedim france sa france2 sartorius stedim fmt sa france2 consiglio di amministrazione supervisory board board management carl zeiss ag germany3 sartorius italy srl italy2 regionalbeirat regional advisory board sartorius stedim italy spa italy2 commerzbank ag hamburg germany3 consejo de administración board director beirat advisory board sartorius spain sa spain2 otto bock holding gmbh co kg germany3 unternehmerbeirat employer advisory board wirtschaftsbeirat economic advisory board gothaer versicherungsbank vvag germany3 norddeutsche landesbank germany3 reinhard vogt conseil dadministration board director sartorius stedim biotech sa france2 board director tap biosystems group ltd uk2 sartorius north america inc usa2 sartorius stedim north america inc usa 2 denver instrument beijing co ltd china2 sartorius scientific instrument beijing co ltd china2 sartorius shanghai trading co ltd china2 sartorius stedim shanghai trading co ltd china2 sartorius stedim malaysia sdn bhd malaysia2 sartorius japan kk japan2 sartorius stedim japan kk japan2 sartorius hong kong ltd china2 sartorius korea ltd south korea 2 sartorius australia pty ltd australia2 sartorius stedim australia pty ltd australia2 verwaltungsrat administrative board 1 information required pursuant sec 285 10 sartorius stedim switzerland ag switzerland german commercial code hgb 2 position held within group chairman2 3 external position held member executive board december 31 2014 consolidated financial statement note executive board supervisory board 157 position held member supervisory board1 december 31 2014 prof dr dres hc arnold picot dr lothar kappich conseil dadministration board director none sartorius stedim biotech sa france2 supervisory board petra kirchhoff sartorius stedim biotech gmbh supervisory board germany chairman2 awo goettingen ggmbh takkt ag germany3 wissenschaftliches institut für infrastruktur und karoline kleinschmidt kommunikationsdienste gmbh scientific institute none communication service wikconsult gmbh germany3 prof dr gerd krieger supervisory board manfred zaffke arag lebensversicherungsag germany 3 supervisory board arag krankenversicherungsag germany3 terex mhps gmbh germany3 gmh guss gmbh germany prof dr thomas scheper vice chairman3 none dr dirk basting prof dr klaus rüdiger trützschler none supervisory board deutsche bank ag germany3 annette becker wuppermann ag germany chairman3 none zwiesel kristallglas ag germany chairman3 verwaltungsrat administrative board uwe bretthauer wilh werhahn kg germany3 none michael dohrmann none 1 information required pursuant sec 285 10 german commercial code hgb 2 position held within group 3 external position held member supervisory board december 31 2014 158 executive board supervisory board supplementary information 160 supplementary information glossary glossary industrial productspecific term bag singleuse membrane filter plastic disposable bag used bioreactors storing liquid thin film foil made polymer porous culture medium intermediate product biopharma structure film suitable filtration application ceuticals monoclonal antibody bioreactor synthetic antibody used particular treatment englishspeaking country bioreactor vessel used cancer hiv autoimmune disease cultivating animal human cell culture medium non englishspeaking country term bioreactor also used pat process analytical technology synonymously term fermentor denote system strategy design analysis control manufacturing used multiply microorganism either case vessel process according quality characteristic interme used obtain cell part one metabolite diate finished product defined analyzed monitored using critical process parameter identified capsule readytouse filter unit consisting filter housing hose pharmerging market connector incorporated filter cartridge according ims health egypt argentina brazil china disposable india indonesia mexico pakistan poland romania russia used synonymously singleuse south africa thailand turkey ukraine venezuela vietnam downstream processing purification collective term various step follow fermentation important step downstream processing cell cultivation upstream processing production biopharmaceuticals example separation purification recombinant protein concentration protein manufactured using genetically modified organism used production therapeutic protein insulin fda food drug administration vaccine u regulatory agency responsible ensuring safety efficacy human veterinary pharmaceutical biological scaleup product medical device food transfer scale increase size used denote progres sion process increase range lab scale pilot fermentation scale process scale retaining technology technical process used produce transform intra material construction geometry throughout extracellular substance help microorganism singleuse reusable product fluid management technology disposable product ie onetime usage reusable product technology system transportation storage designed repeated use biological liquid sterile filter sterilizinggrade filter mechatronics membrane filter whose pore size usually 02 smaller interdisciplinary field combine mechanical electrical product processspecific validation test required electronic engineering intelligent control technology com confirm filter type selected delivers sterile filtrate puter science technology interact compensate distorting effect material property ambient upstream processing condition may accuracy measured result manufacture biopharmaceuticals designates vari ous step take place seeding propagating cell membrane chromatography produce active pharmaceutical ingredient selective separation mixture substance adsorption specifically modified membrane membrane adsorbers validation flowing system documented verification system device process reproducibly deliver desired result supplementary information glossary 161 business economic term amortization fixed asset amortization relates exclusively potential reduction sum intangible asset property plant equipment value goodwill allocation purchase price financial asset intangible asset acquired carried accordance ifrs 3 free float cash flow proportion public company share freely available flow fund financial resource earned investing public definition least 5 daytoday business activity amount cash earned paying expense tax word cash balance goodwill inflow outflow fund difference price paid company business net asset form intangible asset compliance observance applicable law code relevant rule holding company regulation parent company exists purpose owning controlling interest share several legally independent dax mdax sdax tecdax subsidiary subordinate parent company within german stock index transaction service provider organizational hierarchy holding company conduct marketplace organizer deutsche börse ag business exclusively subsidiary insurance ia director officer liability insurance cover super international accounting standard internationally recognized visory executive board member managerial employee accounting principle dvfa sg ifrs method commission society investment profes international financial reporting standard internationally sionals germany dfva ev also commonly referred recognized accounting principle german association financial analysis asset man agement schmalenbachgesellschaft sg one market capitalization leading scientific society area business administration total number share outstanding class issued financial reporting company multiplied corresponding share price ebitda prime standard earnings interest tax depreciation amortization market segment frankfurt stock exchange high context amortization refers exclusively purchase internationally accepted transparency requirement seg price allocation ppa intangible asset acquired according ment intended meet need company seeking ifrs 3 attract attention international investor ebitda margin supply chain management ratio ebitda earnings interest tax depreciation setup coordination integrated flow material amortization sale revenue information finance supply chain entire valueadded process equity ratio ratio equity balance sheet total treasury short mediumterm liquidity management erp stand enterprise resource planning itbased resource underlying planning system adjusted eliminate extraordinary item see definition extraordinary item exceptional onetime expense income restructuring cost nonoperating expense 162 supplementary information index index e acquisition 8 12 15 24 26 30 ff 36 39 43 f 49 earnings 8 12 f 23 30 33 f 39 f 44 48 51 ff 76 60 103 108 114 116 120 ff 131 f 100 102 ff 115 119 121 124 129 141 address 166 ff 148 153 annual financial statement 13 f 52 ff 57 74 77 ff 108 earnings per share 23 34 f 124 149 153 earnings reserve 54 annual shareholder meeting cover 8 12 ff 18 35 55 ebit 23 33 f 100 103 116 148 71 73 f 131 147 151 ebitda 8 f 23 26 30 34 41 44 48 51 66 75 amortization 34 f 53 75 103 109 ff 115 f 125 ff 115 f 145 152 161 appropriation profit 35 55 151 employee 14 23 36 f 45 55 60 69 74 83 86 ff asset 30 39 f 52 54 61 69 75 102 f 105 ff 119 ff 92 95 97 121 133 135 f 147 149 f 138 ff 144 148 161 employee benefit expense 53 77 79 108 f 122 146 f auditor 12 ff 57 68 f 74 149 153 equity 23 30 40 52 54 71 100 ff 107 ff 112 ff 129 131 f 140 ff 147 153 161 b executive board 8 f 12 ff 18 23 35 55 ff 71 ff 87 balance sheet cover 35 f 39 f 52 54 f 61 f 161 105 115 124 f 133 145 ff 149 ff bioprocess solution 8 22 ff 27 29 ff 42 ff 56 f 66 153 f 156 105 115 f 120 ff 149 business development 18 28 30 f 42 46 52 55 f f financial asset 52 54 102 106 f 112 115 131 139 f c 144 148 capital expenditure 36 103 126 ff financial instrument 61 74 106 f 112 f 123 129 136 cash flow 23 30 39 69 101 103 110 113 f 120 138 ff 125 127 130 132 142 144 161 financing 14 33 41 52 61 103 113 119 136 143 cash flow statement 39 financial result 19 33 f 100 103 113 115 f 121 compliance 12 f 56 f 68 73 f 87 98 154 161 123 142 f 148 consolidated finacial statement 13 f 22 30 52 57 68 ff fixed asset 40 52 54 103 109 ff 120 161 74 102 153 forecast report 55 63 corporate governance 13 57 72 ff 81 87 149 foreign exchange foreign exchange rate 41 88 108 currency 23 28 41 57 61 68 101 103 f 108 f 113 f foreign subsidiary 108 123 125 ff 130 ff 140 ff currency translation 101 103 108 f 123 125 ff 130 f g 132 134 f 137 140 f group company 57 ff 68 f 132 f 136 141 143 150 group executive committee 10 f 23 56 group financial statement 52 119 121 depreciation 33 ff 53 103 107 f 110 f 115 f 128 group management report 14 22 ff 146 150 153 161 distribution 24 ff 33 44 48 50 57 ff 91 100 109 h 111 122 128 161 hedging 33 f 41 61 113 123 131 139 141 ff dividend cover 8 14 18 f 35 52 55 71 75 78 103 f 124 131 f 140 146 151 impairment 69 75 109 f 114 125 ff 131 impairment loss 112 125 ff 148 industrial technology 8 13 22 30 33 39 51 f 66 f 86 105 125 147 149 intangible asset 75 102 110 114 116 120 125 ff 129 148 interest income 134 140 inventory 39 58 69 102 f 111 120 f 129 f investment 27 35 f 39 51 ff 55 66 68 108 112 129 139 f investor relation 18 cover supplementary information index 163 index l lab product service 8 12 23 36 46 ff 56 f 66 sale distribution 8 12 22 24 44 48 57 ff 111 122 105 115 f 122 125 149 sale revenue cover 8 f 12 23 ff 28 30 ff 39 43 ff liability 30 39 f 54 61 69 102 f 105 108 f 47 f 51 ff 61 64 ff 75 90 92 100 108 112 ff 120 f 129 ff 136 138 ff 144 148 111 114 116 119 121 f 132 140 f 148 sartorius stedim biotech 22 f 33 52 61 82 117 120 f 127 132 145 ff 150 macroeconomic environment 27 ff 63 security 18 112 134 marketing 37 56 109 111 segment report 69 115 market capitalization 15 f 18 f 161 shareholder structure 19 shareholding 71 n share index 15 f net debt 23 30 39 ff 66 75 145 share cover 8 13 f 15 ff 22 f 32 ff 55 71 f 74 ff net profit 18 23 33 f 53 f 75 78 80 100 f 104 100 104 f 124 131 f 145 ff 124 132 singleuse technology 24 29 44 66 94 statement profit loss 30 33 69 100 105 108 113 p 120 122 132 f 136 141 pension provision 102 112 133 148 stedim transaction 127 phantom stock phantom stock unit 75 79 145 f supervisory board 8 12 ff 18 f 35 56 f 68 71 ff position held 156 f 105 146 149 ff procurement 56 58 61 90 supply chain management 45 50 58 production 8 f 24 26 29 f 33 35 ff 41 44 f 50 sustainability report 74 86 98 56 ff 61 65 f 86 90 ff 107 109 111 120 122 136 product 8 f 22 24 ff 29 35 37 44 f 47 f 50 56 tax 33 f 53 100 ff 109 113 ff 120 123 ff 129 58 f 61 f 86 91 93 f 105 108 110 120 131 ff 138 142 f 148 f profit 12 14 18 23 30 33 ff 52 ff 55 61 69 75 trading volume 16 18 78 ff 100 f 103 ff 108 f 112 ff 120 ff 127 treasury 41 141 129 f 132 f 136 140 ff 151 property plant equipment 54 102 110 114 ff 128 148 u provision 23 54 60 68 f 71 87 89 ff 102 f 112 unqualified audit certificate 14 114 f 120 129 132 f 135 ff 148 w r working capital 23 39 41 58 136 ratio net debt ebitda cover 75 receivables 39 54 57 59 f 68 102 f 109 111 f 114 f 120 f 129 ff 139 f 144 148 region 8 f 12 23 37 43 49 87 95 116 remuneration executive board 12 75 83 research development 33 35 37 45 49 55 59 88 93 109 f 122 f reserve 54 102 104 131 restructuring 69 112 115 result 9 12 ff 30 59 62 76 92 f 113 ff 143 retained profit 14 52 f 54 f 151 risk management system 13 55 ff 68 ff risk opportunity report 56 62 164 supplementary information local presence worldwide local presence worldwide america mississauga canada bohemia ny usa wilmington de usa new oxford pa usa mexico city mexico yauco puerto rico são paulo brazil buenos aire argentina sale production production sale supplementary information local presence worldwide 165 europe africa dublin ireland kajaani finland royston uk helsinki finland stonehouse uk st petersburg russia epsom uk moscow russia vilvoorde belgium goettingen germany paris france guxhagen germany aubagne france poznan poland lourdes france budapest hungary florence italy vienna austria milan italy tagelswangen switzerland madrid spain mohamdia tunisia barcelona spain asia paciﬁc beijing china suzhou china shanghai china hong kong china seoul south korea tokyo japan hanoi vietnam bangkok thailand bangalore india kuala lumpur malaysia singapore singapore melbourne australia 166 supplementary information address address europe germany belgium sartorius ag sartorius stedim plastic gmbh sartorius stedim belgium nv weender landstrasse 94108 karlarnoldstr 21 leuvensesteenweg 248b 37075 goettingen 37079 goettingen 1800 vilvoorde phone 495513080 phone 49551504500 phone 3227560680 fax 495513083289 fax 495515045050 fax 3227560681 infosartoriuscom infosartoriusstedimcom lindreymensartoriuscom sartorius stedim biotech gmbh sartorius stedim system gmbh sartorius belgium nv augustspindlerstr 11 robertboschstraße 57 leuvensesteenweg 248b 37079 goettingen 34302 guxhagen 1800 vilvoorde phone 495513080 phone 4956654070 phone 3227560671 fax 495513083289 fax 4956654072200 fax 3222534595 infosartoriusstedimcom infosartoriusstedimcom infobelgiumsartoriuscom sartorius lab holding gmbh sartorius corporate administration gmbh denmark weender landstrasse 94108 weender landstrasse 94108 37075 goettingen 37075 goettingen sartorius stedim nordic phone 495513080 phone 495513080 lyskaer 3 fax 495513083289 fax 495513083289 2730 herlev infosartoriuscom infosartoriuscom phone 4570234400 fax 4546304030 sartorius weighing technology gmbh austria infodksartoriusstedimcom weender landstrasse 94108 37075 goettingen sartorius stedim austria gmbh sartorius nordic phone 495513080 modecenterstr 22 lyskaer 3 fax 495513083289 1030 vienna 2730 herlev infosartoriuscom phone 43179657630 phone 4570234400 fax 431796576344 fax 4546304030 sartorius lab instrument gmbh co kg separationaustriasartoriuscom infodksartoriuscom weender landstrasse 94108 37075 goettingen sartorius austria gmbh finland phone 495513080 modecenterstr 22 fax 495513083289 1030 vienna sartorius biohit liquid handling oy infosartoriuscom phone 43179657600 laippatie 1 fax 431796576024 00880 helsinki infoaustriasartoriuscom phone 3589755951 fax 358975595292 lhinfofinlandsartoriuscom supplementary information address 167 france hungary netherlands sartorius stedim biotech sa sartorius stedim hungary kft sartorius stedim netherlands bv zone industrielle le paluds kagyló u 5 westblaak 89 avenue de jouques c 91051 2092 budakeszi 3012 kg rotterdam 13781 aubagne cedex phone 3623457227 phone 31306025080 phone 33442845600 fax 3623457147 fax 31306025099 fax 33442845619 ssbsartoriushu officenlsartoriuscom infosartoriusstedimcom sartorius hungary kft sartorius netherlands sartorius stedim fmt sa kagyló u 5 westblaak 89 zone industrielle le paluds 2092 budakeszi 3012 kg rotterdam avenue de jouques c 91051 phone 3623457227 phone 31306053001 13781 aubagne cedex fax 3623457147 fax 31306052917 phone 33442845600 mechatronikasartoriushu officenlsartoriuscom fax 33442845618 infosartoriusstedimcom ireland poland sartorius stedim france sa sartorius stedim ireland ltd sartorius stedim poland sp zoo zone industrielle le paluds unit 41 business centre ul wrzesinska 70 avenue de jouques c 71058 stadium business park 62025 kostrzyn 13781 aubagne cedex ballycoolin road phone 48616473840 phone 33442845600 dublin 11 fax 48618792504 fax 33442846545 phone 35318234394 biuroplsartoriuscom infobiotechfrancesartoriusstedimcom fax 35318089388 infoirelandsartoriusstedimcom sartorius poland sp zoo sartorius stedim aseptics sa ul wrzesinska 70 zone industrielle de saux 6 rue ampère sartorius ireland ltd 62 025 kostrzyn 65100 lourdes unit 41 business centre phone 48616473830 phone 33562427373 stadium business park fax 48616473839 fax 33562420844 ballycoolin road infoplsartoriuscom infosartoriusstedimcom dublin 11 phone 35318089050 sartorius france sa fax 35318089388 2 rue antoine laurent de lavoisier infoirelandsartoriuscom zone dactivité de la gaudrée 91410 dourdan italy phone 33170625000 fax 33164597639 sartorius stedim italy spa commercialfrancebiohitcom via dellantella 76a 50012 antella bagno ripoli florence phone 39055634041 fax 390556340526 infoitalysartoriuscom sartorius italy srl viale alfonso casati 4 20835 muggió monza e brianza phone 3903946591 fax 3903946598 infoitalysartoriuscom 168 supplementary information address russia spain uk ooo sartogosm sartorius stedim spain sa sartorius stedim uk ltd uliza rasstannaya dom 2 korp2 lit polígon le guixeres carrer marcus porcius 1 longmead business centre 192007 st petersburg edifici bcin blenheim road phone 78123802569 0915 badalona barcelona epsom surrey kt19 9qq fax 78123802562 phone 34934648012 phone 441372737159 infosartogosmru fax 34934648020 fax 441372726171 biotech_spainsartoriusstedimcom uksartoriussartoriusstedimcom ooo sartorius icr uliza rasstannaya dom 2 korp2 lit sartorius spain sa sartorius stedim lab ltd 192007 st petersburg avda de la industria 32 unit 6 phone 78123275327 edificio payma stonedale road fax 78123275323 28108 alcobendas madrid stonehouse gloucestershire gl10 3rq russiasartoriuscom phone 34902123367 phone 441453821972 fax 34913588485 fax 441453827928 ooo biohit spainweighingsartoriuscom alanjohnsonsartoriusstedimcom uralskaya str 4 letter b room 03h 199155 st petersburg switzerland sartorius uk ltd phone 78123275327 longmead business centre fax 78123275323 sartorius stedim switzerland ag blenheim road russiasartoriuscom ringstrasse 24a epsom surrey kt19 9qq 8317 tagelswangen phone 441372737102 ooo biohit phone 41523543636 fax 441372729927 petrovskorazumovsky proyezd 29 building 2 fax 41523543646 uksartoriussartoriuscom 127287 moscow biotechswitzerlandsartoriusstedimcom phone 74957481613 automation partnership cambridge ltd fax 74956135577 york way russiasartoriuscom royston hertfordshire sg8 5wy phone 441763227200 fax 441763227201 infotapbiosystemscom supplementary information address 169 north america latin america africa canada argentina tunisia sartorius canada inc sartorius argentina sa sartorius stedim bioprocess sarl 2179 dunwin drive unit 45 int avalos 4251 km 24 route de zaghouan mississauga ontario l5 l 1x2 b1605ecs munro mhamdia bourbiâa 1145 phone 19055697977 buenos aire bp 87 ben arous fax 19055697021 phone 541147210505 phone 21679397014 salescanadasartoriuscom fax 541147622333 fax 21679397019 sartoriusargsartoriuscom infosartoriusstedimcom puerto rico brazil sartorius stedim filter inc carretera 128 int 376 sartorius brasil ltda barriada arturo lluveras avenida senador vergueiro 2962 po box 6 yauco puerto rico 00698 são bernardo campo phone 17878565020 cep 09600004 spbrasil fax 17878567945 phone 551143628900 marcoslopezsartoriuscom fax 551143628901 sartoriusbrsartoriuscom usa mexico sartorius stedim north america inc 5 orville drive sartorius de méxico sa de cv bohemia new york 11716 circuito circunvalación poniente 149 phone 16312544249 ciudad satélite fax 16312544264 53100 estado de méxico phone infosartoriusstedimcom 525555621102 fax 525555622942 sartorius corporation sartoriusmxsartomexcom 5 orville drive bohemia new york 11716 phone 16312544249 fax 16312544252 infosartoriuscom allpure technology inc 80 progress avenue new oxford pa 17350 phone 17176243241 fax 17176243051 salesallpureinccom 170 supplementary information address asia pacific china japan sartorius scientific instrument sartorius stedim shanghai trading co ltd sartorius stedim japan kk beijing co ltd 3 rd floor north wing tower1 4th floor daiwa shinagawa north bldg 33 yu road tianzhu airport 4560 jinke road 1811 kitashinagawa shinagawaku industrial park zone b pudong district shanghai 201210 tokyo 1400001 shun yi district 101300 beijing telefon 862168782300 phone 81337405407 phone 861080426300 fax 862168782332 2882 fax 81337405406 fax 861080426486 infocnsartoriuscom infosartoriuscojp infocnsartoriuscom sartorius shanghai trading co ltd sartorius japan kk sartorius hong kong ltd 3 rd floor north wing tower 1 4th floor daiwa shinagawa north bldg unit 1012 lu plaza 4560 jinke road 1811 kitashinagawa shinagawaku 2 wing yip street pudong district shanghai 201210 tokyo 1400001 kwun tong kowloon hong kong telefon 862168782300 phone 81337405407 phone 85227742678 fax 862168782332 2882 fax 81337405406 fax 85227663526 infocnsartoriuscom infosartoriuscojp enquiryhongkongsartoriuscom india malaysia sartorius stedim biotech beijing co ltd 33 yu road tianzhu airport sartorius stedim india pvt ltd sartorius stedim malaysia sdn bhd industrial park zone b 692 693 jakkasandra lot l3e3b enterprise 4 shun yi district 101300 beijing kunigal road technology park malaysia phone 861080426516 nelamangala bangalore 562123 bukit jalil fax 861080426580 phone 918043505250 57000 kuala lumpur enquirycnsartoriusstedimcom fax 918043505253 phone 60389960622 biotechindiasartoriuscom fax 60389960755 biohit biotech suzhou co ltd ehtansartoriuscommy block 6 2 west jinzhi rd sartorius weighing india pvt ltd suzhou city jiangsu province 215151 692 693 jakkasandra sartorius malaysia sdn bhd phone 8651266160490 kunigal road lot l3e3b enterprise 4 fax 8651266160690 nelamangala bangalore 562123 technology park malaysia infochinabiohitcom phone 918043505250 bukit jalil fax 918043505253 57000 kuala lumpur denver instrument beijing co ltd swilpssartoriuscom phone 60389960622 33 yu road tianzhu airport fax 60389960755 industrial park zone b ehtansartoriuscommy shun yi district 101300 beijing phone 861080426300 fax 861080426486 infocnsartoriuscom supplementary information address 171 singapore thailand australia sartorius stedim singapore pte ltd sartorius thailand co ltd sartorius stedim australia pty 1 science park road 129 rama ix road ltd unit 5 7 11 rodeo drive 0508a capricorn huaykwang dandenong south melbourne singapore science park ii bangkok 10310 victoria 3175 singapore 117528 phone 6626438361 phone 61387621800 phone 6568723966 fax 6626438367 fax 613 87621828 fax 6567782494 enquirythailandsartoriuscom infoaustraliasartoriusstedimcom chooleepangsartoriusstedimcom vietnam sartorius australia pty ltd sartorius singapore pte ltd unit 5 711 rodeo drive 1 science park road sartorius representative office dandenong south melbourne 0508a capricorn unit c 17th floor tower big building victoria 3175 phone 61387621800 singapore science park ii 18 pham hung street fax 61387621828 singapore 117528 dinh tu liem hanoi infoaustraliasartoriusstedimcom phone 6568723966 phone 84437955587 fax 6567782494 fax 84437955589 enquirysingaporesartoriuscom sartoriusvnhnvnnvn south korea sartorius korea biotech co ltd 8th floor solid space 220 pangyoyeokro bundanggu seongnamsi gyeonggido 463 400 phone 82316225700 fax 82316225798 infosartoriuscokr sartorius korea ltd 8th floor solid space 220 pangyoyeokro bundanggu seongnamsi gyeonggido 463 400 phone 82316225700 fax 82316225798 infosartoriuscokr address please visit website internet wwwsartoriuscom 172 supplementary information leerseite leerseite financial schedule annual shareholder meeting goettingen germany april 9 2015 1 payment dividend april 10 2015 publication firstquarter figure 2015 april 20 2015 publication firsthalf figure 2015 july 22 2015 publication ninemonth figure 2015 october 20 2015 german equity forum frankfurt main germany november 23 2015 publication preliminary figure fiscal 2015 january 2016 annual press conference goettingen germany march 2016 annual shareholder meeting goettingen germany april 7 2016 publication firstquarter figure 2016 april 2016 1 subject approval annual shareholder meeting contact petra kirchhoff andreas theisen vice president director corporate communication ir investor relation phone 495513081686 phone 495513081668 petrakirchhoffsartoriuscom andreastheisensartoriuscom publication published financial reporting system firesys sartorius ag michael konrad gmbh corporate communication frankfurt main germany 37070 goettingen germany photography editorial deadline peter ginter february 24 2015 lohmar germany published february 27 2015 translation original germanlanguage annual report order intake sale revenue underlying ebitda ebita million million sartorius ag sartorius group 2014 annual report 6151 6811 7495 8668 9123 851 1102 1366 1611 1726 weender landstrasse 94108 6021 6593 7331 8457 8873 609 855 1122 1325 1372 37075 goettingen germany 950 175 phone 495513080 fax 495513083289 850 145 infosartoriuscom 750 115 wwwsartoriuscom 650 85 550 55 2009 2010 2011 2012 2013 2009 2010 2011 20121 2013 order intake ebitda sartorius group sale revenue ebita 2014 annual report key figure figure given million according ifrs 20137 20127 20117 20107 20097 unless otherwise specified order intake sale revenue earnings order intake 91231 86687 74957 68117 61517 1 7 7 7 sale revenue 8873 8457 7331 6593 60217 1 1 7 7 underlying ebitda 1726 1611 1366 1102 8517 underlying ebitda sale revenue 1951 1901 1867 1677 1417 underlying ebita 13721 13251 11227 8557 6097 underlying ebita sale revenue 1551 1571 1537 1307 1017 net profit noncontrolling interest 5241 4857 4167 3107 737 underlying net profit noncontrolling interest2 6481 6307 5287 3907 2087 research development cost 5381 4901 4437 4267 4027 financial data per share earnings per share2 underlying per ordinary share 3791 3697 3097 2287 1217 per preference share 3811 3717 3117 2307 1237 dividend sartorius ag printed germany publication og0042e141201 order 8600000182 per ordinary share 1003 0947 0807 0607 0407 per preference share 1023 0967 0827 0627 0427 balance sheet balance sheet total 117441 107097 96027 80777 82047 1 7 7 7 equity 4503 4044 3661 3272 31927 1 7 7 7 equity ratio 383 378 381 405 3897 1 7 7 7 gearing 08 08 07 06 077 financials capital expenditure excluding financial asset goodwill 6291 7427 5187 2447 2397 1 7 7 7 capital expenditure sale 71 88 71 37 407 4 1 7 7 7 depreciation amortization 477 406 328 319 3347 1 7 7 7 net cash flow operating activity 1033 532 790 960 14347 1 7 7 7 net debt 3451 3038 2648 1969 22477 1 7 7 7 ratio net debt underlying ebitda 20 19 19 18 267 total number employee december 31 58636 54917 48875 45157 43237 1 fiscal 2013 sartorius group adopted slight change reporting structure result change relate item amortization tax since shown functional expense change cost allocation impact group net profit ensure comparability 2012 business figure previous year restated accordingly 2 excluding noncash amortization 2011 2013 excluding effect fair value adjustment hedging instrument well excluding noncash interest expense share price warrant 2009 3 amount suggested supervisory board executive board sartorius ag 4 excluding amortization financial asset goodwill 5 excluding biohit liquid handling 6 excluding tap biosystems